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Abstract 
Human embryonic stem cells (hESCs) are established from the inner cell mass of 
the pre-implantation blastocyst and are both pluripotent (being able to be differentiated into 
all cell types of the body) and immortal (being able to proliferate indefinitely). When grown 
in culture, they provide a unique in vitro model system that allows us to study the earliest 
steps of human embryogenesis, a developmental process that is otherwise inaccessible to 
experimentation.  
Mitochondria are not only the essential organelles for generating energy in cells but 
also generate reactive oxygen species (ROS) as side-products of aerobic energy 
production. The presence of ROS leads to the progressive accumulation of mutations 
within mitochondrial DNA (mtDNA), resulting in dysfunctional mitochondria. To counteract 
this, it is thought that a selective amplification of healthy mitochondria occurs during 
pre-implantation development, aiming at maintaining the mitochondrial fitness in the 
germline (the ‗bottleneck‘ theory). Embryonic stem cells harvested from the 
pre-implantation blastocyst can be cultured indefinitely in vitro and contain 
metabolically-active mitochondria. Therefore, in this study, we wished to investigate how 
the mtDNA copy number is regulated in cultured pluripotent stem cells. 
Initially, the mitochondrial-encoded as well as the mitochondrial biogenesis-related 
gene expression were analysed in spontaneously differentiating hESCs and during different 
lineage-specific differentiation of hESCs in a time-dependent manner. The 
spontaneously-differentiated hESCs possess more copies of mitochondrial genome in 
mitochondria and early-differentiated hESCs display more mature mitochondrial 
morphology and a higher mitochondrial membrane potential as compared to 
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undifferentiated hESCs. After 7 days of spontaneous differentiation of hESCs, the transcript 
levels of D-loop and PGC1α, the master regulatory gene of the mitochondrial biogenesis, 
were upregulated. We also demonstrated that the early ectoderm and cardiomyocyte 
differentiation is accompanied by an upregulation of PGC1α. While this shows that 
mitochondrial gene expression and biogenesis changes upon differentiation it remained to 
be determined what role mitochondria play in pluripotent stem cells and their differentiated 
derivatives. 
To address this question, we investigated the effect of interference with 
mitochondrial DNA replication (using EtBr) or mitochondrial protein synthesis (using 
chloramphenicol) in fibroblasts. Compared with untreated primary human foreskin 
fibroblasts, the mitochondrial impaired rho-minus fibroblasts showed a lower rate of 
proliferation and a decreased level of mitochondrial gene expression, as well as lower 
mitochondrial membrane potential and greater rate of lactate production. Moreover, the 
mitochondrial-encoded and mitochondrial biogenesis-related genes were upregulated after 
the treatments had been removed. While fibroblasts were able to tolerate mitochondrial 
depletion or inhibition of mitochondrial protein synthesis repeated attempts to generate 
mitochondria depleted, let alone mitochondria null, hESC failed, suggesting that despite the 
notion that hESCs are mainly glycolytic mitochondria are required for pluripotent stem cell 
proliferation and survival.  
These observations next led us to investigate whether the mtDNA copy number 
affects the hESC‘s survival. To this end, we chose to perturb the expression of 
mitochondrial transcription factor A (TFAM), a member of the high-mobility group (HMG) 
family of proteins, which is known to have a role in controlling the mtDNA copy number in 
other cell types. Overexpression of TFAM in hESCs led to an increase in the mtDNA copy 
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number but did not affect hESC morphology, whereas knockdown of TFAM expression 
resulted in dramatically cell death in H9 and Mel 1 hESCs. The data indicate that in contrast 
to other cell types TFAM does not appear to play a central role in mitochondrial biogenesis 
in hESC and that PGC1α may be more important in this respect.  
To investigate the mechanism of mitochondrial turnover in hESC, we investigated 
mitophagy in pluripotent and differentiating hESC. Following a short-term treatment of 
hESCs, with rapamycin (mTOR inhibition), CCCP (depolarisation of the mitochondrial 
membrane), or ethidium bromide (mtDNA damage). Autophagosome numbers were 
increased. Furthermore, after longer-term, EtBr triggered mitophagy events in every single 
cell in a hESC culture. Interestingly we found that during early hESC differentiation, the 
mitophagic activity transiently increased, perhaps indicating that mitochondrial turnover 
may be involved in mitochondrial quality control during very early differentiation of hESCs. 
While there remain many questions to be answered regarding the role and regulation of 
mitochondria in hESC and hESC differentiation this thesis provides several novel insights 
into these processes.  
hESCs represent a unique system to study the molecular mechanisms that control 
mitochondrial quality and quantity and investigating these processes in the most primitive 
human stem cells is highly relevant to understanding the effects of environmental toxins on 
early human development and regenerative medicine approaches for in particular 
mitochondrial diseases.   
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Chapter 1: Introduction 
Embryonic stem cells (ESCs) are derived from the inner-cell-mass (ICM) of 
blastocysts. ESC and induced pluripotent stem cell (iPSC) lines are immortal, meaning that 
they have unlimited proliferation potential. They are also pluripotent; that is, they can 
differentiate into lineages derived from all 3 major germ layers of the embryo. Consequently, 
these cells have been widely investigated in the development of regenerative medicine 
therapies. Human ESCs have been regarded as important research tools for the 
investigation into early development of the human embryo. Mitochondria are the 
powerhouses capable of providing the majority of energy within the cell and performing 
important metabolic functions such as the Krebs cycle. The well-known endosymbiotic 
theory (Martin, Hoffmeister et al. 2001) has suggested that the mitochondrion was originally 
derived from a prokaryotic cell that invaded a larger, nucleated host cell. Mitochondria 
indeed contain their own mitochondrial DNA (mtDNA) in a circular form, similar to the 
bacterial genome. Mitochondrial genomes encode several essential genes of the 
eukaryotic respiratory machinery. However, most of the components of the respiratory 
machinery and factors controlling mitochondrial biogenesis are encoded in the nucleus. 
The cooperation and communication between mitochondria and nuclei are conducted by 
retrograde signals, such as energy supply and redox signaling and this currently 
poorly-understood communication is essential for balancing energy production and 
demand in the cell.  
Mutations or deletions in the mitochondrial genome or nuclear-encoded 
mitochondrial biogenesis-related genes usually result in a spectrum of mitochondrial 
dysfunctions. This can affect a wide variety of tissues, including the brain, heart, liver, 
skeletal muscles, kidney and the endocrine and respiratory systems. Differences in the 
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organs affected may lead to different symptoms, such as myopathies, developmental 
delays and respiratory complications. Human cells lacking mtDNA known as rho zero (ρ˚) 
cells, provide an opportunity to examine cellular processes in the absence of functional 
mitochondria; that is to mimic the cells from patients with mitochondrial depletion syndrome 
(MDS).  
Mitochondria are entirely derived from the oocyte and very little mitochondrial 
biogenesis is thought to occur until the implantation of blastocyst into uterus. Implantation 
results in dramatic environmental alterations, such as increased oxygen and nutrient supply. 
Interestingly, this is also the stage at which the differentiation of the inner cell mass into the 
various tissues and cell types of the body starts to occur. The development of an organism 
demands energy. Mitochondrial dysfunction (stemming from low mtDNA content, for 
example, or from mutations within the mtDNA) within an oocyte may contribute to the failure 
of in vitro fertilization and may affect hESC maintenance and differentiation (Reynier, 
May-Panloup et al. 2001). The role of mitochondria in human embryonic stem cells (hESCs) 
and the mechanism, by which mitochondrial health is maintained in these immortal cells, 
remain unclear.  
Mitochondrial turnover eliminates defective mitochondria to maintain cellular 
homeostasis (Diaz and Moraes 2008). Mitochondrial turnover occurs through a specific 
form of autophagy, an evolutionarily-conserved process in eukaryotic cells that results in 
the breakdown of some of cytoplasmic proteins and organelles within the lysosome in 
response to stress conditions. A key signaling pathway in the regulation of autophagy is the 
mammalian Target of Rapamycin (mTOR) kinase, which senses signals causes by the 
nutrient levels. mTOR regulates protein synthesis in the cell, the status of energy and 
oxygen supply, cell proliferation and cell growth. This mTOR signaling is essential for 
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survival, differentiation, development and homeostasis in all organisms. Autophagy is 
essential during degradation and development of maternal RNAs, proteins and organelles 
in order to activate zygotic transcription and translation at different developmental stages. 
Upon differentiation of hESCs, the mtDNA copy number increases to meet the energy 
requirements of different cell types generated. Both ‗healthy‘ and ‗mutated‘ mitochondria 
could be amplified upon differentiation. There exists a selective mechanism, called 
mitophagy, by which autophagosomes uptake mitochondria. Mitophagic events are a 
highly-selective process controlled by oxidative stress and mTOR and is accompanied by 
loss of membrane potential and ensuing mitochondrial degradation. 
The purpose of the current thesis aimed to examine the role of mitochondria in 
hESCs during maintenance and differentiation. Four initial objectives were formulated to 
guide the investigation: 
Objective 1: To review the gene expression patterns of mitochondria-encoded and 
mitochondrial biogenesis-related genes during spontaneous and directed 
lineage-specific differentiation. 
The gene expression patterns of mitochondria-encoded and mitochondrial 
biogenesis-related genes during the differentiation of human pluripotent stem cells are not 
known. Mitochondria are the major source of energy for eukaryotic cells. To meet rising 
energy demands, cells often expand the pool of mitochondria, a process termed 
mitochondrial biogenesis, which involves the replication of mitochondrial DNA (mtDNA) and 
the synthesis, import, and assembly of essential mitochondrial proteins (Hock and Kralli 
2009). Levels of mtDNA can affect oocyte maturation and subsequent developmental 
processes (Van Blerkom 2004). During cellular differentiation, mitochondria also 
differentiate in a process that involves structural and functional changes. For example, 
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mitochondria within spontaneously differentiating cells increase their membrane potential 
(St John, Ramalho-Santos et al. 2005). This section describes the treatment conditions 
used to promote differentiation and documents the expression of mitochondrial-encoded 
and mitochondrial biogenesis-related genes during spontaneous, lineage-specific-, or 
tissue-specific-differentiation of hESCs.  
Objective 2: To investigate the effects of mitochondrial depletion on human 
fibroblasts and hESCs. 
Environmental toxins might cause mitochondrial dysfunction, which generates 
retrograde signaling from the mitochondria to the nucleus. While this signaling pathway has 
been well described in yeast, the manner in which mammalian cells respond to 
mitochondrial DNA (mtDNA) depletion or the inhibition of mitochondrial protein synthesis 
remains largely unclear. To investigate this response, mitochondria-depleted (rho-minus) 
human fibroblasts were generated with agents that damage mitochondria: ethidium 
bromide, which interferes with mitochondrial DNA replication, or chloramphenicol, which 
interferes with mitochondrial protein synthesis. Gene expression, mitochondrial membrane 
potential, morphology, and metabolic parameters were assessed during and after 
treatment.  
 
Objective 3: To characterize the effects of TFAM overexpression and knockdown on 
the control of mitochondrial biogenesis during the proliferation of hESCs. 
TFAM regulates the stability (Fisher and Clayton 1988) and copy number (Scarpulla 
2008) of mtDNA, and mice lacking Tfam do not survive past embryonic day (E) 8.5 
(Larsson, Wang et al. 1998). We hypothesized that TFAM also controls the mtDNA copy 
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number in hESCs. Therefore, we investigated whether manipulation of TFAM expression 
affected the proliferation or survival of hESCs. First approach was to assess how 
constitutive overexpress or knockdown of TFAM affected the survival of stem cells. The 
second approach was to switch from a constitutive expression system to an inducible 
expression system in order to obtain a better understanding of the relationship between 
TFAM expression and stem cell survival. 
 
Objective 4: To compare mitochondrial turnover (mitophagy) following exposure to 
mitochondrial toxins and during the differentiation of hESCs. 
Mitochondrial turnover is essential for maintaining optimal cellular function within the 
human body. Several diseases have been identified that result from the improper turnover 
of mitochondria. LC3 initially forms a complex that resembles a pre-autophagosomal 
structure, serving as a nucleation site on damaged mitochondria that sends an ―eat-me‖ 
signal. The pre-autophagosomal structure eventually forms a cup-shaped isolation 
membrane that sequesters and delivers damaged mitochondria to autophagosomes (i.e. 
mitophagosomes) and then to autolysosomes. In this study, we investigated the mitophagic 
process during differentiation and after exposure to agents that interfere with mitochondrial 
function. Firstly, we established the GFP-LC3 system as a means to quantitatively measure 
mitophagy. Next, the system was used to understand the dynamics of mitophagy during 
differentiation of hESCs or when cells were challenged with toxins that affect mitochondrial 
function. Furthermore, various mitochondrial toxins were used to study mitophagy during 
stem cell differentiation. 
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Chapter 2: Reivew of Literature 
2.1 Human Pluripotent Stem Cells  
Stem cells are endowed with a unique capacity for self-renewal (Weissman 2000). In 
mammalian development, fertilized oocytes are able to differentiate into all types of cells and 
are thus classified as totipotent. ‗Totipotent‘ is derived from the Latin totus, which means 
‗entire‘. A totipotent stem cell has the ability to generate all cell types found in the embryo 
and in extra-embryonic tissues. Fertilized oocytes divide and progress into 8-cell embryos 
and then blastocysts. Blastocysts are composed of an outer layer of cells, called 
trophoblasts, and inner cells, which form the inner cell mass (ICM). The ICM can develop 
into all cell types of the adult body and is therefore called ‗pluripotent‘, a term derived from 
the Latin plures, meaning ‗several‘ or ‗many‘. Pluripotent stem cells, such as mouse 
embryonic stem cells (mESCs), human embryonic stem cells (hESCs), and induced 
pluripotent stem cells (iPSCs), can differentiate into ectoderm, mesoderm, endoderm, and 
germ cells (Lemoli, Bertolini et al. 2005). 
Once blastocyst-derived cells have fully differentiated into tissues or organs, stem 
cells that reside in various tissues and organs remain in order to generate new tissue or 
repair damaged tissue. These stem cells, known as multipotent stem cells or adult stem 
cells (ASCs), include mesenchymal stem (or stromal) cells (MSCs) and hematopoietic stem 
cells (HSCs). Their differentiation ability is limited compared to that of totipotent and 
pluripotent cells. For example, hematopoietic stem cells, which are found in bone marrow, 
can differentiate into erythrocytes and white blood cells (including macrophages). These 
types of cells are important for homeostasis because they enable the steady self-renewal of 
tissue.  
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There are different types of pluripotent stem cells: embryonic stem cells (ESCs), 
induced pluripotent stem cells (iPSCs), embryonic germ cells (EGCs), and embryonic 
carcinoma cells (ECCs). ESCs are isolated from the ICM of the blastocyst (Figure 2.1) 
(Thomson, Itskovitz-Eldor 1998), whereas iPSCs are artificially generated by 
reprogramming somatic cells using a defined set of transcription factors. iPSCs are similar 
to hESCs in morphology, gene expression, and differentiation ability (Chen, Gulbranson et 
al. 2011). Human embryonic germ cells (hEGCs) are derived from the primordial germ cells 
(PGCs) and are pluripotent stem cells (Thomson and Odorico 2000). Embryonic carcinoma 
cells (ECCs) are stem cells derived from teratocarcinomas, which are tumors that arise from 
embryonic tissues such as those from the testis or ovary, or from cultures of explanted cells 
(Przyborski, Christie et al. 2004). ECCs are considered the malignant counterparts of 
hESCs.  
 
2.2 Embryonic Stem Cells (ESCs) and induced pluripotent stem cells (iPSCs) 
Evans and Kaufman (1981) were the first to derive ESCs from an early mouse 
embryo (Evans and Kaufman 1981). In 1998, Thomson and colleagues reported the first 
successful derivation of hESC lines (Norman, Fischer et al. 2010); these lines are still 
widely used. They are capable of proliferating extensively in their undifferentiated state in 
vitro and have the ability to differentiate into all three germ layers (Shamblott, Axelman et al. 
1998, Thomson and Odorico 2000). The embryo-derived hESCs were established from 
blastocysts discarded during in vitro fertilization (IVF) procedures. 
iPSCs are an artificially generated type of pluripotent stem cell. iPSCs are 
reprogrammed from adult somatic cells to acquire stem cell-like properties through the 
forced expression of a combination of transcription factors, such as Oct4, Sox2, Nanog, 
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c-myc, KLF4, and Lin28. Takahashi and Yamanaka introduced four pluripotent genes-Oct4, 
Sox2, c-myc, and Kruppel-like family transcription factor 4 (Klf4)—that could reprogram 
mouse fibroblasts into mouse-induced pluripotent stem cells (miESCs) or human fibroblasts 
into human-induced pluripotent stem cells (hiPSCs) (Takahashi and Yamanaka 2006). 
Thomson and colleagues used Oct4 and Sox2 in combination with Nanog and Lin-28 
homolog (Lin28), instead of c-myc and Klf4, to reprogram human fibroblasts into hiPSCs 
(Yu, Vodyanik et al. 2007). These iPSCs express stem cell markers and can differentiate 
into three germ layers in a teratoma in vivo.  
iPSCs have the advantage that they do not require the destruction of an embryo. 
Moreover, given their origin, they provide a perfect match to the cell donor (are fully 
isogenic) and thus would likely avoid rejection by the donor‘s immune system. 
 
Figure 2.1 hESC isolation and culture procedures. hESCs are derived from the inner cell 
mass of the blastocyst (left). For long-term culture, hESCs are grown on inactivated mouse 
embryonic fibroblasts used as a feeder layer (Hoffman and Carpenter 2005). 
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2.3 Characterization of Undifferentiated hESCs 
Undifferentiated hESCs express high levels of cell surface antigens that can be used 
as stem cell-specific pluripotency markers. These antigens include: (1) glycolipids, such as 
the stage-specific embryonic antigens SSEA-3 and SSEA-4 (Kannagi, Cochran et al. 1983); 
(2) glycoproteins, such as TRA-1-60 and TRA-1-81 (Badcock, Pigott et al. 1999); and (3) 
alkaline phosphatase (Thomson, Itskovitz-Eldor et al. 1998, Reubinoff, Pera et al. 2000, 
Henderson, Draper et al. 2002). Pluripotency markers include the transcription factors 
Octamer-4, POU domain, class 5, transcription factor 1 (OCT4 or POU5F1) (Goto, Adjaye 
et al. 1999, Hansis, grifo et al. 2000, Mitsui, Tokuzawa et al. 2003, Sperger, Chen et al. 
2003, Hart, hartley et al. 2004, Zangrossi, Marabese et al. 2007);sex-determining region 
Y-box 2 (SOX2) (Avilion, Nicolis et al. 2003); and Nanog homeobox (NANOG) (Ivanova, 
Dimos et al. 2002, Pan and Thomson 2007).These molecular markers provide a means of 
identifying pluripotent stem cells, and a decrease in their expression can be used to monitor 
the onset of differentiation. The molecular mechanisms underlying the self-renewal of 
hESCs have not been fully elucidated.  
 2.4 Gene Expression Analysis of hESCs 
Investigating gene expression in various stem cell lines could give important insights 
into how stem cells control pluripotency and differentiation. A number of studies have 
measured hESC gene expression to investigate related molecular mechanisms and have 
reported differential gene expression in different hESC lines. Rao and Stic (2004) reported 
a 75% similarity in the microarray profiles of two lines; in a another study, 48% of the 
expressed genes were restricted to one or two lines (Abeyta, Clark et al. 2004). However, 
variations in gene expression have been observed in hESC lines derived within the same 
laboratory (Ginis, Luo et al. 2004) and even in the same hESC lines (38%) after three 
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passages in different media (Rao, Calhoun et al. 2004). Gene expression also changes 
during spontaneous differentiation (Aghajanova, Skottman et al. 2006). For example, the 
expression of leukemia inhibitory factor (LIF) and its receptors is low in undifferentiated 
hESCs, but increases during differentiation. Differential DNA methylation of 
pluripotency-associated promoters such as NANOG and OCT4/POU5F1 has been 
observed in pluripotent and differentiated cells. Understanding gene expression in hESCs 
will help shed light on the molecular basis of normal differentiation and the abnormal 
processes that underlie human developmental disorders. 
Several external signals that maintain stem cell pluripotency have been 
characterized. External signals are also thought to play important roles in the regulation of 
ESC self-renewal and differentiation. For example, the pluripotency of hESCs is maintained 
by several signaling pathways (Ohtsuka and Dalton 2008): 
 The Fibroblast Growth Factor (FGF) Signaling Pathway 
Exogenous bFGF is an essential factor in a defined hESC culture medium used for 
the maintenance of undifferentiated hESCs and hiPSCs in vitro. Withdrawal of bFGF 
induces the downregulation of pluripotency markers and the differentiation of hESCs. 
This suggests that FGF signaling plays an important role in self-renewal and 
pluripotency regulation in human ES cells and iPSCs (Xu, Peck et al. 2005, Eisenberg, 
Knauer et al. 2009).  
 The Transforming Growth Factor-β (TGF-β)/Activin/Nodal-SMAD2/3 Signaling Pathway 
The TGF-β/Activin/Nodal branch is highly active in undifferentiated hESCs. The 
pathway supports the self-renewal of undifferentiated hESCs by activating SMAD2/3 
and inducing the expression of the pluripotency markers Oct4 and Nanog (James, 
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Levine et al. 2005, Vallier, Alexander et al. 2005). The TGF-β/Activin/Nodal-SMAD2/3 
signaling pathway is important in maintaining the self-renewal and pluripotency of 
hESCs (Valdimarsdottir and mummery 2005). 
 The Phosphoinositide-3-Kinase (PI3K) Signaling Pathway 
The PI3K protein is highly expressed in undifferentiated cells and is downregulated 
in differentiated ESCs (Di Cristofano, Pesce et al. 1998, Takahashi, Murakami et al. 2005, 
Armstrong, Hughes et al. 2006). Blocking the PI3K signaling pathway with the PI3K 
inhibitor LY294002 results in the loss of pluripotency markers and initiates cellular 
differentiation (Paling, Wheadon et al. 2004). In addition, activation of the PI3K signaling 
pathway induces the PI3K-dependent phosphorylation of PKB/Akt and GSK-3α/β proteins. 
2.5 Propagation of Undifferentiated hESCs 
Initially, hESCs were grown on irradiated mouse feeders or human foreskin 
fibroblasts (Inzunza, Gertow et al. 2005). However, exposure to animal-derived culture 
constituents is a drawback of the feeder-dependent systems (Sidhu, Walke et al. 2008). 
Given that hESCs and hiPSCs are attractive candidates for future human cell 
transplantation, it is important to optimize good manufacturing practice (GMP)-compliant 
systems for the derivation, scale-up, and banking of cells and their corresponding quality 
assurance controls (Unger, Skottman et al. 2008, Ausubel, Lopez et al. 2011). Therefore 
feeder-free systems are increasingly used in combination with xeno-free defined culture 
medium and GMP-compliant coating substrates specially designed for hESC growth (Yoon, 
Chang et al. 2010), including laminin and fibronectin.  
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2.6 Pluripotent Stem Cell Differentiation 
In vitro and in vivo, hES and iPS cells can differentiate into cell types from the three 
primitive germ layers: ectoderm, mesoderm, and endoderm (Thomson, Itskovitz-Eldor et al. 
1998, Reubinoff, Pera et al. 2000, Thomson and Odorico 2000) (Figure 2.2). The 
differentiation capacity of these cells is typically tested by assessing their spontaneous 
differentiation in cell culture (i.e. in vitro formation of embryonic bodies or EBs). Upon the 
removal of growth factor (e.g. bFGF) or feeder layers and/or transfer to suspension 
conditions, hESCs undergo spontaneous unguided differentiation into various cells 
representative of the different germ layers. In two-dimensional (2D) spontaneously 
differentiated hESCs, the different morphologies appeared to be epithelial cells, neural cells 
with axons and dendrites, and cells with mesenchymal characteristics (Odorico, Kaufman 
et al. 2001). In suspension, the hESCs form multicellular aggregates of differentiated and 
undifferentiated cells called embryoid bodies (EBs), which resemble early post-implantation 
embryos and frequently progress through a series of differentiation stages (Itskovitz-Eldor, 
Schuldiner et al. 2000). Typically, EBs are allowed to grow for several days or weeks, with 
samples taken at intervals for analysis via flow cytometry or immunocytochemical staining. 
In vitro and in vivo assessments of differentiation involve determining whether the derived 
cells have acquired a variety of ectoderm-, mesoderm-, and endoderm-like properties (and 
loss of markers for pluripotency). In vivo assessment of pluripotency is performed by 
xenografting hESCs and iPSCs into severe combined immune-deficient (SCID) mice and 
observing the formation of teratomas with derivatives of all three germ layers, which 
indicates that the injected stem cells have the ability to differentiation along three lineages 
(Thomson, Itskovitz-Eldor et al. 1998, Reubinoff, Pera et al. 2000). 
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2.7 Directed Differentiation 
To direct the differentiation of ESCs towards a particular cell type, such as a neuronal 
cell type or a cardiomyocyte cell type, hESCs in monolayer culture are exposed to certain 
growth factors or stimuli and extracellular matrix components, either directly or indirectly 
through feeder cells (Schuldiner, Yanuka et al. 2000).  
Retinoic acid (RA) induces human embryonic stem cells to differentiate into the 
ectodermic lineage (Guan, Chang et al. 2001). RA and its receptors play important roles in 
the development of the central nervous system by initiating the cellular differentiation of 
neuronal precursors (Niederreither and Dolle 2008). Several papers have reported that RA 
induces neuronal differentiation in neuroblastoma cell lines (SH-SY5Y human 
dopaminergic neuroblastoma cells) (Constantinescu, Constantinescu et al. 2007, Lopes, 
Schroder et al. 2010) and human promyelocytic leukemia HL-60 cells (Racanicchi, 
Montanucci et al. 2008). Further, RA also induces embryonic stem cells to differentiate into 
neuronal cells (Guan, Chang et al. 2001, Parsons, Teng et al. 2011, Liu, Liu et al. 2012), 
including neurons and glial cells. In order to improve the efficiency and reproducibility of 
neuronal differentiation, several studies have attempted to add small molecules. For 
example, Idelson M et al. have demonstrated that nicotinamide promotes the differentiation 
of hESCs into neural cells and subsequently into retinal pigment epithelium (RPE) cells 
(Idelson, Alper et al. 2009). Moreover, Lu SJ et al. have described a robust system that 
efficiently generates large numbers of hemangioblasts from multiple hESC lines and 
produces functional homogeneous RBCs with oxygen-carrying capacity on a large scale 
(Lu, Feng et al. 2010). The markers of early ectodermdifferentiation are paired box gene 6 
(PAX6), SRY (sex determining region Y)-box 1 (SOX1), nesting, and glial fibrillary acidic 
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protein (GFAP). Briggs JA et al. have demonstrated successful neuronal differentiation via 
a sophisticated protocol (Briggs, Sun et al. 2013).  
Mesoderm differentiation has been extensively studied, particularly the families of 
protein growth factors that control the early stages of mesoderm formation in 
cardiomyocytes (Mummery, Zhang et al. 2012). Hudson J et al. have used small molecules 
to target the wingless/INT (Wnt) signaling pathway in order to induce the differentiation of 
hESCs into beating cardiomyocytes (Hudson, Titmarsh et al. 2012). Biomarkers for early 
mesoderm-differentiation include T-box factor Brachyury (BRY or T), the homeodomain 
protein MIXL1, and myosin (Hudson, Titmarsh et al. 2012). 
Endoderm differentiation forms several tissues, including the liver, lung, thyroid, and 
foregut endoderm. The families of protein growth factors that control the early stage of 
endoderm differentiation into the anterior-ventral domain of the foregut endoderm are 
targeted by signaling through Nodal, a member of the transforming growth factor-B (TGF-B) 
superfamily and the SMAD signaling pathway (Kim, Yoon et al. 2011). The biomarkers of 
early endoderm differentiation are insulin-like growth factor 2 (IGF2) and gata binding factor 
(GATA4); SRY (sex determining region Y)-box 17 (SOX17) is also an indicator of the 
definitive foregut endoderm (Kanai-Azuma, Kanai et al. 2002, Nakanishi, Kurisaki et al. 
2009). Little is known about the expression of mitochondrial biogenesis-related genes 
during hESC lineage-specific differentiation. 
32 
 
 
 
Figure 2.2 Undifferentiated hES cells (A) can give rise to cell types from the three primitive 
germ layers: (B) neuronal cells in ectoderm-lineage differentiation, (C) pancreatic cells in 
endoderm-lineage differentiation, and (D) cardiomyocytes in mesoderm-lineage 
differentiation. This figure is adapted from Hoffman and Carpenter 2005, Wobus and 
Boheler 2005). 
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2.8 Mitochondrial Biology: Introduction 
The mitochondrion is a dual-membrane organelle which is found in all eukaryotic 
cells except erythrocytes and lense tissue. The mitochondrion is composed of the outer 
mitochondrial membrane, the intermembrane space (the space between the outer and 
inner membranes), the inner mitochondrial membrane, the cristae space (formed by 
in-folding of the inner membrane), and the matrix (the space within the inner membrane) 
(Figure 2.3).  
 
Figure 2.3 Structure of a mitochondrion. This figure is modified from (Frey and Mannella 
2000). 
The human mitochondrial genome consists of a 16.5-kb double-stranded circular 
DNA molecule that contains both non-coding and coding regions. The largest non-coding 
sequence in mammalian mtDNA is the displacement-loop (D-loop), which contains 
promoters and origins of replication. The coding regions contain 37 genes, including 2 
ribosomal RNA (rRNA) genes, 22 transfer RNA (tRNA) genes, and 13 genes that encode 
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subunits of the respiratory complexes (I, III, IV, and V) (Figure 2.4) (Chan 2006). Alkaline 
gradient centrifugation separates mtDNA into a heavy strand (H-strand) and a light strand 
(L-strand) based on differential contents of guanosine (G) and cytosine (C). The H-strand 
encodes 2 rRNAs, 12 polypeptides, and 14 tRNAs, while the L-strand encodes one 
polypeptide (ND6) and 8 tRNAs. The genetic code of mitochondria is similar to the 
universal genetic code, with three exceptions: 1) the TGA codon codes for tryptophan in 
mtDNA instead of stop in nuclear DNA, 2) AGA and AGG code for stop in mtDNA instead of 
arginine in nuclear DNA, and 3) ATA codes for methionine in mtDNA instead of isoleucine 
in nuclear DNA (Anderson, Bankier et al. 1981). It is thought that mitochondria originally 
derived from endosymbiotic prokaryotes because they share many features. For example, 
the circular mitochondrial genome is very similar to the genomes of bacteria (Martin, 
Hoffmeister et al. 2001). 
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Figure 2.4 Schematic representation of the human mitochondrial genome. mtDNA is a 
double-stranded circular molecule of approximately 16.5 kb, consisting of a heavy (H) 
strand and a light (L) strand. mtDNA consists of non-coding and coding regions. The 
non-coding D-loop (displacement loop) region contains the origin of heavy strand 
replication (OH), and the transcription promoters for both strands (HSP and LSP). The 
origin of light strand replication (OL) is found approximately two-thirds of the way around the 
genome (at 16024–16569 and 1–576). The coding region encodes 13 protein subunits of 
the electron transport chain (ETC), 12 on the heavy strand and 1 on the light strand (ND6), 
along with 22 tRNAs and 2 rRNAs that are necessary for mtDNA transcription and protein 
synthesis. Proteins encoded by mtDNA, indicated in yellow, include ND1, 2, 3, 4, 4L, 5, and 
6 (NADH dehydrogenase; Complex I); CYTB (cytochrome b; Complex III); COX1, 2, and 3 
(cytochrome c oxidase; Complex IV); and ATP6 and 8 (ATP synthase; Complex V).  
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Mitochondrial respiratory activity occurs via the electron transport chain (ETC). The 
ETC is composed of five complexes: Complex I (NADH dehydrogenase, also called ND), 
Complex II (succinate dehydrogenase), Complex III (cytochrome reductase), Complex IV 
(cytochrome C oxidase, also called COX), and Complex V (ATP synthase). Energy 
obtained from the transfer of electrons through these complexes is used to pump protons 
from the mitochondrial matrix into the intermembrane space. The sum of the pH gradient 
and the membrane potential (Δψ), which arises from the net movement of positive charge 
across the inner membrane, is known as the proton motive force (PMF; ΔP= ΔµH+ + Δψ), 
which accumulates across the mitochondrial inner membrane. The proton motive force 
allows ATP synthase (Complex V) to transfer protons back into the matrix to generate ATP 
from ADP and inorganic phosphate (Pi). As electrons flow through the complexes, they 
eventually reach Complex IV, where they are used to generate water from hydrogen ions 
and molecular oxygen (Figure 2.5) (Wallace and Fan 2010). 
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Figure 2.5 Stylized representation of the electron transport chain (ETC), the final stage of 
cellular respiration, where oxidative phosphorylation (OXPHOS) takes place. The ETC 
consists of five protein complexes that contain polypeptides encoded by the nuclear and 
mitochondrial genomes (except for Complex II). The flow of electrons through the first four 
complexes releases protons (H+) from the mitochondrion and establishes the mitochondrial 
membrane potential. The transfer of these protons back into the mitochondrion through 
Complex V generates ATP. This figure is modified from (Zeviani and Di Donato 2004). 
Abbreviations: CoQ, coenzyme Q; Cyt C, cytochrome C; ANT, adenosine nucleoside 
transporter; ADP, adenosine diphosphate; ATP, adenosine triphosphate.  
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2.9 Mitochondria Are Dynamic Organelles 
A mitochondrion is not a discrete, autonomous organelle; rather, it is part of a 
dynamic network akin to the endoplasmic reticulum. Mitochondria are highly dynamic 
organelles that are constantly engaged in fusion and fission in the cell, as demonstrated, for 
instance, in mouse embryonic fibroblasts (Chen, Detmer et al. 2003). In dividing cells, the 
mass of this mitochondrial network steadily increases throughout the cell cycle; it normally 
divides more or less equally between daughter cells. During fusion and fission, the 
synthesis of the vast majority of mitochondrial components is required, including lipids and 
proteins that are imported into pre-existing organelles, thereby enlarging the structure. 
Mitochondria have maintained a fission system in order to split the enlarged organelle mass. 
Once a sufficient volume of organelle has been generated and the cell is ready to divide, 
the mitochondria segregate between the cells of the next generation. The relative rates of 
fusion and fission determine the morphology of the mitochondrial network at any given 
time.  
Multiple proteins are involved in mitochondrial fusion and fission. Several important 
players are involved in the mitochondrial fusion mechanism in mammalian cells, such as 
mitofusin 1 (MFN1), mitofusin 2 (MFN2), and optic atrophy 1 (OPA1) (Westermann 2010). 
These three proteins are large GTPases that localize to different sites in mitochondria 
(Detmer and Chan 2007, Liesa, Palacin et al. 2009). MFN1 and MFN2 insert into the outer 
membrane and form homo- and hetero-oligomers; OPA1 is found at the intermembrane 
space partially anchored to the inner membrane (liesa, Palacin et al. 2009, Westermann 
2010). The presence of mitofusins on adjacent mitochondria is required during fusion 
because they form complexes in-trans that tether the mitochondria together (Meeusen, 
McCaffery et al. 2004). Inhibition of mitofusins results in mitochondrial fragmentation and 
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poor mitochondrial function (Chen, Detmer et al. 2003, Rakovic, Grunewald et al. 2011). 
Inhibition of OPA1 leads to mitochondrial fragmentation and severe aberrations in the 
structure of the cristae owing to a loss of mitochondrial fusion (Olichon, Baricault et al. 2003, 
Griparic, van der Wel et al. 2004, Chen and Chan 2005). However, the specific functions of 
these proteins in membrane fusion remain to be determined (Youle and Karbowski 2005). 
In vitro, mitochondrial fusion of both the outer and inner membranes requires GTP 
hydrolysis; the mitochondrial membrane potential is also required for inner membrane 
fusion (Meeusen, McCaffery et al. 2004). 
In mammalian cells, mitochondrial fission is regulated by fission 1 (mitochondrial 
outer membrane) homologue (FIS1) and dynamin-related protein 1 (DRP1). FIS1 is 
localized uniformly on the mitochondrial outer membrane. During mitochondrial fission, 
DRP1 is recruited from the cytosol to the outer membrane. The majority of DRP1 is located 
in the cytosol, but a subpool is localized to punctate spots on microtubules. A subset of 
these puncta mark future sites of fission (Smirnova, Griparic et al. 2001, Youle and 
Karbowski 2005), and DRP1 plays a role in membrane constriction during fission. Inhibition 
of FIS1 and DRP1 inhibits fission, resulting in the elongation of mitochondrial tubules 
(Zeviani and Di Donato 2004). However, inhibition of FIS1 does not disrupt the mitochondrial 
localization of DRP1 (Zeviani and Di Donato 2004). DRP1 plays a role in membrane 
constriction during mitochondrial fission. However, the precise mechanism of fission 
remains to be determined.  
Mitochondrial fission and fusion events are important processes not only in the 
normal functioning of the cell but also in pathophysiological situations in different cells and 
tissues (Table 2.1). For example, mitochondrial fission mediated by DRP1 is a necessary 
step for cell death in apoptosis (Frank, Gaume et al. 2001).  
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Table 2.1 Diseases associated with perturbations in the mitochondrial fusion/fission 
machinery. This table is modified from (Detmer and Chan 2007). Abbreviations: CMT2A, 
Charcot-Marie-Tooth type 2A; MFN2, mitofusin-2; OPA1, optic atropohy-1; DRP1, 
dynamin-related protein-1. 
Diseases 
Mitochondrial 
function 
Gene Description 
CMT2A Fusion MFN2 Autosomal dominant peripheral neuropathy 
ADOA Fusion OPA1 Autosomal dominant optic atrophy (ADOA) 
Unnamed Fission DRP1 Neonatal lethality 
 
2.10 Mitochondrial Defects 
Mitochondrial diseases often result from mtDNA mutations and represent common 
inherited conditions. One of every 7,634 newborns is affected by mitochondrial dysfunction 
(Debray, Lambert et al. 2007). Mitochondrial diseases are a heterogeneous group of 
disorders in which mitochondrial dysfunction can affect tissues with varying severity. The 
effects are often more prominent in neurons of the brain and in skeletal muscles, which 
require more energy than other tissues. 
Within mtDNA, several types of mutations have been identified, including 1) point 
mutations, 2) large-scale rearrangements, and 3) depletion of mtDNA resulting from a 
reduction in the mtDNA copy number (Zeviani and Antozzi 1997, Zeviani and Di Donato 
2004). Depletion of mtDNA is an autosomal recessive trait that can cause severe illnesses, 
such as neurodegenerative disorders (Zeviani and Antozzi 1997, Zeviani and Di Donato 
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2004, St John and Lovell-Badge 2007). Profound reductions in mtDNA are responsible for 
a series of syndromes that are collectively referred to as mtDNA-depletion syndromes 
(Deodato F 2009). Patients with these syndromes present with myopathy, 
encephalomyopathy, and mitochondrial neurogastrointestinal encephalomyopathy 
syndromes (Deodato F 2009). Pathologies associated with these syndromes vary widely 
and can manifest in utero or later in life. To study the consequences of mtDNA dysfunction, 
animal and cellular models with mitochondrial mutations, deletions, or depletion have been 
generated.  
 
2.11 Mitochondrial Dysfunction in Animal and Cellular Models  
The symptoms of mitochondrial dysfunction caused by mutations or deletions in the 
mitochondrial genome or by mitochondrial depletion can be observed in whole animals and 
cellular models. Several studies have described mice with abnormal mitochondria resulting 
from mutations or deletions in the mitochondrial genome. These mutations cause 
conditions that phenocopy Pearson and Kearns-Sayre syndromes (Wallace 1999, Inoue, 
Nakada et al. 2000). The mice exhibit numerous symptoms indicative of mitochondrial 
dysfunction, with clinical phenotypes associated with human diseases (Inoue, Nakada et al. 
2000, Sligh, Levy et al. 2000), including: (1) abnormalities of the optic nerve in the retina, (2) 
decreases in cytochrome c-oxidase (COX) activity, (3) ragged-red fibers in muscle, (4) a 
high lactic acid concentration, and (5) death from kidney failure (acidosis). Furthermore, the 
progeny of the mice exhibit several features: (1) inherited mtDNA mutations, homoplasmic 
or heteroplasmic, (2) a severely affected survival rate, with many dying in utero or in the 
first few days after birth, (3) growth retardation, (4) abnormal mitochondrial morphology in 
skeletal and cardiac muscle, and (5) progressive myopathy, myofibril disruption and loss, 
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and dilated cardiomyopathy. Tissues derived from normal hESCs or tissues repaired using 
a gene therapy approach carry normal mtDNA. Inducing hESCs with normal mtDNA to 
differentiate into specific cell types might help in the treatment of mitochondrial dysfunction 
generated by mutations, deletions, and depletion of the mitochondrial genome. Therefore, 
hESCs could be a useful model for understanding the etiology of mitochondrial-related 
diseases.  
To demonstrate the importance of mitochondrial morphology and function in 
cell-specific functions, mitochondria-depleted cells called rho-zero cells (ρ˚), which are 
depleted of mtDNA, were generated in vitro through the application of different drugs, such 
as ethidium bromide, antibiotics, or the nucleoside analogue reverse transcriptase inhibitor 
(NARTI, an anti-HIV drug). ρ˚ cells exhibit several common features: (1) they become 
autotrophic, relying on pyrimidine (uridine) and pyruvate supplementation for cell growth 
(Armand, Channon et al. 2004, Miceli and Jazwinski 2005); (2) they have a low mtDNA 
copy number and low expression of mitochondrial-encoded genes, but not of 
nuclear-encoded genes; (3) they have low mitochondrial respiratory chain complex 
activities, with the exception of complex II; (4) they have low ATP concentrations, 
respiration rates (oxygen consumption), and mitochondrial membrane potential; (5) they 
shift from aerobic to anaerobic metabolism if given supplemental pyruvate; and (6) they 
have an immature mitochondrial structure with reduced numbers of cristae membranes, 
circular morphology, and loss of tubular structure.  
Upon a reduction in oxygen consumption, several studies have found that 
antioxidants can reverse the increased ROS production in ρ˚ cells. In addition, ρ˚ cells have 
decreased levels of cell proliferation, mitotic cyclin gene expression, cyclin-dependent 
kinase inhibitors, retinoblastoma 1 phosphorylation, and telomerase activity (Park, Choi et 
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al. 2004, Schroeder, Gremmel et al. 2008). In ρ˚ cells, upregulation of mitochondrial 
biogenesis-related genes, relative to expression in control cells, has been observed 
(Miranda, Foncea et al. 1999, Joseph, Rungi et al. 2004). 
Interestingly, it has been suggested that ρ˚ cells have increased resistance to 
apoptosis. However, they exhibit a normal distribution of cytochrome c within mitochondria 
during staurosporine-induced apoptosis (in spite of low mtDNA levels and respiratory 
function deficiencies). Consistently, caspase 3 activation and DNA fragmentation are not 
affected in ρ˚ cells. However, the localization of NF-κB is altered (i.e. more NF-κB in the 
nucleus than in the cytoplasm), which might be related to the observed resistance to 
apoptosis. Moreover, in ρ˚ cells, a greater amount of mass is associated with lysosome and 
peroxidation production (King and Attardi 1989, Appleby, Porteous et al. 1999, Miranda, 
Foncea et al. 1999). Remarkably, the differentiation of SH-SY5Y neuroblastoma cells into 
neuron-like cells is not affected by defective mitochondria, as indicated by the presence of 
long neurites and secretory granules, which are typical of differentiating neuroblastoma 
cells (Miller, Trimmer et al. 1996). 
 
2.12 Assessing mtDNA Integrity, Copy Number, and Mitochondrial Biogenesis 
Mitochondria have their own protein-coding DNA but also import a large number of 
nuclear-encoded proteins. Therefore, mitochondrial biogenesis requires precise 
coordination between the nuclear and mitochondrial genomes. Because of the complex 
and dynamic nature of mitochondria, the analysis of mitochondrial biogenesis within a 
population of cells is difficult and requires measurements of multiple parameters, such as: 
(1) the volume and number of mitochondria via microscopy, (2) mtDNA copy number, (3) 
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levels of mtDNA-encoded transcripts, (4) levels of mitochondrial biogenesis-related 
transcription factors (e.g. TFAM, NRF1, POLG, and PGC1α) via qPCR, (5) levels of 
biogenesis molecular markers via western blotting, and 6) mitochondrial rates of translation 
by in vivo labeling (Medeiros 2008). Details of these techniques are provided below. 
First, mitochondrial morphology can be visualized and measured by fixing, 
dehydrating, sectioning, and staining cells and tissue sections for analysis with 
transmission electron microscopy (TEM). The method is time-consuming, but generates 
reliable, quantitative data. TEM analysis also requires expensive equipment and the 
assistance of an experienced TEM operator.  
Second, mitochondrial mass can be visualized and measured using fluorescent dyes. 
Analysis of stained samples using microscopy or flow cytometry yields quantitative results. 
Several fluorescent dyes are available for measuring the mitochondrial mass or Δψ 
(mitochondrial potential). Mitochondrial mass is typically measured using MitoTracker 
(Molecular Probes, Invitrogen) or 10-n-nonyl-acridine orange. The latter binds cardiolipin, 
which is predominantly found in the inner mitochondrial membrane.  
Third, common PCR and qPCR techniques can be used to assess the levels of 
mtDNA, mtDNA-encoded transcripts, and mitogenesis-associated transcription factors (e.g. 
TFAM, NRF1, and PGC1α). Because mitochondria have their own genomes, the amount of 
mtDNA is roughly proportional to the number of mitochondria, although each mitochondrion 
has multiple copies of mtDNA. mtDNA has traditionally been quantified using Southern blot 
analysis (Tang, Halberg et al. 2012), but the use of qPCR techniques is becoming more 
common. qPCR methods typically compare levels of mtDNA and nuclear DNA to determine 
the mtDNA copy number (i.e. the number of mitochondrial genomes per cell) (Hoschele, 
Wiertz et al. 2008). The measurements typically use a variety of primer sets, such as those 
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for NADH dehydrogenase subunit I (ND1), along with primers specific for nuclear-encoded 
housekeeping genes, which are used for normalization purposes. In addition, the D-loop is 
critical for the replication and transcription of mtDNA (Takamatsu, Umeda et al. 2002). 
Expression of D-loop elements can be used to determine the mtDNA copy number. 
However, when quantifying levels of mtDNA, it is important to use target sequences that 
are not commonly deleted in disease or by aging. 
The quality of mtDNA is typically determined via DNA sequencing or microarray 
analysis (Maitra, Cohen et al. 2004) (Table 2.2). These techniques are expensive and must 
be repeated multiple times because of the heteroplasmy of mtDNA. mtDNA sequencing 
can be used to detect polymorphic sites and to determine maternal relationships between 
individuals. Molecular techniques such as these have led to the creation of the Human 
Mitochondrial Genome Database (MtDB), which contains many human mtDNA sequences, 
a list of known mutation hotspots, and a catalogue of polymorphic sites (Ingman and 
Gyllensten 2006).  
Fourth, antibodies directed against proteins encoded by the mitochondrial genome 
or proteins critical for mitogenesis (e.g. TFAM, NRF1, POLG, and PPARGC1A) can be 
used (Williams, Scholte et al. 2001). Many of these antibodies are commercially available 
(Invitrogen, Sigma-Aldrich, MitoSciences, and Santa Cruz Biotechnology). Mitochondria 
can be measured by assessing complex (I, II, IV, and V) activities, fission/fusion rates, and 
oxygen consumption. GFP, targeted by a leading signaling peptide to mitochondria, is used 
to measure fission/fusion rates. During oxidative phosphorylation, the transfer of electrons 
to oxygen and the oxidation of substrates is used to generate ATP. Thus, oxygen 
consumption can be one of the most informative and direct measures of mitochondrial 
function.  
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Table 2.2 Methods for the analysis of mtDNA mutations or mtDNA copy number 
Method for the analysis of mtDNA 
mutations 
Sample type Reference 
Oligonucleotide array Total DNA 
(Maitra, Cohen et al. 2004, 
Maitra, Arking et al. 2005) 
Sequence analysis of PCR-amplified 
products 
Total DNA 
(Polyak, Li et al. 1998, Fliss, 
Usadel et al. 2000, Maitra, 
Cohen et al. 2004) 
qPCR (mitochondrial-encoded gene, 
ND1, COX2)  
cDNA  
(Cunningham, Rodgers et al. 
2007) 
qPCR (mitochondrial-encoded genes and 
non-coding region, D-loop)  
Total DNA 
(Kanki, Ohgaki et al. 2004, St 
John, Amaral et al. 2006, 
Amaral, Ramalhoo-Santos et 
al. 2007, Armstrong, Tilgner 
et al. 2010) 
PCR (ND4, CYTB, and COXI) and 
western blot (COXI and COXII) 
cDNA and 
proteins 
(Jeng, Yeh et al. 2008) 
Southern and northern blot 
(mitochondrial-encoded genes) 
Total DNA 
and total RNA 
(Larsson, Oldfors et al. 1994, 
Garstka, Schmitt et al. 2003, 
Ekstrand, Falkenberg et al. 
2004, Maniura-Weber, 
Goffart et al. 2004, 
Pohjoismaki, Wanrooij et al. 
2006). 
Southern blot (Alpha-32P-dCTP labeled 
random primed probes generated against 
a 16-kb mtDNA template) 
Total DNA (Rebelo, Williams et al. 2009 
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2.13 Mitochondrial Biogenesis: Introduction 
Mitochondrial biogenesis to generate new mitochondria involves all cellular 
processes. There are several transcription factor regulators of mitochondrial biogenesis. 
During adaptation to changing environmental situations, inputs from all cellular processes 
promote mitochondrial biogenesis, including the synthesis, import, and assembly of 
essential mitochondrial components, as well as the replication of mtDNA (Hock and Kralli 
2009).  
2.14 Mitochondrial DNA Replication  
Mitochondrial DNA is replicated and transcribed within mitochondria. In these 
semi-autonomous organelles, mtDNA replication takes place independently from the cell 
cycle and from nuclear DNA replication. Transcription factors involved in mtDNA biogenesis, 
encoded by nuclear DNA, regulate mtDNA replication and mtDNA transcription (Moraes 
2001).  
The process of DNA replication differs in mitochondria and the nucleus. Replication 
of mtDNA depends on nuclear DNA-encoded regulatory proteins, particularly 
mtDNA-specific polymerase gamma (POLG). POLG consists of two subunits: the catalytic 
subunit, responsible for elongation of the daughter DNA strands, and the accessory subunit, 
responsible for primer recognition and proofreading activity (Gray and Wong 1992). 
Synthesis starts at one of the multiple origins of replication of the heavy strand (OH) in the 
D-loop region using a short RNA primer, which is complementary to the light strand DNA 
(Xu and Clayton 1995). The leader sequence is then removed from the remainder of the 
light strand transcript by the mitochondrial RNA processing endoribonuclease (RNase MRP) 
(Figure 2.6) (Shadel and Clayton 1997), allowing it to form a triple-stranded RNA-DNA 
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hybrid. mtDNA synthesis continues until it reaches the origin of replication of the light strand 
(OL), which is situated approximately 10 kbp downstream of the OH. At this time, synthesis 
of the light strand starts (Garesse and Vallejo 2001). mtDNA replication is carried out by 
POLG, which has 3′–5‘ exonuclease and 5′-deoxyribose phosphate lyase activities, 
assisted by the helicase TWINKLE, which unwinds the DNA duplex, and by single-strand 
binding proteins (mtSSB), which maintain the DNA in a single strand (Moraes 2001, 
Falkenberg, Larsson et al. 2007).  
 
Figure 2.6. Schedmatic of mitochondrial replication. The H-strand and L-strand are 
depicted with bold and thin black lines, respectively. Firstly, TFAM (yellow box), TFBM 
(green box), and mtRNA polymerase (light blue box) bind to the L-strand promoter to 
produce an RNA transcript (red arrow). Secondly, the RNA transcript extends across the 
conserved sequence blocks (CSBs) and forms an RNA/DNA hybrid (dashed lines) in a 
stable loop configuration. This loop configuration subsequently generates RNA primers 
(green arrow). The RNase MRP (dark blue circle) then cleaves the RNA primers from the 
loop structure. Lastly, the RNA primer (thin line attached to the circle) and DNA polymerase 
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initiate heavy-strand (OH) DNA replication (heavy arrows with attached circle). This figure 
was modified from (Shadel and Clayton 1997).  
Two types of mtDNA replication models have been proposed: the asynchronous 
strand displacement model (Clayton 1982) and the strand-coupled bidirectional replication 
model (Holt, Lorimer et al. 2000). In the asynchronous strand displacement 
model,replication of mtDNA is unidirectional and asynchronous, with initiation of replication 
at two replication origins (OH and OL) (Clayton 1982, Brown, Cecconi et al. 2005). 
Transcription starts from a light-strand promoter (LSP), which forms an R-loop, a triplex 
structure containing the transcript RNA. The RNA serves as a primer for the initiation of 
H-strand synthesis from the replication origin of H-strand, OH, in the D-loop region. The 
D-loop is a DNA triplex structure composed of a displacement loop and a stretch of DNA. 
Many of the DNA synthesis events prematurely terminate at about 700 bases, resulting in 
the formation of a D-loop structure. This 700-base nascent H-strand is termed 7S DNA or 
the D-loop strand. If H-strand synthesis does not terminate prematurely, DNA synthesis 
undergoes a complete replication cycle. Displacement of the parental H-strand as 
single-stranded DNA continues until synthesis reaches the replication origin of L-strand, OL, 
located approximately two-thirds of the genome downstream from OH. Once exposed on a 
single-stranded H-strand, the OL region assumes a special stem-loop structure, which 
initiates the synthesis of an RNA primer for L-strand DNA synthesis (Clayton 1992, Schmitt 
and Clayton 1993, Shadel and Clayton 1997, Kang and Hamasaki 2006, Krishnan, Reeve 
et al. 2008). The two new DNA molecules are ligated to form the circular double-stranded 
mtDNA. Because the lagging L-strand synthesis is delayed, replication proceeds 
asymmetrically. This unique property of mtDNA replication has not been observed with 
either mammalian nuclear DNA or bacterial DNA. 
50 
 
 
The second model, proposed by Holt and Jacobs, is a bidirectional replication model 
of mtDNA replication in which replication initiates at one replication zone and proceeds 
symmetrically in both directions. The model is based on the observation of replication 
intermediates in 2D gels (Holt, Lorimer et al. 2000, Yang, bowmaker et al. 2002, Bowmaker, 
Yang et al. 2003, Krishnan, Reeve et al. 2008). Both mtDNA strands replicate at the same 
time from the same replication origin in the D-loop; this might be an alternative replication 
mechanism, with the choice of mechanism determined by variations in transcription factor 
binding or in the number of dNTPs present within mitochondria in different cell types. In the 
studies describing strand-coupled bidirectional replication, no replication intermediates 
harboring long single-stranded DNA, indicative of asymmetric replication, were found. In 
contrast, Y-fork intermediates, typical of nuclear DNA replication, were observed. On the 
basis of these observations, it was concluded that lagging strand synthesis must occur 
simultaneously and symmetrically with eading strand synthesis, as is generally seen in 
DNA replication. Because mitochondria contain a large amount of RNA, Holt and Jacobs 
proposed that the long single-stranded ‗intermediates‘ observed by Clayton and Shadel 
(Shadel and Clayton 1997) were due to degradation of mitochondrial RNA during mtDNA 
preparation (Yang, Bowmaker et al. 2002). In addition, they proposed that H-strand 
synthesis initiated from a broad 5-kb region located downstream of the D-loop region and 
not from OH (Bowmaker, Yang et al. 2003, Yasukawa, Yang et al. 2005, Kang and 
Hamasaki 2006, Falkenberg, Larsson et al. 2007). 
The exact contributions of the two mechanisms of mtDNA replication remain to be 
determined. The balance between the two replication mechanisms is thought to influence 
the mtDNA copy number under several physiological and developmental conditions (Holt, 
Lorimer et al. 2000). The asynchronous mechanism of mtDNA replication occurs in growing 
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cells with a lower mtDNA synthesis rate that maintain a stable mtDNA copy number for the 
daughter cells. In cells in which the mtDNA copy number is increasing, the bidirectional 
replication mechanism is predominantly observed. The bidirectional replication mechanism 
is also more common in cells transiently depleted of mtDNA (Holt, Lorimer et al. 2000, 
Moraes 2001). These findings suggest that the first model is responsible for the 
maintenance of mtDNA and the second model is used primarily when mtDNA amplification 
is required (Holt, Lorimer et al. 2000).  
 
2.15 Mitochondrial Transcription 
The transcription of mtDNA depends upon factors encoded within the nucleus. 
These include mitochondrial transcription factor A and B (TFAM, TFB1M and TFB2M), 
nuclear respiratory factors 1 and 2 (NRF1 and NRF2), and members of the peroxisome 
proliferator-activated receptor gamma coactivator 1 family of regulated coactivators 
(including PGC1α and PGC1β) (Scarpulla 2008).  
A number of factors regulate mitochondrial biogenesis. For example, DNA 
polymerase gamma (POLG) is the catalytic subunit of the mtDNA polymerase and is 
responsible for mtDNA replication (Graziewicz, Longley et al. 2006). Mitochondrial 
transcription factors (e.g. TFAM, TFB1M, and TFB2M) localize to mitochondria, bind 
mtDNA, and stimulate the transcription of mtDNA (Kelly and Scarpulla 2004, Gleyzer, 
Vercauteren et al. 2005). TFAM, TFB1M, and TFB2M are induced in response to signals 
that promote mitochondrial biogenesis (Figure 2.7) (Scarpulla 2008, Hock and Kralli 2009). 
TFAM is a key activator of mtDNA transcription during mitochondrial genome replication. 
TFAM binds the two major promoters in the mitochondrial genome: the light-strand and 
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heavy-strand promoters (Larsson, Wang et al. 1998, garstka, Schmitt et al. 2003). There 
are other regulators of nuclear-encoded transcription factors, such as nuclear respiratory 
factors (NRF1 and NRF2). NRF1 and NRF2 (also known as GA-binding protein, GABP) are 
transcription factors that act within the nucleus to regulate genes that encode components 
of the mitochondrial respiratory system and many genes involved in the replication of 
mtDNA (Evans and Scarpulla 1990, Virbasius, Virbasius et al. 1993). PGC1α also affects 
mitochondrial biogenesis by regulating the expression of numerous transcription factors 
(e.g. the NRFs) that are involved in the transcription and replication of mtDNA (Puigserver, 
Rhee et al. 2003).  
By examining the regulatory network that controls mitochondrial function and 
biogenesis, many relevant transcription factors, coactivators, and signaling pathways have 
been identified. As one would expect, perturbation of the mitochondrial biogenesis 
machinery dramatically affects cellular physiology and development. Studies have provided 
important insights into the dynamic and coordinated control of nuclear and mitochondrial 
genes during development (Table 2.3) (Scarpulla 2008). For example, knockout of NRF1 in 
mice results in mtDNA depletion, loss of Δψ, and blastocyst growth defects, resulting in 
embryonic lethality between E3.5 and E6.5 (Huo and Scarpulla 2001). Knockout of the 
catalytic subunit of POLG in mice results in mtDNA depletion, cytochrome oxidase 
deficiency, and embryonic lethality between E7.5 and E8.5 (Hance, Ekstrand et al. 2005). 
Knockout of TFAM in mice results in mtDNA depletion and severe respiratory chain 
deficiency, with embryonic lethality between E8.5 and E11.5 (Larsson, Wang et al. 1998).  
A variety of therapeutic interventions (e.g. dietary supplements, exercise therapy, 
and chemicals) have been used to induce mitochondrial biogenesis. For example, 
resveratrol induces mitochondrial biogenesis and improves aerobic capacity in mice 
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through histone modifications and activation of PGC1α (Lagouge, Argmann et al. 2006). 
Moreover, upregulation of the expression of PGC1 family members stimulates 
mitochondrial oxidative phosphorylation (OXPHOS). Caffeine and 
5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) enhance PGC1α 
expression in the skeletal muscles of rodents in vivo (Irrcher, Ljubicic et al. 2009, McConell, 
Ng et al. 2010). Benzafibrate is also a known activator of the PPAR/PGC1α pathway. When 
added to cell lines with defective mitochondria, it improves several indicators of 
mitochondrial function (e.g. the activity of some mitochondrial enzymes and the levels of 
mitochondrial proteins) (Bastin, Aubey et al. 2008). 
 
 
 
Figure 2.7 Transcriptional activation from the D-loop promoter region of mtDNA. The 
transcription complex is composed of TFAM, TFB (comprising TFB1M and TFB2M), and 
mitochondrial RNA polymerase (POLRMT). TFAM unwinds the DNA and forms a complex 
with TFB and POLRMT. Together, they initiate transcription from the bidirectional 
promoters present within the D-loop (Scarpulla 2008). 
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Table 2.3 Mouse gene knockouts of nuclear-encoded regulators of transcription that have 
been implicated in mitochondrial biogenesis (Scarpulla 2008). 
Gene 
knockout 
Viability Mitochondrial phenotype Reference 
TFAM  
(germ line) 
Embryonic lethal 
between E8.5 and 
E11.5 
mtDNA depletion, severe 
respiratory chain deficiency 
(Larsson, 
Wang et al. 
1998).   
Catalytic 
subunit of 
POLG 
Embryonic lethal 
between E7.5 and E8.5 
mtDNA depletion, cytochrome 
oxidase deficiency 
(Hance, 
Ekstrand et al. 
2005) 
NRF-1 
Embryonic lethal 
between E3.5 and E6.5 
mtDNA depletion, loss of Δψ, 
blastocyst growth defect 
(Huo and 
Scarpulla 
2001) 
NRF-2 
(GABP) 
Pre-implantation lethal Not determined 
(Ristevski, 
O'Leary et al. 
2004) 
 
2.16 Mitochondrial Transcription Factor A (TFAM) 
Several transcription factors play important roles in mitochondrial biogenesis. One of 
them is TFAM, which controls the mtDNA copy number (Ekstrand, Falkenberg et al. 2004) 
and stimulates mtDNA transcription in vitro and in vivo (Maniura-Weber, Goffart et al. 2004). 
TFAM (also known as mitochondrial transcription factor 1, mtTFA, mtTF1, TCF6, and 
TCF6L2) was initially characterized as a monomeric 25-kDa protein comprising a signal 
peptide (mitochondrial leading peptide, MLP) and two high-mobility group (HMG) motifs, 
which share strong similarities across species (Figure 2.8) (Fisher and Clayton 1988, 
Diffley and Stillman 1991, Parisi, Xu et al. 1993, Dairaghi, Shadel et al. 1995, Ohgaki, Kanki 
et al. 2007). Abf2p, the yeast homologue, shares similar features but lacks the 
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carboxy-terminal tail, which is essential for transcription activity. If added to the Abf2p 
protein, the tail is sufficient to convert the protein into a transcriptional activator (Dairaghi, 
Shadel et al. 1995). The Abf2p protein does not have a role in transcription but packages 
mtDNA. This has led many to speculate that TFAM might also have DNA-packaging 
activities. While there is 81% similarity between the mouse and human TFAM peptide 
sequences, human TFAM is a poor activator of mouse mitochondrial transcription in vitro, 
despite its strong capacity for non-specific DNA binding (Ekstrand, Falkenberg et al. 2004). 
Conversely, mouse TFAM cannot substitute for human TFAM.  
  
Figure 2.8 TFAM alignment across a wide range of species. The image shows the 
N-terminal region, HMG boxes 1 and 2, linker region, and the C-terminal tail of TFAM in 
human, mouse, rat, and yeast. The amino acid residues conserved in all 4 species are 
indicated in red. The amino acid residues conserved in 3 species are indicated in blue. The 
dashes indicate sequence gaps due to different amino acid compositions. Abbreviations: 
Human, Homo sapiens; Mouse, Mus musculus; Rat, Rattus norvegicus; and Yeast, 
Saccharomyces cerevisiae. 
Levels of TFAM were altered in a patient suffering from mtDNA depletion and are 
greatly decreased in tissue culture cell lines lacking mtDNA (Larsson, Oldfors et al. 1994). 
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The HMG motifs in TFAM recognise specific mtDNA regulatory sequences and bind 
upstream of the light- and heavy-strand promoters (OL and OH) of the mitochondrial 
genome in a non-specific fashion (Fisher, Lisowsky et al. 1992, Garstka, Schmitt et al. 
2003), while facilitating the synthesis of RNA primers that are necessary to initiate mtDNA 
replication and transcription (Xu and Clayton 1995). 
 TFAM has a higher affinity for DNA near the light strand promoter (LSP) than for 
DNA near the heavy strand promoter (HSP) and stimulates transcription to a much greater 
extent from the LSP than from the HSP in vitro (Fisher and Clayton 1985, Falkenberg, 
Gaspari et al. 2002).  
Early in vitro transcription studies dissecting the human mitochondrial transcription 
machinery showed that, in addition to mitochondrial RNA polymerase, a number of 
transcription factors were necessary for specific transcription initiation from mitochondrial 
promoters (Fisher and Clayton 1988). Low levels of TFAM are sufficient to recruit other 
replication factors (TFBMs and POLRMT) for mtDNA replication in order to increase the 
mtDNA copy number (Seidel-Rogol and Shadel 2002, Alam, Kanki et al. 2003). TFAM is 
absolutely necessary for mtDNA maintenance during development (Larsson, Wang et al. 
1998). Moreover, in addition to its transcription factor activity, TFAM might function to 
protect and package mtDNA (Kanki, Ohgaki et al. 2004, Kang, Kim et al. 2007). Its 
non-specific DNA binding activity shows that TFAM is involved in the transcriptional 
regulation of mtDNA. Studies have shown that the estimated molar ratio between TFAM 
and mtDNA in mammals varies from 1 TFAM molecule per 15-20 bp of mitochondrial 
genome (Alam, Kanki et al. 2003) to 1 TFAM molecule per 35-50 bp of mitochondrial 
genome (Maniura-Weber, Goffart et al. 2004, Cotney, Wang et al. 2007). Additionally, 
several studies have shown that mtDNA is organized in a chromatin-like higher-order 
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structure, of which TFAM might be an integral part (Spelbrink, Li et al. 2001, Alam, Kanki et 
al. 2003, Garrido, griparic et al. 2003). The studies indicate that TFAM could be a stabilizing 
factor in mitochondrial chromatin that plays a role in maintaining chromatin integrity.  
2.17 Manipulation of TFAM Expression Levels in Cellular Models 
Overexpression of TFAM in a human epithelial carcinoma cell line (HeLa) results in 
an increase in mtDNA copy number, whereas knockdown of TFAM results in a gradual 
decrease in mtDNA, which corresponds to the gradual decrease in TFAM protein (Kanki, 
Ohgaki et al. 2004). Thus, TFAM plays an important role in the replication and transcription 
of the mitochondrial genome. Moreover, PGC1α, an upstream regulator of TFAM, 
enhances the expression of TFAM and increases levels of mtDNA (Wu, Puigserver et al. 
1999). Interestingly, while TFAM is absolutely required for in vitro mitochondrial 
transcription, physiologically high levels of TFAM negatively impact mitochondrial 
transcription (Parisi, Xu et al. 1993, Falkenberg, Gaspari et al. 2002, Ylikallio, Tyynismaa et 
al. 2010).  
The amount of TFAM localized to the mitochondria decreases during 
spermatogenesis in humans (Larsson, barsh et al. 1997) and mice (Larsson, Garman et al. 
1996). This has been proposed as a functional mechanism for specifically reducing mtDNA 
copy number in maturing sperm and thereby reducing paternal mtDNA transmission to 
future generations. Interestingly, the reduction in mtDNA copy number resulting from 
reduced TFAM levels is not mirrored by an increase in mtDNA copy number following 
overexpression of TFAM in cultured HEK cells (Maniura-Weber, Goffart et al. 2004). The 
majority of TFAM protein is found in the chromatin fraction of PC3 and SKR1 cells. 
SiRNA-mediated knockdown of TFAM expression downregulates 596 genes, including 
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baculoviral IAP repeat-containing 5 (BIRC5). Conversely, BIRC5 is upregulated when 
TFAM is overexpressed. In contrast, cyclin-dependent kinase inhibitor p21 (CDKN1A) is 
upregulated in TFAM-knockdown cells. Chromatin immunoprecipitation was used to 
demonstrate that TFAM binds the BIRC5 promoter in the nucleus. Among 
TFAM-overexpressing cells,a greater proportion of cells are in the G2/M phase of the cell 
cycle; in contrast, among TFAM-knockdown cells, more are in G1 and fewer are in G2/M. 
This suggests that TFAM localizes to the nucleus and regulates nuclear genes and cellular 
growth in a manner dependent on the level of TFAM expression. The studies demonstrate 
that TFAM overexpression has different effects depending on the cell type. Overall, these 
results suggest that TFAM is involved in mitochondrial biogenesis.  
TFAM-deficient human fibroblasts have low mitochondrial activity (as assessed by 
MitoTracker staining), more hydrogen peroxide, more aerobic glycolysis, and greater 
L-lactate secretion than control cells (Balliet, Capparelli et al. 2011). Furthermore, 
TFAM-deficient fibroblasts promote breast cancer tumor growth in vivo without increasing 
tumor angiogenesis. TFAM-deficient fibroblasts increase the mitochondrial activity of 
adjacent cancerous epithelial cells. This might mean that the downregulation of TFAM 
enhances processes that support tumorigenesis in fibroblasts, including glycolytic 
metabolism. In conclusion, the transcription factor TFAM is indispensable for the 
maintenance of active mammalian mitochondria. TFAM recognizes sequences upstream of 
mitochondrial promoters, and it is absolutely essential for mitochondrial transcription 
initiation.  
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2.18 Animal Models of TFAM Knockdown 
The necessity of TFAM for the maintenance of mtDNA during embryonic 
development has been well documented (Larsson, Wang et al. 1998). Several studies have 
described mouse models of TFAM depletion and TFAM knockout. Larsson et al. first 
established a TFAM knockout mouse model (Larsson, Wang et al. 1998). The 
heterozygous knockout mice exhibited reduced mtDNA copy number in all tissues and 
cardiac respiratory chain deficiency, while the homozygous knockout mice did not develop 
beyond E10.5 because of severe mtDNA depletion and the absence of electron transport 
chain (ETC) function. Homozygous knockout mouse embryos exhibited numerous enlarged 
mitochondria with abnormal cristae and severe mtDNA depletion accompanied by the 
absence of oxidative phosphorylation. At day E8.5, TFAM-deficient embryos were smaller 
than littermate controls; the fomer had delayed neural development, no optic discs, no 
recognizable cardiac structures, and indistinct somites (Larsson, Wang et al. 1998). These 
data indicate that TFAM is critical for controlling the number of mtDNA copies during 
development. 
To clarify the role of TFAM during embryonic development, conditional knockout 
strategies have been used to eliminate TFAM from specific tissues. When TFAM 
expression was specifically disrupted in the heart and muscle of mice, all conditional 
tissue-specific TFAM knockouts presented with mitochondrial disease in the affected tissue, 
resulting from a loss of mtDNA, loss of mitochondrial transcripts, and severe respiratory 
chain deficiency (Wang, Wilhelmsson et al. 1999, Li, Wang et al. 2000, Sorensen, Ekstrand 
et al. 2001, Wredenberg, Wibom et al. 2002, hansson, Hance et al. 2004, Silva, Aires et al. 
2008). As a result, respiratory chain activity decreased dramatically in heart tissue, which 
also exhibited dilated cardiomyopathy and atrioventricular heart conduction blocks (Wang, 
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Silva et al. 2001). Symptoms of heart failure were also identified, such as an increase in 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression and a decrease in 
calcium ATPase 2. However, there was no indication of fibrosis, necrosis, or infiltration of 
inflammatory cells. Apoptosis was detected in hearts with TFAM knockout: levels of TUNEL 
staining (DNA fragmentation), active caspases 3/7, Bax, and Bcl-xL were all elevated. 
Increased levels of GPX and SOD2 activated the oxidative defense mechanism. These 
studies demonstrate that the loss of TFAM results in increased levels of apoptosis (li, Wang 
et al. 2000). When TFAM was eliminated from pancreatic beta cells, the mice developed 
diabetes approximately 5 weeks later (Silva, Kohler et al. 2000). The characteristics of the 
pancreatic beta cells included severe mtDNA depletion, deficient oxidative phosphorylation, 
morphologically abnormal mitochondria, and the inability to release insulin when stimulated 
by glucose. Another study showed that TFAM bound to damaged DNA and that binding 
increased in the presence of p53, suggesting that TFAM has a direct role in the regulation 
of apoptosis (Yoshida, Izumi et al. 2002). TFAM has been shown to bind with high affinity to 
cisplatin-damaged DNA, suggesting that TFAM acts as a recruitment factor for the repair 
mechanism in mitochondria and the nucleus (Yoshida, Izumi et al. 2002). 
Mice with tissue-specific knockout of TFAM in forebrain neurons (MILON mice) 
survived for a surprisingly long time (Sorensen, Ekstrand et al. 2001). When the mice were 
4 months of age, many neurons had severe respiratory chain deficiencies and displayed 
increased sensitivity to excitotoxic stress, but the mice still appeared normal. MILON mice 
died from massive synchronized neurodegenerative events in the neocortex and 
hippocampus at 5-6 months of age without showing any major upregulation of oxidative 
defenses. In cortical neurons that lacked TFAM, apoptosis, DNA fragmentation, and the 
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expression of caspase 3 and 7 increased. In addition, the neurons were more vulnerable to 
excitotoxic stress. 
TFAM has also been specifically knocked out in dopaminergic (DA) neurons, 
generating a transgenic mouse termed ―MitoPark‖ (Galter, Pernold et al. 2010). Two other 
studies generated mice in which the TFAM gene was specifically inactivated in DA neurons 
(Ekstrand, Terzioglu et al. 2007, Ekstrand and Galter 2009). In early adulthood, MitoPark 
mice exhibited a progressive Parkinson‘s disease (PD) phenotype, which slowly impaired 
motor function. They developed progressive symptoms that replicated many of the clinical 
features of PD, such as bradykinesia, rigidity, and abnormal gait. The behavioral 
disturbances correlated with a slow degeneration of the nigro-striatal DA pathway. Primarily, 
DA neurons in the substantia nigra pars compacta were lost; at later stages, the ventral 
tegmental area neurons also succumbed. Many surviving DA neurons displayed abnormal 
morphology and contained alpha-synuclein and ubiquitin-immunoreactive inclusions, 
similar to Lewy bodies observed in PD. This phenotype was accompanied by reduced 
mtDNA expression and respiratory chain defects within midbrain neurons. Intraneuronal 
inclusions also developed, and the cells eventually died (Ekstrand, Terzioglu et al. 2007, 
Galter, Pernold et al. 2010). These findings suggest that mitochondrial dysfunction plays a 
role in PD. Collectively, these studies demonstrate that TFAM is important for mtDNA 
maintenance. Novel strategies to treat mitochondrial disorders and neurological diseases 
will likely involve the manipulation of TFAM expression (Keeney, Quigley et al. 2009). 
These studies also support the experimental rationale for the manipulation of TFAM 
expression in this thesis.  
Mice that lack TFAM in Schwann cells (TFAM-SCKO mice) are viable, but with age 
they develop sensory and motor deficits, resulting from a progressive peripheral 
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neuropathy (Viader, Golden et al. 2011). The mice exhibit early loss of small, unmyelinated 
fibers, followed by demyelination and degeneration of large-calibre axons. Within Schwann 
cells of TFAM-SCKO mice, the mtDNA content was severely depleted, and respiratory 
chain abnormalities were prevalent. However, the proliferation and survival of Schwann 
cells were not affected. Moreover, TFAM has been selectively eliminated from neurons and 
glia of the enteric nervous system (ENS), leading to an 80% reduction in total mtDNA 
content within the ENS, which induced severe respiratory chain deficiencies. Many 
enlarged mitochondria with distorted cristae were found specifically within enteric neurons 
and glia. Mitochondrial dysfunction in these cells resulted in high levels of apoptosis and 
disruption of gastrointestinal motility (Viader, Wright-Jin et al. 2011). The mice (designated 
TFAM-ENSKO) were initially viable, but by 4 weeks of age they were significantly smaller 
than littermate controls. At 6–8 weeks of age, TFAM-ENSKO mice developed abdominal 
distension with mild phenotypic abnormalities. At 10-12 weeks of age, enteric 
neurodegeneration in the proximal small intestine (SI) was profound. Massive dilation of the 
proximal SI, accompanied by contraction of the distal SI, was also observed. By 12 weeks 
of age, the majority of TFAM-ENSKO animals had died. Interestingly, the ENS is not 
uniformly affected in TFAM-ENSKO mice: both regional and neuronal subtype-specific 
effects are observed. This regional and subtype-specific variability in susceptibility to 
mitochondrial defects results in an imbalance of inhibitory and excitatory neurons that likely 
accounts for phenotypes associated with TFAM-ENSKO mice. At 12 weeks of age, the 
relative abundance of inhibitory input to the proximal SI results in distension, while the 
relative loss of inhibitory input to the distal SI leads to constriction. Small molecules (such 
as rotenone and antimycin) were used to inhibit the mitochondrial electron transport chain. 
Disrupting mitochondrial respiration induced neurite degeneration within 24 h and 
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subsequently induced enteric neuron apoptosis. Together, these results suggest that 
mitochondrial defects stimulate axonal degeneration, which precedes the loss of enteric 
neurons. Overall, the study suggests that mitochondria are essential for the survival of 
axonal neurons and for normal peripheral nerve function; that mitochondria play a role in 
Schwann cells, glial cells in the enteric nervous system (ENS); and that mitochondrial 
dysfunction within neurons contributes to human peripheral neuropathies. 
The multiple links between TFAM expression or activity and mitochondrial 
dysfunction suggest that TFAM is an important driving force in neurodegenerative disorders, 
including Parkinson‘s disease, as well as in diabetes and mtDNA depletion disorders, such 
as infantile mitochondrial myopathy, fatal childhood myopathy, skeletal muscle and 
mitochondrial encephalomyopathy, ocular myopathy, exercise intolerance, and muscle 
wasting (Larsson, Oldfors et al. 1994, Poulton, Morten et al. 1994, Siciliano, Mancuso et al. 
2000, Tessa, Manca et al. 2000, Choi, Kim et al. 2001, Belin, Bjork et al. 2007). 
2.19 Role of the Mitochondrion during Pre-implantation Stages: Introduction 
The pre-implantation stages of development include the fertilized zygote; the two-, 
four-, eight-, and 16-cell morula (pre-embryo); and the blastocyst. The amount of mtDNA 
present during these stages depends on the number of mtDNA copies in the oocyte at 
fertilization, because mtDNA replication is initiated only post-implantation. As such, the 
mtDNA copy number at fertilization is an important determinant of subsequent 
developmental success (Spikings, Alderson et al. 2007), and a certain minimum mtDNA 
copy number is required for an oocyte to reach implantation (Spikings, Alderson et al. 2007). 
In addition, embryonic mtDNA copy numbers decrease between the 2- and 8-cell stages, 
suggesting an active mtDNA degradation process. In mature murine and human oocytes, 
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the critical threshold is estimated at 100,000 mtDNA copies (Piko and Taylor 1987, Reynier, 
May-Panloup et al. 2001, Santos, El Shourbagy et al. 2006). It has also been shown that 
low levels of mtDNA (or mtDNA mutations) in the ovary are associated with ovarian 
dysfunction (May-Panloup, Chretien et al. 2005). 
2.20 Mitochondrial Bottleneck during Pre-implantation Stages 
During the earliest stages of development (between fertilization and implantation), 
the mtDNA inherited by an organism appears to pass through a genetic bottleneck. This 
implies that there is selective elimination of mitochondrial genomes, which ensures that 
only a small number of mtDNA molecules are passed to the next generation.  
Very little mitochondrial replication occurs during the pre-implantation stages of 
development (Piko and Matsumoto 1976, Ebert, Liem et al. 1988) (Figure 2.9). The mtDNA 
copy number within a single primordial germ cell (PGC) is ~1350–3600 at 7.5-13.5 days 
post-coitum (Cao, Shitara et al. 2007). To establish the number of mtDNA molecules within 
PGCs, Wai et al. (2008) used OCT4-GFP to identify these cells. They measured a low 
mtDNA copy number in early PGCs, suggesting that a mitochondrial bottleneck occurs in 
the early PGC. Furthermore, the number of mtDNA copies in the female germ line is lower 
than in male germ cells, suggesting that the mitochondrial genetic bottleneck is less 
important in the male germ line than in the female one. However, mtDNA mutations can 
alter sperm motility (Spiropoulous, Tumbull et al. 2002, Cree, Samuels et al. 2008) but do 
not affect fertility (Wai, Ao et al. 2010). Moreover, partial knockdown of TFAM in blastocysts 
does not affect fertilization or pre-implantation development in mice, but it does alter 
post-implantation embryonic viability. In contrast, male fertility is not affected by TFAM 
knockdown (Wai, Ao et al. 2010). 
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Figure 2.9 Changes in mtDNA copy number per cell during implantation stages. This figure 
is modified from (Wai, Ao et al. 2010). 
In theory, all mitochondrial genomes within an organism should be identical. 
However, because mutations to mtDNA are inherited from the maternal line, wild-type and 
mutant mtDNA can coexist (heteroplasmy) (Figure 2.10). Examination of heteroplasmic 
mice and humans has revealed that mtDNA genotypes shift extremely rapidly in offspring 
and can even return to homoplasmy within a few generations (at least in some progeny) 
(Kaneda, Hayashi et al. 1995, Marchington, Hartshorne et al. 1997, Inoue, Nakada et al. 
2000, Fan, Waymire et al. 2008). The number of heteroplasmic mutations varies widely 
among offspring, suggesting that mutant mtDNA molecules are eliminated during 
development. 
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Figure 2.10 The possible origin of pathogenic mtDNA deletions. This figure is modified from 
(Chinnery, DiMauro et al. 2004).  
 
Overall, these studies indicate that a drastic reduction in mtDNA copy number does 
not occur in PGCs. Rather, the genetic bottleneck associated with mtDNA seems to result 
from the selective replication of a subpopulation of mitochondrial genomes. This is 
accompanied by strong selection against mutations within the germ line. This has been 
demonstrated in studies of an ND6 frame-shift mutation (Fan, Waymire et al. 2008) and a 
large deletion (Sato, Nakada et al. 2007, Cao, Shitara et al. 2009). 
It has been proposed that primordial female germ cells contain a small number of 
mtDNA molecules to permit rapid genetic drift toward populations of pure mutant or pure 
wild-type mtDNA. A process for selecting mitochondrial mutations has been proposed for 
mice and humans (Kaneda, Hayashii et al. 1995, Marchington, Hartshorne et al. 1997, Fan, 
Waymire et al. 2008, Inoue, Noda et al. 2010). Although the mechanism by which 
deleterious mtDNA mutations are recognized and eliminated remains unclear, selection 
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might be based on mitochondrial ‗fitness‘. For example, mitochondria that produce the most 
ROS undergo apoptosis or mitochondrial turnover. Understanding the genetic bottleneck 
associated with mitochondria will facilitate the development of therapeutic strategies that 
block the transmission of mitochondrial disease from mother to progeny and ensure the 
safety of hESC-derived therapeutic agents. 
2.21 Analysis of Mitochondrial Behavior in Stem Cells 
Mitochondrial properties have been used to assess oocyte competence during 
oocyte development in various species, including Xenopus laevis, Artemia franciscana, 
Equus caballus, Sus scrofa, Mus musculus, and Rattus norvegicus (Vallejo, Lopez et al. 
1996, El Shourbagy, Spikings et al. 2006, Facucho-Oliveira, Alderson et al. 2007, 
Kameyama, Filion et al. 2007, Mohammadi-Sangcheshmeh, Held et al. 2011). Changes in 
mitochondrial morphology from the late morula to the early post-implantation stages of 
embryogenesis have been closely examined in monkeys and rats (Shepard, Muffley et al. 
2000). During this time, the number of cristae increases, but the cristae appear tubular or 
vesicular. New cristae begin to form from blebs of the inner mitochondrial membrane, 
resulting in a lamellar appearance. Mitochondrial properties have also been investigated in 
a variety of species, using adult monkey stem cells, porcine oocytes, mESCs, hESCs, and 
hiPSCs (St John, Ramalho-Santos et al. 2005, Cho, Kwon et al. 2006, St John, Amaral et al. 
2006, Spikings, Alderson et al. 2007, Armstrong, Tilgner et al. 2010).  
The extent to which the analysis of mitochondria in human pluripotent stem cells 
reflects the inner cell mass of the blastocyst remains to be determined, given that hESCs 
and iPSCs are usually cultured for long periods of time in vitro before analysis. It is likely 
that mitochondrial properties shift in culture as mitochondria adapt to the culture conditions. 
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Indeed, hESCs grown in hMSC-CM (conditioned medium derived from human 
mesenchymal stem cells) or mTeSR exhibited lower mitochondrial membrane potential (Δψ) 
and lower expression of mtDNA-encoded genes and mitochondrial biogenesis-related 
genes then cells grown in hFF-CM (conditioned medium derived from human foreskin 
fibroblasts) (Ramos-Mejia, Bueno et al. 2012). Moreover, mtDNA and the bioenergetics 
profiles of hESCs and hiPSCs can be altered to provide a growth advantage for culture 
passage (Maitra, Arking et al. 2005, Prigione, Lichtner et al. 2011). 
Prigione and co-workers (2011) have shown that hiPSC lines exhibit varying levels 
of homoplasmic and heteroplasmic mtDNA mutations and display a number of point 
mutations, but not large-scale rearrangements (e.g. long insertions or deletions) (Prigione, 
Lichtner et al. 2011). These studies suggest that the accumulation of mitochondrial 
mutations correlates with the level of mitochondrial damage and could affect the 
differentiation ability of neural stem cells and hematopoietic stem cells (Norddahl, Pronk et 
al. 2011, Wang, Esbensen et al. 2011).  
Overall, undifferentiated hESCs and hiPSCs share similar features (Oh, Kim et al. 
2005, St John, Ramalho-Santos et al. 2005, Cho, Kwon et al. 2006, Prigione, Lichtner et al. 
2011, Panopoulos, Yanes et al. 2012). These features include: (1) high expression of 
pluripotency markers, (2) a low mtDNA copy number and a low level of 
mitochondrial-encoded genes, (3) a low level of mitochondrial complex activities and 
mitochondrial biogenesis, (4) a spherical and immature mitochondrial structure (i.e. poorly 
developed cristae) located around the nucleus, (5) restricted oxidative capacity, including a 
lower mitochondrial membrane potential and low levels of oxygen consumption, ROS 
production, and intracellular ATP generation, (6) a greater reliance on glycolysis (anerobic 
metabolism) than on oxidative phosphorylation (aerobic metabolism) for energy generation, 
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(7) low levels of intracellular peroxide and mitochondrial superoxide, and (8) defensive 
systems, including glutathione S transferase (GSTA3), glutathione peroxidise 2 (GPX2), 
and heat shock protein 1 (HSPA1B and HSPB)1 (Armstrong, Tilgner et al. 2010). 
hESCs and hiPSCs have a similar metabolic status. They are more reliant on 
anaerobic metabolism, which breaks down glucose to form two molecules of pyruvic acid 
and generates ATP without oxygen in a manner that is less efficient than ATP production 
through oxidative phosphorylation. Studies have shown that a stimulator 
(D-fructose-6-phosphate, F6P) of anaerobic metabolism improves the reprogramming from 
somatic cells (aerobic metabolism) by shifting to hiPSCs, which have an hESC-like 
morphology (anaerobic metabolism), when compared to the effects of an anaerobic 
metabolism inhibitor (2-deoxy-D-glucose, 2-DG) (Panopoulos, Yanes et al. 2012). However, 
other studies have shown that inhibition of mitochondrial complexes (i.e. using a Complex 
III inhibitor such as antimycin) in hESCs with low mitochondrial activities does not alter the 
expression of pluripotency markers and that mitochondrial morphology is immature (Varum, 
Momcilovic et al. 2009). Moreover, inhibition of oxidative phosphorylation in mitochondria 
(i.e. with protonophore carbonyl cyanide m-chlorophenylhydrazone, CCCP, which 
depolarizes the mitochondrial membrane potential) does not affect pluripotent gene 
expression. The cells still use similar energy sources from anaerobic metabolism (i.e. low in 
oxygen consumption and ATP production and more glycolytic flux), have a similar 
methylation pattern, and are able to differentiate into three different lineages in mESCs and 
hESCs (Mandal, Lindgren et al. 2011). Therefore, glycolysis is required to support the 
proliferation of self-renewing ESCs.  
hESCs and hiPSCs have a similar metabolic status, although small differences exist. 
hESCs have more unsaturated fatty acid metabolites (i.e. ω-6 and ω-3 fatty acids, 
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arachidonic acid, linoleic acid, docosapentaenoic acid, and adrenic acid) than do hiPSCs, 
which generate energy by breaking down fatty acids in the beta-oxidation pathway to 
acetyl-coA, which then enters the Citric Acid Cycle (TCA) in mitochondria (Panopoulos, 
Yanes et al. 2012). This suggests that inhibition of oxidative pathways is important for 
maintaining pluripotency in pluripotent stem cells. Early in vivo and in vitro studies 
confirmed that the metabolic pathway from lipids is significantly upregulated during oocyte 
maturation. There is a higher concentration of unsaturated lipids, such as linoleic acids and 
palmitic acid, and a lower concentration of total saturates in human preimplanation 
embryos. The concentrations increase upon oocyte differentiation in the course of embryo 
development, indicating that energy generation plays an essential role in the maturation of 
oocytes (Waterman and Wall 1988). Unsaturated fatty acids induce the expression of 
uncoupled proteins (UCPs). UCP2 has been found in the inner mitochondrial membrane; it 
is able to uncouple the oxidation of substrates in the electron transport chain from ATP 
synthesis, thus dissipating energy as heat and potentially affecting metabolic efficiency 
(Pecqueur, Bui et al. 2008). Pecqueur and Bui‘s study demonstrated that undifferentiated 
hESCs express more UCP2 than do differentiated hESCs and that the level of UCP2 
expression does perturb the metabolic transition or impair hESC differentiation.  
Gain-of-function (GOF) UCP2 has several effects: (1) it promotes mitochondrial fatty 
acid oxidation but does not cause a major metabolic shift (i.e. there is no significant change 
in oxygen, glucose consumption, ATP, or lactate production), (2) it does not affect 
three-lineage differentiation, but does alter the quantity and quality of embryonic bodies 
(EBs), (3) it reduces cell proliferation and viability, (4) it increases ribose generation from 
glucose in undifferentiated hESCs, relative to that in differentiated hESCs, and (5) it 
enhances resistance to glucose starvation by inducing autophagy. These findings indicate 
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that UCP2 has differential effects on proliferation and survival in undifferentiated and 
differentiated hESCs because of differences in the cells‘ metabolism. Expression of GOF 
UCP2 might help shunt pyruvate away from oxidation in mitochondria and towards the 
pentose phosphate pathway (PPP) by upregulating glycolytic flux. Loss-of-function (LOF) 
UCP2 also has several effects: (1) it maintains the expression of pluripotency markers, (2) it 
improves cell proliferation, and (3) it facilitates the metabolic transition from fatty acid 
oxidation to oxidative metabolism (i.e. reduced lactate and ATP production). This suggests 
that loss of UCP2 reduces the metabolic activity of hESCs but does not affect their 
pluripotency status. Overall, these findings demonstrate that UCP2 acts as a metabolic 
regulator of hESC energy metabolism by preventing mitochondrial glucose oxidation and 
facilitating glycolysis via a substrate shunting mechanism in order to maintain the 
pluripotency of undifferentiated hESCs or facilitate early differentiation. This suggests that 
mitochondria are directly involved in controlling the pluripotency of hESCs. 
The mitochondrial membrane potential (Δψ) has been used as a measure of 
mitochondrial competence during development. One study observed an increase in 
mitochondrial membrane potential, evaluated using JC-1, during the preimplantation stages 
(Acton, Jurisicova et al. 2004). This suggests that the mitochondrial membrane potential 
progressively changes during the stages of development, reflecting constant fusion and 
fission and demands for different amounts of energy. Schieke and co-workers (2008) 
demonstrated a correlation between the mitochondrial membrane potential and 
differentiation ability in mESCs (Schieke, Ma et al. 2008). mESCs colonies have different 
levels of mitochondrial metabolism; those with a higher ΔΨ have a higher overall metabolic 
rate. Stem cells with a high Δψ also exhibit high levels of tumor formation, lactate 
production, oxygen consumption, and ATP production. In contrast, stem cells with a low Δψ 
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are more likely to differentiate into mesodermal lineage cells (Schieke, McCoy et al. 2008). 
Under serum-starvation conditions, mESCs with a low Δψ are more likely to be in early G1 
phase, whereas those with a higher Δψ are more likely to be in late G1 phase (Schieke, 
McCoy et al. 2008). This suggests that changes in the mitochondrial membrane potential 
correlate with pluripotency and/or the efficiency of differentiation.  
 
2.22 Mitochondrial Property Changes upon Differentiation  
Different tissues have different energy demands, and mitochondrial morphology can 
therefore vary widely. The number and structure of mitochondria in skeletal muscle, heart, 
and liver, can vary widely; developing heart cells contain larger mitochondria than other 
cells, such as skin or neural tubes. However, the protein compositions of mitochondria in 
different tissues are similar (Forner, Foster et al. 2006). Mitochondrial morphology in 
cardiac myocytes and neurons can change during the aging process, possibly because 
oxidative damage leads to mitochondrial damage and a reduction in the mitochondrial 
membrane potential (Terman, Dalen et al. 2004).  
Several studies have investigated the relationship between mitochondrial properties 
and cell-type specific differentiation, such as neurogenesis, osteogenesis, adipogenesis, 
and cardiogenesis (Cordeau-Lossouam, Vayssiere et al. 1991, Komarova, Ataullakhanov 
et al. 2000, St John, Ramalho-Santos et al. 2005, Chung, Dzeja et al. 2007, Ducluzeau, 
Priou et al. 2011). Several methods can be used to stimulate hESC differentiation, such as 
the formation of embryoid bodies (St John, Ramalho-Santos et al. 2005, Cho, Kwon et al. 
2006). Differentiating hESCs have a greater mitochondrial mass and a higher mtDNA copy 
number when compared with undifferentiated hESCs (Cho, Kwon et al. 2006, Chung, Dzeja 
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et al. 2007, Saretzki, Walter et al. 2008). Common changes in mitochondrial properties 
include: (1) upregulation of mitochondrial-encoded and mitochondrial biogenesis-related 
genes (TFAM and POLG) (Facucho-Oliveira, Alderson et al. 2007, Facucho-Oliveira and St 
John 2009, Armstrong, Tilgner et al. 2010), (2) more mature mitochondrial morphology (i.e. 
distinct cristae and a dense matrix), (3) upregulated mitochondrial respiratory activity and 
increased ATP production (Cho, Kwon et al. 2006, Ramalho-Santos, Varum et al. 2009), 
and (4) a metabolic shift from glycolysis (anaerobic metabolism) to oxidative 
phosphorylation (aerobic metabolism) in spontaneous or induced-differentiation cells. The 
same metabolic shift has been observed during cardiomyogenesis from hESCs (Chung, 
Dzeja et al. 2007). During cardiomyogenesis, the mitochondrial morphology changes from 
spherical, cristae-poor, and peri-nuclear to elongated with abundant and well-organized 
cristae and a cytosolic pattern in cardiomyocytes. The metabolic shift from anaerobic to 
aerobic metabolism during cardio-differentiation indicates that the maturation of 
mitochondrial properties is essential during cardiomyogenesis. 
 
2.23 Autophagy: Introduction 
Autophagy is derived from the Greek words auto, which means self, and phagy, 
which means to eat. The autophagic process breaks down cellular components and plays a 
particularly important role during periods of starvation and when organelles are damaged. 
Autophagy allows cells to maintain a critical balance between the synthesis, degradation, 
and recycling of cellular structures. This balance is important during development, 
homeostasis, and cell proliferation. Three types of autophagy have been described: 
chaperone-mediated, microautophagy, and macroautophagy (Cuervo 2004). 
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Chaperone-mediated autophagy involves the direct translocation of proteins with specific 
protein motifs across lysosomal membranes; chaperone proteins that interact with 
lysosomal membrane proteins facilitate the translocation. Microautophagy is the direct 
intake of cytoplasm by invagination of lysosomal membranes. Macroautophagy, often 
referred to simply as autophagy, involves the formation of double membrane vesicles 
around organelles and other cytoplasmic components that then fuse with lysosomes 
(Levine and Klionsky 2004).  
Autophagosomes are double-membrane cytosolic vesicles that encapsulate and 
break down cellular components to supply nutrients to the cell (Tolkovsky, Xue et al. 2002). 
Autophagy is a major mechanism by which starving cells reallocate nutrients from 
non-essential to essential processes. However, insufficient or excessive regulation of 
autophagy can cause cell injury (Levine and Yuan 2005). Therefore, appropriate regulation 
of autophagy is essential.  
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Figure 2.11 Stages of autophagosome formation in selective and non-selective pathways. 
Autophagosome formation can be stimulated by the environment or drugs. Following an 
inductive signal, autophagosome formation, mitochondrial engulfment, mitochondrial 
breakdown, and export of metabolic components occur in both pathways. This figure is 
modified from (Yen and Klionsky 2008). 
 
The process of autophagy involves five discrete steps: (1) induction at the 
pre-autophagosomal structure (PAS), (2) growth and elongation of the isolation membrane 
of autophagosomes, (3) sequestration of cargo within the autophagosome, (4) fusion with 
the lysosome/vacuole to form the autolysosome, and (5) degradation of the cellular 
components by lysosomal proteases and release of the metabolic products into the 
cytoplasm (Kundu and Thompson 2008) (Figure 2.11). The autophagosome membrane 
was initially thought to derive from ribosome-free regions of the rough endoplasmic 
reticulum (RER). However, other studies have presented evidence supporting that 
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autophagosome membranes derive from the RER (Suzuki, Kirisako et al. 2001, McEwan 
and Dikic 2010, Rambold and Lippincott-Schwartz 2011). Thus the origin of phagosome 
membranes remains to be determined.  
The majority of the molecular mechanisms and genes that control autophagy (ATG 
genes) were discovered in a yeast model (Ohsumi and Mizushima 2004), but the 
mechanism of mitochondrial autophagy (mitophagy) remains to be investigated. Atg 
proteins are categorized by function. For example, Uth1p, which resides in the outer 
mitochondrial membrane, is involved in autophagic induction (Kissova, Deffieu et al. 2004). 
Atg9 functions in membrane protein recycling. The Atg12-Atg8 complex, comprising a pair 
of ubiquitin-like proteins, promotes vesicle extension and completion (Yorimitsu and 
Klionsky 2004). Studies have shown that Atg3, 5, and 7 participate in quality control and 
cell remodelling during T-lymphocyte and adipocyte differentiation (Lafontan 2008, Pua, 
guo et al. 2009, Jia and He 2011). During the oocyte to embryo transition, autophagy is 
activated within four hours of fertilization. The degradation of maternal proteins and the 
regeneration of amino acids and proteins is important for the subsequent differentiation of 
the fertilized oocyte (Mizushima and Levine 2010). During the recycling of cytosolic material, 
autophagy might provide building blocks for cells to generate ATP. Autophagy also plays a 
crucial role in programmed cell death during mammalian morphogenesis (Qu, Zou et al. 
2007). Beclin1 and Atg5 might be essential for cavitation, the process by which the 
proamniotic cavity is formed during embryonic development. Collectively, these data 
suggest that autophagy provides cells with ATP for essential processes and contributes to 
tissue sculpting during embryonic development. 
The Atg12-Atg5-mediated pathway for the sequestration and formation of 
autophagosomes in yeast involves the binding of Atg16, which translocates to the isolation 
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membrane and functions as a linker in the formation and elongation of autophagosomes 
(Ohsumi and Mizushima 2004, matsushita, Suzuki et al. 2007). Studies suggest that the 
yeast protein Atg32 is a transmembrane receptor that directs autophagosome formation to 
mitochondria for mitophagy. Atg32 localizes on mitochondria and binds to the adaptor 
protein Atg11 during selective types of autophagy; it is then recruited to and imported into 
the vacuole along with mitochondria (Kanki and Klionsky 2009, Tolkovsky 2009, Okamoto 
and Kondo-Okamoto 2012). This suggests that mitochondria are specifically targeted for 
degradation. In some instances, mitochondria have been shown to be ubiquitin-tagged for 
autophagy. This is the case for sperm mitochondria that are eliminated after oocyte 
fertilization (Sutovsky, Moreno et al. 2000). Although it has been suggested that 
mitochondria are selected for autophagy depending on the level of oxidative damage to 
their membrane, this hypothesis has not been investigated (Terman and Brunk 2004).  
LC3 is a mammalian autophagosomal orthologue of the yeast protein Atg8. In 
mammalian cells, Atg4B cleaves newly synthesized pro-LC3 into its cytosolic form, LC3-I, 
thus exposing the C-terminal glycine 120. LC3-I is then activated by Atg7p, an E1-like 
enzyme, and conjugated to phosphatidylethanolamine (PE) by Atg3p, an E2-like enzyme 
(Kabeya, Mizushima et al. 2000, Tanida, Ueno et al. 2004). LC3-II (16 kDa) has slightly 
higher mobility than LC3-I (18 kDa) when run on SDS-PAGE gels. LC3-II is selectively 
incorporated into forming and newly formed autophagosomes. After the autophagosome 
fuses with the lysosome, LC3-II is trapped on the inner surface of the double membrane 
autophagosome and degraded when deconjugated from PE by Atg4 (Mizushima, 
Yamamoto et al. 2004).  
Autophagy has been demonstrated during neuronal, adipocyte, and T-lymphocyte 
differentiation. A reduction in autophagic activity abolishes differentiation or downregulates 
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differentiation in adipocyte cells, which exhibit decreased expression of differentiation 
markers, lipid accumulation, and low levels white adipose, leading to a lean body mass 
(Zeng and Zhou 2008, Singh, Xiang et al. 2009, Zhao, Huang et al. 2010). Moreover, 
autophagy has been reported to play a crucial role in T-lymphocyte development (Pua, Guo 
et al. 2009). The essential role of autophagy in maintaining T-lymphocyte survival and 
proliferation has been demonstrated using mouse models with knockout of Atg5 or Beclin 1, 
which possess a Bcl-2 homology 3 domain (BH3-only Atg6 in yeast). Loss of Atg5 or Beclin 
1 results in T-lymphocyte deficiency and cell death, with disruption of T-cell proliferation 
and a reduction in the number of mature total thymocytes and peripheral T and B 
lymphocytes (Pua, Guo et al. 2009, Arsov, Adebayo et al. 2011).  
Dysregulated autophagy has been linked to neurodegenerative diseases and cancer, 
but the mechanisms are not well understood. Autophagy is thought to be essential for 
healthy aging and longevity. The target of rapamycin (TOR) pathway, which regulates 
autophagy, is one of three highly conserved signaling pathways that affect lifespan (Yen 
and Klionsky 2008, Eisenberg, Knauer et al. 2009).  
2.24 The Mammalian Target Of Rapamycin Signaling Pathway: (A) How does the 
mTOR pathway work? 
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates 
autophagy through its downstream effector, S6 kinase (Codogno and Meijer 2005, Kapahi, 
Chen et al. 2010). mTOR phosphorylates S6K on T389, leading to S6K activation and the 
phosphorylation of its downstream substrate, S6 (Figure 2.12). Generally, mTOR plays a 
central role in the ability of cells to sense growth signals, amino acid levels, and energy 
levels and make decisions that affect protein translation, cell growth, and proliferation 
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(Mizushima and Levine 2010). The mTOR complex comprises mTORC1 and mTORC2, 
which share three common subunits (mTOR, mlST8, DEPTOR). In addition, mTORC1 has 
two specific proteins (RAPTOR and PRAS40), while mTORC2 has three specific proteins 
(RICTOR, mSIN1, and Protor-1) (Shahbazian, Roux et al. 2006, Yang and Guan 2007). 
Activation of mTORC1 leading to the phosphorylation of S6 kinase and the inactivation of 
the translation repressor 4E-BP suppresses autophagy, activates mitochondrial 
metabolism, and inhibits ESC differentiation (Tee and Blenis 2005, Shahbazian, Roux et al. 
2006, Yang and Guan 2007). Rapamycin is a macrolide fungicide that inhibits mTOR 
signaling by binding to FK506-binding protein 12 (FKBP12) (Hidalgo and Rowinsky 2000). 
mTORC1 is more sensitive than mTORC2 to short-term exposure to rapamycin (Kapahi, 
Chen et al. 2010).  
 
Figure 2.12. The mTOR signaling pathway. TSC1/2 and Rheb are the major upstream 
regulators of mTORC1. Several external signals affect the mTOR signaling pathway, such 
as low energy. When the intracellular ATP concentration is low, AMPK becomes active and 
subsequently activates the TSC2/1 complex and mTORC1 downstream pathway to 
regulate cellular energy levels. This figure is modified from (Yang, Yang et al. 2008). 
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The Mammalian Target Of Rapamycin Signaling Pathway: (B) How does the mTOR 
pathway respond to and regulate energy demand? 
The mTOR signaling pathway also cooperates with the tuberous sclerosis complex 
(TSC) to control mitochondrial biogenesis and energy metabolism. TSC-mTOR is an 
energy-sensing pathway. In ATP-depleted conditions, TSC2 forms a complex with TSC1 
and activates AMP activated kinase (AMPK) to change the intercellular ATP/AMP ratio 
(Zhou, Su et al. 2009).  
One study has demonstrated that the TSC-mTOR pathway is essential for 
maintaining quiescence and ROS production in HSCs (Chen, Liu et al. 2008). Depletion of 
TSC1 in HSCs results in a shift from quiescent status to upregulation of mitochondrial 
biogenesis and ROS production. Inhibition of mTOR expression by rapamycin leads to a 
reduction in the interaction between mTOR, raptor, and the rapamycin-dependent 
transcription factor ying-yang1 (YY1), which interacts with PGC1α (Cunningham, Rodgers 
et al. 2007). Disruption of YY1 expression decreases mitochondrial-encoded gene 
expression and respiration (i.e. oxygen consumption), which is consistent with decreased 
PGC1α expression (Cunningham, Rodgers et al. 2007). During the reprogramming of 
fibroblasts to cells with an ESC-like morphology by reprogramming factors, cells transition 
to a state with a lower mitochondrial number and an immature mitochondrial structure and 
shift from aerobic to anaerobic metabolism. It has been suggested that the mTOR signaling 
pathway affects mitochondrial dynamics to segregate mitochondria by targeting defective 
mitochondria to autophagosomes (mitophagy).   
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The Mammalian Target Of Rapamycin Signaling Pathway: (C) How does the mTOR 
pathway relate to mitochondrial biogenesis and stem cell behavior? 
The mTOR signaling pathway regulates metabolism, cell growth, and ATP/ADP 
status in cells. Inhibition of mTOR activity by rapamycin in either HEK 293 cells or mESCs 
alters mitochondrial biogenesis to produce effects such as low expression of 
mitochondrial-related phosphoproteins, low oxygen consumption, loss of mitochondrial 
membrane potential, loss of ATP synthetic capacity, reduced lactate production, slower 
rates of proliferation, and disruption of the Δψ (Schieke, Phillips et al. 2006, Schieke, 
McCoy et al. 2008). When mESCs were sorted into two populations with low and high 
mitochondrial membrane potential, the population with a low mitochondrial membrane 
potential was found to reside in early G1 phase, whereas the population with high 
mitochondrial membrane potential resided in late G1 phase and exhibited higher mTOR 
expression, respiration, and oxidative capacity (Schieke, Ma et al. 2008). Indeed, the 
mTOR signaling pathway plays a role in maintaining the self-renewal and pluripotency of 
hESCs (Zhou, Su et al. 2009, Easley, Ben-Yehudah et al. 2010).  
Inhibition of the mTOR pathway by rapamycin represses mTOR/S6k, which 
enhances osteoblastogenesis, and promotes differentiation into mesoderm and endoderm 
lineages (Zhou, Su et al. 2009, Lee, Yook et al. 2010). This indicates that activation of the 
mTOR pathway can promote differentiation in hESCs. Disruption of S6K-mediated 
transcription in the mTORC1 pathway by rapamycin in undifferentiated hESCs does not 
alter cell viability or the expression of pluripotency markers, whereas p70S6K 
overexpression in hESCs induces hESC differentiation (Easley, Ben-Yehudah et al. 2010). 
The level of mTOR/p70S6K might be a crucial factor for maintaining pluripotency status in 
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undifferentiated hESCs and for maintaining high levels of protein synthesis during 
differentiation.  
mTOR signaling allows cells to survive by increasing autophagy, thereby promoting 
the degradation of internal proteins and organelles to generate the energy and raw 
materials necessary for survival when extracellular nutrients are scarce. mTOR signaling 
allows cells to grow when there are enough extracellular nutrients. Therefore, nutrient 
depletion or inhibition of TOR with the drug rapamycin induces autophagy. 
 
2.25 Selective Autophagy and Mitophagy 
Mitophagy is an autophagic process that selectively degrades damaged 
mitochondria (Kim, Lee et al. 2010). The selective degradation of mitochondria by 
autophagosomes, called mitophagy, occurs in response to different conditions, such as 
nutrient depletion, mitochondrial dysfunction, or red blood cell maturation. During nutrient 
depletion or caloric restriction, which can increase longevity, Uth1p (Atg1) activates 
autophagosome formation to break down unnecessary organelles for use as building 
blocks and nutrients and to increase the removal of oxidatively damaged mitochondria and 
mutated mtDNA (Camougrand, Kissova et al. 2004, Kissova, Deffieu et al. 2004, Keeney, 
Quigley et al. 2009).  
Mitochondrial damage or dysfunction is one of the main inducers of mitophagy. 
Increased mitochondrial dysfunction might occur in the post-mitotic cells of aged organisms 
that exhibit abnormal mitochondrial morphology (i.e. swelling, low number of cristae, and 
destruction of inner membranes) (Ermini 1976, Beregi, Regius et al. 1988, Terman 1995). 
Autophagic events decrease during aging; ATP production and respiration are lower in 
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aged animals than in younger ones (Terman 1995). There is frequent mitochondrial 
turnover in tissues such as the brain, heart, liver, and kidney (Menzies and Gold 1971). 
Mitochondria are more vulnerable to oxidative damage and have less robust DNA repair 
systems when compared with the nucleus (Yakes and Van Houten 1997, Gredilla, Bohr et 
al. 2010). Damage to mtDNA could result in the synthesis of abnormal mitochondrial 
proteins or disrupt synthesis altogether, which would exacerbate mitochondrial dysfunction. 
In this process, damaged mitochondria (i.e. those with a compromised Δψ or 
overproduction of ROS) release signals that promote uptake by autophagosomes, 
triggering degradation (Sandoval, Thiagarajan et al. 2008). This provides a mechanism for 
mitochondrial quality control and a general, controlled cytoprotective response.  
In neurodegenerative diseases, for example, the cell benefits from mitophagy 
through the selective removal of damaged and free radical-generating mitochondria. 
Parkinson‘s disease (PD) is a common neurodegenerative movement disorder 
characterized by tremors, muscular rigidity, bradykinesia, and postural instability 
(Bossy-Wetzel, Schwarzenbacher et al. 2004). PD may be induced by an environmental 
toxin, 1-methyl-4-phenylpyridinium (MPP+), an inhibitor of Complex I in the electron 
transport chain. A precursor of MPP+, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), can also induce Parkinsonism (Abou-Sleiman, Muqit et al. 2006), as can genetic 
inheritance of PD-related genes (e.g. Parkin and PINK1), for example, in 
autosomal-recessive juvenile-onset Parkinsonism (ARJP) (Bossy-Wetzel, 
Schwarzenbacher et al. 2004, Choi, Woo et al. 2008, Harvey, Wang et al. 2008, Mellick, 
Siebert et al. 2009). Studies of the mitochondrial proteins Parkin and PINK1 have 
established a direct link between defective mitochondria and mitophagy (McBride 2008, 
Narendra, Tanaka et al. 2008, Lutz, Exner et al. 2009). Parkin (encoded by PARK2) is an 
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E3 ubiquitin ligase and is the first protein known to bind eight Zn2+ ions. Binding to zinc 
through conserved cysteine-rich motifs is essential for structural maintenance, an 
observation that explains the significance of the cysteine-based ARJP mutations found 
throughout Parkin (Giasson and Lee 2001, Hristova, Beasley et al. 2009). Studies have 
shown that loss of Parkin function results in vulnerability to oxidative damage, 
dopaminergic neuron loss, and abnormal mitochondrial structure (i.e. swollen, distorted 
mitochondrial morphology and fragmented cristae). Loss-of-function mutations in Parkin 
decrease ATP production and enhance fission activity, resulting in cell death (Greene, 
Whitworth et al. 2003, Whitworth, Theodore et al. 2005, Lutz, Exner et al. 2009). Loss of 
Parkin activity also results in the loss of a cellular monitor of dysfunctional mitochondria, 
whereas overexpression of Parkin could help to protect against toxicity and mark damaged 
mitochondria for degradation (Petrucelli, O‘Farrell et al. 2002, McBride 2008, Narendra, 
Tanaka et al. 2008).  
Phosphatase and tensin homolog-induced putative kinase 1 (PINK1, also known as 
PARK6) is a mitochondrial serine/threonine kinase that functions as a sensor of 
mitochondrial or cellular stress and is thought to prevent mitochondrial dysfunction 
(Bossy-Wetzel, Schwarzenbacher et al. 2004, McBride 2008). Studies have shown that 
loss-of-function mutations in PINK1 result in defects in mitochondrial morphology, 
dynamics, and function. This leads to an imbalance in mitochondrial fusion and fission in 
Drosophila (Lutz, Exner et al. 2009). Moreover, high levels of PINK1 kinase activity are 
important for the translocation of Parkin to mitochondria, whereas overexpression of Parkin 
alone results in a cytosolic localization (Yang, Ouyang et al. 2008, Geisler, Holmstrom et al. 
2010, Vives-Bauza, Zhou et al. 2010). Studies have demonstrated that Parkin targets 
dysfunctional mitochondria and recruits PINK1 to damaged mitochondria with low 
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membrane potential to promote autophagic degradation after treatment of cells with CCCP 
(Narendra, Jin et al. 2010). The Parkin-PINK1 mechanism depends on voltage-dependent 
inhibition in the clearance process. Through the proteolytic cleavage function of PINK1, 
cleaved fragments are cleared by the proteasome (Narendra, Jin et al. 2010).  Overall, 
signals such as an increase in ROS production or a reduction in Δψ recruit the cytosolic 
form of Parkin and PINK1 to fragmented mitochondria, which promotes the engulfment of 
mitochondria by autophagosomes for degradation (McBride 2008, Narendra, Tanaka et al. 
2008).  
Mitophagy plays an essential role during differentiation when the elimination of 
mitochondria is required, such as during the differentiation of reticulocytes into erythrocytes 
(red blood cells). The autophagic gene Nix (also called Bnip3L) (Sandoval, Thiagarajan et 
al. 2008) is upregulated in erythroid cells during terminal differentiation (Aerbajinai, Giattina 
et al. 2003, Sandoval, Thiagarajan et al. 2008). Nix, a BH3-only member of the Bcl-2 family, 
induces mitophagy by disrupting the Δψ(Sandoval, Thiagarajan et al. 2008). Therefore, 
autophagy is important for maintaining homeostasis during development, differentiation, 
and macromolecule synthesis and degradation (Mizushima and Levine 2010). 
Mitophagy is also important for maintaining the number and function of mitochondria 
during differentiation and de-differentiation. Knockdown of growth factor erv1-like (Gfer) in 
ESCs upregulates dynamin-related protein 1 (DRP1) and results in decreased pluripotency 
marker expression, smaller embryoid bodies (EBs), and loss of mitochondrial function (i.e. 
mitochondrial membrane potential, cytochrome c expression). Knockdown of Gfer in ESCs 
was also associated with fragmentation of mitochondria and an increase in apoptosis that 
reduced the number of cells but did not affect differentiation ability (Todd, Damin et all. 
2010) By contrast, overexpression of Gfer in ESCs reduced the expression of DRP1 and 
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maintained pluripotency marker expression, the size of EBs, mitochondrial function (i.e. the 
mitochondrial membrane potential), and mitochondrial morphology (elongated with 
well-defined cristae). The findings suggest that Gfer modulates mitochondrial fission activity 
to preserve mitochondrial function while maintaining pluripotency status in ESCs. Another 
study investigated the response of ESCs to a reduction in mitochondrial membrane 
potential induced by treatment with CCCP. Moreover, the study demonstrated that Parkin 
was upregulated in clustered perinuclear mitochondria when mitochondrial function was 
attenuated by CCCP treatment (Narendra, Tanaka et al. 2008, Vives-Bauza, Zhou et al. 
2010, Mandal, Lindgren et al. 2011). These observations may suggest that mitophagy is 
the mechanism that controls mitochondrial quality within hESCs. hESCs do not contain a 
large number of mitochondria during the inner cell mass-derivation stage. In addition, 
hiPSCs exposed to a reprogramming factor were reprogrammed and transformed into cells 
with an hESC-like morphology from somatic cells. iPSCs and hESCs have similar 
metabolic and mitochondrial properties.  
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Chapter 3: Methods and Procedures 
3.1 Cell Lines and Cell Cultures 
All reagents were purchased from Invitrogen (Carlsbad, CA, USA) unless otherwise 
stated. Human embryonic stem cell (hESC) lines were cultured on human foreskin 
fibroblasts (hFFi) as a feeder and Matrigel with DMEM/F12 + 20% knockout serum 
replacement (KOSR) + 1x L-glutamine solution (L-glut) + 1x non-essential amino acids 
(NEAA) or conditioned medium (CM). HEK 293FT cells were cultured in DMEM with 10% 
FBS for 2 to 3 days between passages. The hESC lines (Mel1, hES3, or H9) were cultured 
using inactivated human foreskin fibroblasts as a feeder in DMEM/F12 with L-glut 
supplemented with 20% KOSR, 1x NEAA, and 90 µM β-mercaptoethanol. For short-term 
experimental purposes, hESC lines were maintained on Matrigel with conditioned medium, 
which was collected from inactivated hFFi, and hESC culture medium. Cells were 
passaged after the addition of 4 mg/ml collagenase I for 5 minutes and washed twice with 
DMEM/F12. Cells were gently scraped to break colonies into clumps. Cell clumps were 
centrifuged at 1,000 rpm for 3 minutes, resuspended in fresh KOSR medium, and gently 
transferred to a new dish coated with hFFi cells at 7,000 cells/cm2 or Matrigel.  
3.2 Harvesting and Passaging Cell Cultures:  
(A) Human fibroblasts 
At 80% confluence, cells were observed under microscope before splitting. Before 
undergoing the splitting process, the culture medium, 1x PBS (wash solution) and TrypLE 
(to detach cells from surface) were pre-warmed to 37°C and the culture medium in the cell 
culture flask was suctioned off and discarded. Cells were then washed once with 1x PBS to 
remove all remnants of the culture medium. The 1x PBS was removed through suction and 
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TrypLE was added and incubated with the cells at 37°C for 10 minutes until the cells were 
detached from the surface (checked by microscope). A fixed volume of additional fresh 
culture medium was added to attenuate the activity of TrypLE by dilution. Cells were split 
1:4 or 1:6 and transferred to a new flask together with the growth medium with the contents 
described using: 500 µl for each well for a 24-well plate, 1.5 ml for each well in a 6-well 
plate, 4 ml total for small flasks and 15 ml total for medium flaks. After each splitting, the 
flask was marked with a new passage number.  
(B) Human embryonic stem cells (hESCs) co-cultured with human feeder (hFFi) or 
hESCs grown on Matrigel 
At 80% confluence, cells were observed under microscope before splitting. Before 
splitting, the culture medium, 1x PBS (wash solution) and Collagenase V (1 mg/ml) (to 
detach cells from surface) were pre-warmed to 37°C and then the original culture medium 
on the cell culture flask was suctioned off and discarded. Cells were then washed for one 
time with 1x PBS to remove all the remnant of the culture medium. The 1x PBS was 
removed and Collagenase V was added to the cells at 37°C for 3 minutes until the cells 
were detached from the surface (checked by microscope). hESCs co-cultured with hFFi 
with hESCs‘ culture medium (DMEM/F12 with L-Glut supplemented with 20% KOSR, 1x 
NEAA and 90 µM β-Mercaptoethanol). hESCs grown on Matrigel with conditioned medium 
(CM) (McElroy and Reijo Pera 2008). The preparation of CM was collected the hESCs‘ 
culture medium from the hFFi (20,000 cells/cm2) every day for one week and filtered with 
0.22μm filter after adding an additional 4 ng/ml bFGF. The Matrigel-coated plates were 
prepared by slowly thaw the BD Matrigel hESC-qualified Matrix (BD, #354277) stock 
solution on ice at 4°C to avoid gel formation and dilute the Matrigel stock solution (1:15) in 
cold DMEM/F12 medium. Incubate the Matrigel-coated plates for 1-2 hour(s) at room 
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temperature or overnight at 4°C. A fixed volume of fresh culture medium was added to stop 
the activity of Collagenase V. Cells were usually split into 1:4 or 1:6 and transferred to a 
new growth flask together with the growth medium with the contents described as follows: 
500 µl for each well of a 24-well plate, 1.5 ml for each well of a 6-well plate, 4 ml total for 
small flasks and 15 ml total for medium flaks.  
(C) Differentiation of hES Cell Cultures: Spontaneous-Differentiation  
Spontaneous Differentiation: hESCs were either differentiated spontaneously or in 
response to retinoic acid (RA, 10 µM; Sigma-Aldrich) and were allowed to precede for up 
to 14 days in T-25 culture flasks (Figure 4.1). Retinoic acid (RA, 10 µM; Sigma-Aldrich) 
induced experiment was applied from the method used in this published reference paper 
(Parsons, Teng et al. 2011). For these experiments, cells were cultured in DMEM/F12 with 
knockout serum replacement medium lacking bFGF and β-mercaptoethanol. DMSO 
vehicle was added to the differentiation medium to serve as a negative control. Cells were 
atmosphere with 5% CO2. 
(D) Differentiation of hES Cell Cultures: Lineage-Specific Differentiation 
Methods for the lineage-specific-differentiation of hESCs into ectoderm, endoderm, 
mesendoderm, and cardiomyocytes (Fig 4.1).  
Directed Ectoderm Differentiation: The differentiation of hESCs into neural lineages 
was performed using the method of Briggs and Wolvetang et al (Briggs, Sun et al. 2013). 
Briefly, hESCs were attached and transferred to a Matrigel-coated dish and cultured in 
N2B7 media supplemented with 10 μM SB431542 (Calbiochem) and 5 μM Dorsomorphin 
(DM, also known as Compound C, Sigma-Aldrich) for 6 days. After 6 days, the medium 
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was replaced with N2B7 medium supplemented with 5 μM Dorsomorphin and cells were 
cultured for additional 6 days to form neurospheres.  
Definitive Endoderm Differentiation: The method for the differentiation of hESCs into 
definitive endoderm was according to (D‘Amour, Agulnickk et al. 2005). Once the cells were 
70-80% confluent, differentiation was initiated by washing with PBS on Matrigel-coated 
dishes and then incubating in RPMI (Invitrogen) containing 100 ng/ml activin A and 25 
ng/ml WNT3A (R&D) without FBS (Sigma-Aldrich) for 24 hours. On the second day, cells 
were then treated with RPMI containing 0.2% FBS and 100 ng/ml activin A for 24 hours. For 
the third day, cells were maintained in RPMI containing 0.5% fetal bovine serum and 100 
ng/ml activin A. Cultured cells were characterized after 3 days of differentiation. 
Mesendoderm and Cardiomyocyte Differentiation: The differentiation of hESCs into 
mesendoderm was performed according to reference (Hudson, Titmarsh et al. 2012). 
hESCs cultures were obtained from ASCC StemCore in a conditioned medium (CM) and 
expanded by daily exchanging the medium until the colonies were ~90% confluent in the 
centre of the wells. CM was then replaced with a basal medium comprised of RPMI 1640 
medium supplemented with 2% B27 supplement and 1% penicillin/streptomycin (RPMI 
B27). For primitive streak-like cell induction, 20 ng/ml bone morphogenetic protein-4 
(BMP-4) and 6 ng/ml activin A were added to the basal medium. The basal medium was 
then exchanged for every 3 days. The medium was then replaced by RPMI B27 only and 
exchanged for every 2 days until day 16. After this time, cells were cultured in 
un-supplemented RPMI B27 and the medium was exchanged for every 2 days. The 
difference between the medium contents for mesendoderm differentiation and 
cardiomyocyte differentiation is IWP-4, a small molecule inhibitor of Wnt production 
(Hudson, Titmarsh et al. 2012). After 3 days of differentiation, the medium for 
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cardiomyocyte differentiation RPMI B27 with 5 µM IWP-4 was added and the medium was 
exchanged every 2 days until day 15.  
3.3 Cryopreservation of Cell Cultures 
Generally, the cells used in this thesis were cryopreserved by re-suspension the 
cells in a cryopreservation medium (1 ml) followed by a stepwise freezing (~1°C/minute) 
with a ―Mr Frosty‖ (Nalgene) in a -80°C freezer. After 3-5 days, the cryopreserved cells 
were then storred in a liquid nitrogen tank until use.  
Thawing medium (Fibroblasts: fibroblast DMEM culture medium; hESCs: 
conditioned medium) was pre-warmed to 37°C first. The cell suspension of thawed cells (at 
37°C) was transferred to a 4 ml of the thawing medium. 
Additional thawing medium was then added drop by drop while agitating 
continuously. After 500 μl of thawed medium was added the cell suspension was 
centrifuged at room temperature at 1000 rpm for 5 minutes. The supernatant was discarded 
and the cell pellet was resuspended in another 500 μl thawed medium and again 
centrifuged as the condition described above. Lastly, the cell pellet was resuspended in 
1000 μl culture medium and seeded in a 6-well plate. 
3.4 Karyotypic Analysis 
Cells were seeded in T25 flasks and cultured according to the conditions described 
above. When reaching confluency, cells were treated with trypsin for 5 to 10 minutes at 
37°C before harvest. The trypsin was then neutralized by the culture medium for further 
karyotype analysis. Analysis of G-banded metaphase chromosomes was performed on 
samples produced according to standard procedures from the School of Medicine at the 
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University of Queensland. Karyotypes were assessed at the cytogenetic laboratory of the 
School of Medicine at the University of Queensland. 
3.5 Preparation of mtDNA-Depleted Primary Human Fibroblasts  
Human fibroblast cells were grown in a complete DMEM medium (Dulbecco‘s 
modified Eagle‘s medium supplemented with 50 μg/ml uridine (Sigma-Aldrich), 10% FBS, 1 
mM sodium pyruvate (Gibco) and 1% penicillin/streptomycin (P/S) in the presence of 100 
ng/ml Ethidium bromide (EtBr) or 100 μg/ml chloramphenicol (CAP) in a high-glucose 
medium (4500 mg/ml) (Gibco). EtBr and CAP were kept in the media for 6 weeks. After 6 
weeks cells were fed with complete DMEM media without EtBr or CAP for another 2 weeks. 
Cells were kept between 30% and 80% confluence with excess fresh medium to ensure an 
exponential growth. Cells were harvested followed by the extraction of genomic DNA and 
RNA. 
3.6 Production of Lentiviral Supernatants and Infection of Target Cells 
Lentiviral vectors were produced in HEK293T cells, purchased from Invitrogen. 
HEK293T cells are human embryonic kidney cell lines with a eukaryotic expression plasmid 
encoding the temperature-sensitive mutation derived from the SV40 large T-antigen 
(DuBridge, Tang et al. 1987). In this study, they served as a cell line for packaging and 
producing of lentiviral particles. The produced viruses were tested in vitro by transducing to 
different cell lines (Appendix Tables 2 and 10) and analysed by the methods described 
below.  
Infectious lentiviral particles are generally produced via three main lentiviral genes 
that are encoded in the retroviral genome. Those include: (1) Gag: encoding a polyprotein 
required for viral capsid assembly, (2) Pol: encoding four main enzymes, such as protease, 
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integrase, reverse transcriptase and RNase H required for reverse transcription of the RNA 
genome and finally (3) Env: encoding the necessary viral glycoproteins required for 
budding at cellular membranes (Llano, Gaznick et al. 2009). Since pENTR-EF1α-TFAM 
and pLKO-TFAM shRNAs lack all of the aforementioned viral structural genes, two 
additional plasmids encoding the lentiviral structural genes were introduced. 
Stocks of all viral plasmids were prepared using Nucleospin Plasmid 
Midi-Preparation Kit and stock concentrations were adjusted to 1 μg/μl. Production of viral 
particles was conducted over a period of five days according to the protocol elaborated as 
follows: 
 Day 1: Plating the viral packaging cell line. The HEK293T cells were used as the 
standard cell line for packaging and producing infectious viral particles. HEK293T 
cells were plated at a density of 3x106 cells/flask in a T25 flask in 3 ml aliquots of 
medium and were left to grow overnight at 37°C with atmosphere containing 5% 
CO2.  
 Day 2: Transfection of HEK293T cells with viral plasmids: HEK293T cells were 
transfected by all employed viral plasmids in the presence of the standard 
Lipofectamin plus transfection reagent (Invitrogen). This is an organic polymer with a 
high cationic-charge potential to facilitate binding to anionic surface receptors for 
promoting the process of endocytosis (Kichler, Remy et al. 1995). To this end, 
phenol red-free DMEM/F12 medium without serum, but with other additives were 
used to prepare the transfection solution. The transfection solution mixed with 
plasmids in each T25 flask was set up as shown in the Appendix Table 10.  
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Meanwhile, all viral plasmids (i.e. viral plasmid or pCMV 8.2, VSVG together with the 
Gag/Pol/Env plasmids) were also prepared in phenol red-free DMEM/F12 medium 
containing DMEM/F12 medium (500 µl), plus reagent (4 µl), Lipofectamin transfection 
regent (LTX, 8 µl). Total plasmid concentration per T25 flask contains 1 μg of viral plasmid, 
2 μg of pCMV 8.2 (encoding for Env gene) and 1 μg of VSVG (encoding each for Gag and 
Pol gene). The prepared transfection solution was then rapidly added to the viral plasmid 
mixture and vortexes. The mixture was incubated at room temperature for 30 minutes. The 
medium was then removed from the HEK293T cells and replaced with 4 ml of phenol 
red-free DMEMF12 medium with 5% KSR. After 20 minutes, the 2 ml transfection mixture 
was dropwisely added to the dish and incubated overnight at 37°C. Next day, the HEK293T 
medium was replacd by KSR medium. 
 Day 5: Harvesting of viral particles and storage: HEK293T supernatants containing 
infectious viral particles were filter-sterilized using a 0.45 um nitrocellulose filter. The 
aliquots of the sterilized cell-free supernatants were stored at -80°C use. 
3.7 Transduction (Infection) of Target Cells 
In general, transduction or infection refers to the entry of the virus into the host cell 
with certain exogeneous gene sequences being integrated into the cellular genome of the 
host. Briefly, target cells (hESCs) were plated in 6-well cell culture plates at a density of 
2x105 to 5x105 cells per well in 1 ml aliquots of medium and allowed to grow overnight. For 
the second day, the medium of the target cells was removed and replaced with 2 ml of 
undiluted viral stock solution containing 8 μg/ml polybrene and 10 ng/ml bFGF. For the 
negative controls (i.e. un-transduced cells), viral particles were omitted. Cells were 
incubated for additional 6 to 8 hours. Transduction was ultimately stopped by incubating 
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cells in their own medium for 72 hours prior to the harvesting step and also further growing 
the cells. To downgrade the transduced cells from Biosafety Level 2 to Biosafety Level 1, 
culture medium of cultured transduced cells were harvested after 72 hours of transduction 
and filter-sterilized using 0.45μm nitrocellulose filters. The cell-free filtrate was later 
subjected to further analysis to assess the absence of virus particle production. 
3.8 Cloning of Human EF1α-LC3-GFP and TFAM cDNA 
EF1α-LC3-GFP construct, encoding LC3 (GenBank ID: NM_032514), was obtained 
from Dr. Prescott as a kindly gift to establish hES3-LC-GFP single cells. The feature of 
LC3-GFP plasmid was generated by Tim Tra using the following methods. The 
LC3-GFP-pENTRTM-directional plasmid (10 fmole) and the pENTR-EF1α plasmid (10 fmole) 
were simultaneously cloned into the pLenti6/R4R2/V5-DEST vector using LR Clonase II 
Plus (MultiSite Gateway®  Technology; Invitorgen) to generate the expression plasmid of 
pLenti6-EF1α-TFAM. After proteinase K digestion, the plasmid was used to transform into 
One Shot ®  Stbl3 competent E.coli cells (Invitrogen) for plasmid purification and sequence 
confirmation. Expression of the LC3-GFP was driven by the EF1α promoter using a 
replication-incompetent lentivirus and the LC3-GFP lentivirus plasmid was amplified by 
One Shot ®  Stbl3 competent E.coli cells (Invitrogen). 
The cDNA encoding human TFAM (GenBank: NM_003201) was obtained by 
RT-PCR from human embryonic stem cells (hESCs) using TFAM-forward primer (5‘- 
CACCATGGCGTTTCTCCGAAG-3‘) and TFAM-reverse primer (5‘- 
TTAACACTCCTCAGCACCATATTTTCGTTG-3‘). TFAM cDNA was amplified by PCR. 
PCR reactions were performed by using 0.5 μl pFusion high fidelity hot start enzyme with 
10 μl of 5x pFusion buffer, 1.5 μl of 10mM dNTP, 1 μl of 10 μM of each pair of forward and 
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reverse primers, 1 μl of 200 ng/μl cDNA and sterile water added to 50 μl total volume. PCR 
reaction conditions were set as follows: 98°C for 1 minute, followed by 30 cycles at 98°C for 
10 seconds, 56°C for 20 seconds, 72°C for 30 seconds and a final extension at 72°C, for 10 
minutes before cooling down at 4°C. The TFAM amplification product was 741 base pairs 
(bps) and was analysed by running in 1.5% agarose gel electrophoresis followed by UV 
visualization. The product was purified with using the Agarose Gel DNA Extraction Kit 
(Roche) and cloned into the pENTRTM-directional entry vector (Invitrogen). The sequence 
of the TFAM cDNA was confirmed by PCR amplification and sequencing. EF1α (human 
elongation factor-1α) promoter plasmid and EF1α-GFP expression plasmid were kindly 
provided by members in the Wolvetang group. The TFAM-pENTRTM-directional plasmid (10 
fmole) and the pENTR-EF1α plasmid (10 fmole) were simultaneously cloned into the 
pLenti6/R4R2/V5-DEST vector using LR Clonase II Plus (MultiSite Gateway®  Technology; 
Invitorgen) to generate the pLenti6-EF1α-TFAM expression plasmid. After proteinase K 
digestion, the recombination reaction was transformed into One Shot ®  stbl3 competent 
E.coli cells (Invitrogen) for further plasmid purification and sequence confirmation. 
Expression of the TFAM cDNA was driven by the EF1α promoter while using a 
replication-incompetent lentivirus. 
3.9 shRNA Cloning  
shRNA constructs were specific to TFAM to knockdown TFAM (termed TFAMi 
shRNA) and a non-specific, control construct (termed ―targetless‖). Anneal 5 μl of 1 μg/μl of 
double-stranded oligo (dsOligo) with 5 μl of 10x NEB buffer 2 and 35 μl of sterile water by 
heating the sense and antisense sequence at 95°C for 4 minutes. Next step is the slow 
cooling down at room temperature for 5 to 10 minutes. Serial dilution of dsOligo to 200 ng 
mixed with T4 DNA ligase (New England Biolab) to further perform the ligation reaction with 
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50 ng of pLKO-1 TRC-cloning vector (Addgene) digested by AgeI and EcoRI in order to 
insert dsOligo at 95°C, overnight. Transform 5 μl of the ligation mix into XL1Blue competent 
E. coli. The reaction mixture was then incubated in ice for 30 minutes and then heat 
shocked for 30 seconds and then incubated in ice for another 30 minutes. Afterwards, the 
reaction mixture was mixed with 1 ml of LB without antibiotics for 1 hour of shaking 50 to 
100 μl of the mixure containing 100 μg/ml ampicillin was applied on LB agar plates.    
PCR was used to screen all the possible positive clones which may have inserted 
dsOligo. The thermal cycling profile of the PCR reaction was: 95°C for 4 minutes, 36 cycles 
at 95°C for 30 minutes, 60°C for 30 minutes and 72°C for 30 minutes and finally extending 
at 72°C for 5 minutes. Next, the plasmid DNA was prepared using the plasmid extraction kit 
(Macherey) according to the manufacturer‘s instructions. Different clones were inoculated 
in 5 ml LB with 100 μg/ml ampicillin overnight at 37°C shaking in the speed of 180 rpm. 
They were then transferred to 100 ml liquid with 100 μg/ml ampicillin for 12 hours at 37°C, 
180 rpm. The pellets were collected by centrifuging the bacteria supernatant in 50 ml tubes 
(BD). A small amount of plasmid DNA with sequencing primer was prepared to sequence 
the vector. Lastly, different clones TFAM shRNAs and pLKO-targetless were generated. 
pLKO-targetless vector served as used as the negative control. 
3.10 Plasmid DNA Purification:  
(A) Minipreparation 
E. coli cells from glycerol stocks (freeze cultures) containing plasmid were streaked 
on an LBamp100 agar plate and grown overnight in a 37°C incubator. Stationary phase 
cultures in LBamp100 agar were started by single colonies and incubated overnight while 
vigorously shaking at 37°C. 4 ml of overnight bacterial culture was harvested by 
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centrifugation at 200 rpm for 30 seconds at room temperature. The supernatant was 
discarded. Plasmids were purified from stored E. coli culture pellets using NucleoSpin 
Plasmid Column (Macherey), buffer A1 (resuspension buffer), A2 (lysis buffer), A3 
(neutralization buffer), AW and A4 (wash buffers) and AE (eluation buffer). The protocol 
followed the manufacturer‘s instructions. The pellets obtained in the previous step were 
added to 250 µl of buffer A1 and inverted and vortexed until the pellet were completely 
dissolved. Solution was then added 250 µl of buffer A2 and inverted before being incubated 
at room temperature for 5 minutes. 300 µl of Buffer A3 was added and the solution was 
inverted for several times to mix well before it was poured into a filter attached to a 
collecting tube. The lysate was then transferred to the column and centrifuged at 200 rpm 
for 5 minutes. The flow through was then removed and 500 µl of buffer AW preheated to 
50°C was added to column and centrifuged at 200 rpm for 1 minute. 600 µl of buffer A4 was 
added to the column and centrifuged at 200 rpm for 1 minute. The flow through was 
discarded and re-centrifuged at 200 rpm for 2 minutes. The plasmid DNA was eluted with 
50 µl of buffer AE at room temperature for 1 minute and centrifuged at 200 rpm for 1 minute. 
The concentration of DNA was measured by Nano-drop ND-1000 (NanoDrop) before all the 
samples were stored at -20°C seal. 
(B) Midipreparation 
E. coli cells from glycerol stocks (freeze cultures) containing plasmid were streaked 
on an LBamp100 agar plate and grown overnight in a 37°C incubator. Stationary phase 
cultures in LBamp100 agar were started by single colonies and incubated overnight by 
vigorously shaking (200 rpm) it at 37°C. 1 ml of overnight bacterial culture was added into 
each flask (100 ml of LBamp100). The flasks were then vigorously shaken at 180 rpm in a 
37°C incubator overnight. The bacterial cells were harvested by centrifugation at 200 rpm 
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for 15 minutes at 4°C. The bacterial pellet left on the bottom after centrifugation was stored 
at -20°C until being used. The supernatant was discarded. Plasmids were purified from 
stored E. coli culture pellets using NucleoBond Xtra Column (Macherey), buffer RES-EF 
(resuspension buffer), LYS-EF (lysis buffer), NEU-EF (neutralization buffer), FIL-EF (QIA 
filter wash buffer), EQU-EF (equilibration buffer), ENDO-EF (wash buffer) and ELU-EF 
(elution buffer). The protocol followed the manufacturer‘s instructions. The pellet obtained 
in the previous steps was added into 8 ml of buffer RES-EF and inverted and vortexed until 
the pellet was completely dissolved. Solution was then added to the 8 ml of buffer LYS-EF 
and inverted before it was incubated at room temperature for 5 minutes. Buffer NEU-EF 
was pre-chilled before use: 8 ml was added and the solution was inverted for several times 
to mix before it was poured onto a filter attached to a collecting tube. The lysate was then 
incubated for 10 minutes on ice and centrifuged at 200 rpm for 10 minutes. 15 ml of buffer 
EQU-EF was added to column and the column was slowly emptied by gravity flow. The 
supernant of mixture was then added into the column and was allowed to bind to the resin 
coated on the column by gravity flow. Several washing steps were conducted and the 
following contents would elaborate on these steps. 5 ml of FIL-EF, 35 ml of ENDO-EF and 
15 ml of WASH-EF were applied to wash the column slowly through gravity flow. The 
plasmid DNA was eluted with 5 ml of buffer ELU-EF. The DNA was then precipitated by 
adding 3.5 ml room temperature isopropanol. The solution was mixed and centrifuged at 
200 rpm for 60 minutes at 4°C. Supernatant was carefully decanted and discarded. The 
pellet obtained after centrifugation was washed with 2 ml 70% room temperature ethanol 
and centrifuged at 200 rpm for 60 minutes at 4°C. Supernatant was carefully decanted and 
discarded. The pellet was left to air-dry for 10 minutes before being re-dissolved in 
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autoclaved water. Concentration of DNA was measured with Nano-drop ND-1000 
(NanoDrop) before samples were stored at -20°C until being used. 
3.11 Sequencing of cDNA 
The dideoxynucleotide sequencing method was applied to confirm the sequence of 
the interested gene. Sanger sequencing was performed using BigDye Terminator reagents 
(Applied Biosystems). The sequencing primer was used at a concentration of 10 nM. The 
sequencing product was purified by plasmid DNA before sending to the Australian Genome 
Research Facility (AGRF) for analysis performed by the chromatograph. The 
chromatograph was viewed using Chrome software. 
3.12 Genomic DNA Isolation 
Total genomic DNA was isolated from cultured human cells using a commercial kit 
(Qiagen) and the concentration was determined by NanoDrop 1000 spectrophotometer 
(Thermo Scientific). Mitochondrial DNA (mtDNA) copy number was determined by real-time 
PCR using an ABI Prism 7500Fast thermocycler (Applied Biosystems). The -ACTIN gene 
was simultaneously amplified as a normalization control standard. Amplification was 
performed as the procedures described as follows: 95°C for 1 minute, 40 cycles at 95°C for 
30 seconds, 52°C for 30 seconds; and final dissociation to generate a melting curve for 
verification of amplification product specifically. During PCR amplification, the concentration 
of amplified products was measured continuously by measuring fluorescence emission 
strength. Then gDNAs were used for quantitative real-time PCR (qPCR) analysis. 
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3.13 RNA Extraction & cDNA Generation 
Total RNAs were extracted using Qiagen RNA extraction kit (Qiagen) followed by 
DNase treatment (Qiagen) and the same RNA sample was used for quantitation by 
real-time PCR, or cDNA cloning. The cDNAs were then synthesized as follows: in a single 
reaction, 1 μg of RNA quantified by NanoDrop, (NanoDrop 1000, Thermo Scientific) was 
mixed with RNase-free water and 1 μl of oligo d(T)20 (500 μg/ml) (Geneworks) to reach the 
final volume of 12 μl, then it was incubated at 65°C for 5 minutes. After incubation, the 
reaction was placed on ice before the addition of 4 μl of 5x first-strand buffer and 2 μl of 0.1 
M DTT (Invitrogen) and then incubated at 37°C for 2 minutes. Finally, 1 μl (200 U) of 
M-MLV reverse transcriptase (Invitrogen) was added into the mixture and was incubated at 
37°C for 50 minutes followed by an extension period for 15 minutes at 70°C.The cDNA 
generated in previous steps was then used for quantitative real-time PCR (qPCR) analysis. 
3.14 Quantitative Real-time PCR (qPCR) 
The expression of gene was quantitated using the ABI 7500 real-time PCR detection 
system (Applied Biosystem) which uses fluorescein as an internal passive reference dye for 
the purpose of normalization of well-to-well optical variation. PCR amplifications were 
carried out in a total volume of 10 μl, containing 5 μl of 2x SYBR Green supermix (Applied 
Biosystem), 0.2 μl of 10 μM primers and 0.2 μl of cDNA samples mixed with sterile water. 
The reaction was initiated at 95°C for 2 minutes, followed by 40 three-step amplification 
cycles consisting of 30 seconds denaturation step at 95°C, 30 seconds annealing step at 
52°C and 30 seconds extension step at 72°C. The final dissociation stage was run to 
generate a melting curve for verifying the specificity of amplification. Real-time qPCR was 
monitored and analysed by the ABI 7500 fast optical system software (Applied Biosystem). 
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Single primer in each sample was carried out in triplicate. Relative mRNA levels were 
calculated using the comparative Ct method (Applied Biosystem instruction manual) and 
presented by their ratio to their biological controls. The fold change in expression of each 
target mRNA relative to -ACTIN was calculated as 2-Δ(ΔCt), where ΔCt=Ctgenes-ΔCt -ACTIN. 
-ACTIN transcript levels were confirmed to correlate well with total RNA amounts and 
therefore were used for normalization throughout. All primer pairs used were confirmed to 
approximately double the amount of product within one cycle and to yield a single product 
of the predicted sizes. Primers were designed by Seqtool 
(http://seqtool.sdsc.edu/CGI/BW.cgi#) or (http://pga.mgh.harvard.edu/primerbank/). At the 
end of PCR reactions, the specificity of the PCR products was confirmed after observing 
the presence of a single peak while using 2% gel electrophoresis stained with EtBr and 
visualized under UV light. For the calculation of PCR efficiencies, standard curves were 
generated from assays made with serial dilutions of cDNA from experiments with triplicate, 
which enabled the determination of the Ct values and PCR efficiencies of each individual 
assay and the calculation of the correlation relation between them. The PCR efficiency (E) 
was calculated according to the equation E= (10 [1/-slope] -1). The E is around 110% to 90% 
when the slope falls between -3.1 to -3.6. The slope was calculated by plotting the dilution 
fold of cDNA versus their Ct values 
(http://www.stratagene.com/techtoolbox/calc/qpcr_slope_eff.aspx). 
3.15 Cell-Staining protocols 
(A) Live-cell staining protocols 
The live-cell staining experiments were separated into two parts: (1) JC-1 staining: 
Cells were grown in wells with normal culture media. The culture medium was removed 
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and cells were washed with PBS twice for 5 minutes at room temperature. The 
mitochondrial membrane potential was determined by using 5, 5‘, 6, 6‘-tetrachloro-1, 1‘, 3, 
3‘-tetraethylbenzimidazolylcarbocyanine iodide (JC-1, Sigma-Aldrich). JC-1 is a 
fluorescent dye with cationic and lipophilic properties that accumulates in mitochondria 
depending on differential membrane potentials. High membrane potential is indicated as 
JC-1 aggregates and low membrane potential is indicated as JC-1 monomers. Studies 
have shown that JC-1 is the better fluorescent dye compared with other (Salvioli, Ardizzoni 
et al. 1997). JC-1 monomers and JC-1 aggregates were emitted at 488 nm (green) and 
561 nm (red), respectively. Next, a probe was diluted to the optimal concentration for 
working in a buffer (200 µl for 1 well of a chamber slide) and incubated for 30 minutes at 
37˚C. Then the cells were washed with PBS twice for 5 minutes at room temperature. The 
DNA was counterstained with 10 μM of Hoechst 33258 in PBS and the cells were covered 
and incubated for 5 minutes. The cells were then washed with PBS twice for 5 minutes at 
room temperature. Images were acquired via a 10x objective lens with a fluorescence 
microscope. Each sample was compared with a control. (2) hES-LC3-GFP cells staining 
with MitoTracker staining: Cells were grown in wells with normal culture media. The culture 
medium was removed and washed with PBS twice for 5 minutes at room temperature. 
Mitochondria were marked and determined using MitoTracker Deep Red dye (Invitrogen). 
Next, the probe was diluted in a blocking buffer and incubated at 37°C for 30 minutes. The 
cells were washed with PBS twice for 5 minutes at room temperature. Images were 
acquired through a 10x objective lens with a fluorescence microscope. 
(B) Timelapse Image Analysis of Mitophagy in Live hESCs 
The hES-LC3-GFP cell line was manually cut and seeded on Matrigel in 6 well 
plates and grown to ~80% confluency for 2 days prior to initiating the experiments of 
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phase-contrast timelapse microscopy. The required agent (200 nM rapamycin, 50 µM 
CCCP, 100 ng/ml EtBr; Sigma-Aldrich) was added to the medium and cells were 
incubated under 5% CO2 
induced by withdrawing bFGF for 7 or 14 days, or induced by RA (Sigma-Aldrich). The 
cells were washed with PBS, stained with 100 nM MitoTracker Red (Invitrogen) in PBS for 
30 minutes at 37°C and then washed again. Finally, the hESC medium was added. The 
experiment was continued and each one of the serial images was acquired for every 1 
710). Each sample was compared with undifferentiated hESCs. Images were analysed 
using Zen 2008 Light Edition software (Carl Zeiss).  
(C) Immuno-Staining Protocols: Fixed-cell staining 
The cells were grown on coverslips with normal culture media. The culture medium 
was removed and washed with PBS twice for 5 minutes at room temperature. The cells 
were then fixed with 4% paraformaldehyde solution in PBS for 15 to 20 minutes. They 
were removed from the fixation solution and washed with PBS twice for 5 minutes at room 
temperature. (When staining nuclear markers, cells require permeabilization while 
incubated in 0.1% Triton X-100 in PBS/TBS for 20 minutes at room temperature.) The cells 
were washed with PBS twice for 5 minutes at room temperature. The non-specific binding 
was blocked by using a sufficient volume of 4% goat serum solution in PBS (200 µl for 1 
well of a chamber slide). The cells were incubated for 30 minutes at room temperature. 
Next, the primary antibodies were diluted to working concentration with blocking buffer and 
added to the cells for 1 to 2 hour(s) at room temperature or 4oC overnight (Appendix Table 
9). Then the cells were washed with PBS twice for 5 minutes at room temperature. Next, 
the secondary antibodies were diluted to working concentration with blocking buffer before 
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added to the cells for 1 hour at room temperature. The cells were then washed with PBS 
twice for 5 minutes at room temperature. The DNA was counterstained with 1 μg/ml of 
DAPI in PBS and the cells were covered and incubated for 5 minutes. Then the cells were 
washed with PBS twice for 5 minutes at room temperature. The slides were mounted using 
Vectashield or ProLong Gold following the manufacturers‘ instructions. Images were 
acquired via a 10x objective lens with a fluorescence microscope. Each sample was 
compared with the control. 
(D) Immuno-Staining hES-LC3-GFP Fixed-Cell Staining 
hES-LC3-GFP cells were grown on coverslips in normal culture medium or 
differentiation medium. They were fixed with 2% (w/v) paraformaldehyde at room 
temperature for 20 minutes and then stained with antibodies to pluripotency markers 
POU5F1 (Santa-Cruz Biotechnology) and tumor recognition antigens (TRA-1-60. 
Millipore). After incubation with the primary antibody, the cells were washed three times in 
phosphate-buffered saline (PBS) and incubated with the appropriate secondary antibody 
(1:2,000, goat anti-mouse Alexa 488 (or goat anti-rabbit Alexa 568)-conjugated IgG, 
Invitrogen) at room temperature for 30 minutes (Appendix Table 9). The cells were then 
washed with PBS and mounted in mounting medium containing DAPI (Sigma-Aldrich). 
microscope (Zeiss LSM 710). 
3.16 Transmission Electron Microscopy (TEM)  
Electron photomicrographs for mitochondrial morphology of hESCs were prepared 
as described previously (Graham and Orenstein 2007). In brief, cell pellets were washed 
in PBS buffer and fixed with the final concentration of 2.5% glutaraldehyde in PB buffer for 
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15 minutes. Pellets were then post-fixed in osmium tetroxide (OsO4) and dehydrated 
through a series of acetone solutions and embedded in epoxy. Thin sections were stained 
with uranyl acetate (Fahmy‘s) and lead citrate. Images were acquired by using a 
JEOL1010B microscope (Japanese Electron Optics Laboratories, Peabody, MA). 
3.17 Flow Cytometry General Protocol 
Cells were stained using the following general protocol. The specific protocol is 
indicated in the relevant chapter. All flow cytometry analysis was conducted by either an 
LSRII or ACCURI flow cytometer (BD Biosciences) with (generally) 10,000 counts taken 
from per sample. Negative control was indicated by staining with secondary antibodies for 
all analysis to distinguish the signal form noisy background and non-specific binding. 
Fluorescence gates for positive cells were set to give false positive rates of <1%.   
(A) Live-imaging Flow Cytometry and Data Acquisition 
The hES-LC3-GFP cell line was seeded on Matrigel in T-25 flasks and grown for 2 
days until ~80% confluent. The desired agent (200 nM rapamycin, 50 µM CCCP, 100 
ng/ml EtBr; Sigma-Aldrich) was added to the medium and cells were incubated under 5% 
CO2 at 37°C for 2 hours. Differentiation was either spontaneously induced by withdrawing 
bFGF for 7 or 14 days or induced by RA (Sigma-Aldrich). The cells were then trypsinized 
using TrypLE (Invitrogen) and collected into 15-ml centrifuge tubes. The cells were 
washed with PBS, stained with 100 nM MitoTracker Deep Red (Invitrogen) for 30 minutes 
at 37°C and then washed again. They were analysed by flow cytometry at 488 nm with 
simultaneous fluorescence image captured at 633 nm using the ImageStream system 
(Amnis Corporation, Seattle, WA). Data represents the results of triplicate analyses. For all 
samples, populations were gated for both GFP and single cells and processed further by 
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spot counting. Once cells of interest were gated, the feature of spot count analysis could 
be performed. Spot counts of LC3 punctuate of representative cells were then applied to 
the default mask for autophagosome analysis using ImageStream Data Exploration and 
Analysis Software (IDEAS) v3.0. 
(B) Flow Cytometry for Live-cell Staining 
Cells were harvested in a single cell-suspension using trypsin. The suspension was 
gently and repeatedly suctioned in and out to break up the aggregates. The cells were 
centrifuged for 5 minutes at 1000 rpm and supernatant was removed and resuspended in 1 
ml blocking buffer. The non-specific binding was blocked by sufficient volume of 500 µl of 
4% goat serum solution in PBS and incubating for 15 minutes at room temperature. Next, 
the primary antibodies were diluted in blocking buffer and incubated on ice for 20 minutes 
(Appendix Table 9). For controls, only secondary antibodies or vehicles were used. The 
cells were washed by centrifuging them for 3 minutes at 1000 rpm and the supernatant was 
removed and resuspended in 1 ml of PBS twice for 3 minutes at room temperature. Next, 
the secondary antibodies were diluted to working concentration in a blocking buffer and 
incubated on ice for 20 minutes (Appendix Table 9). The cells were washed by centrifuging 
them for 3 minutes at 1000 rpm and the supernatant was removed and resuspended in 250 
µl of PBS for twice. The cells were transferred to flow cytometry tubes on ice and analysis 
was conducted by the flow cytometer. Each sample would be compared with a control. 
Each sample, representing 10,000 events of counting, was analysed using appropriate 
software and measured in triplicate. The flow cytometry data are all the averages of 
triplicate experiments.  
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(C) Flow Cytometry for Mitochondrial Staining of Living Cells 
The cells were harvested in a single cell-suspension approach using trypsin. The 
suspension was gently and repeatedly suctioned in and out to break up aggregates. The 
cells were centrifuged for 5 minutes at 1000 rpm and the supernatant was removed and 
resuspended in a 1 ml working solution of probes such as MitoTracker Deep Red dyes 
(Invitrogen) or 5, 5‘, 6, 6‘-tetrachloro-1, 1‘, 3, 3‘-tetraethylbenzimidazolylcarbocyanine 
iodide (JC-1, Sigma-Aldrich) (Appendix Table 9). JC-1 is a fluorescent dye with cationic and 
lipophilic properties and it accumulates in mitochondria depending on differential 
membrane potentials. A high membrane potential is indicated by JC-1 aggregates and a 
low membrane potential is indicated by JC-1 monomers. Studies have shown that JC-1 is 
the better fluorescent dye compared with others (Salvioli, Ardizzoni et al. 1997). JC-1 
monomers and JC-1 aggregates were emitted at 488 nm (green) and 561 nm (red), 
respectively. Next, the probe was diluted into blocking buffer and incubated at 37°C for 30 
minutes. The cells were washed by centrifuging them for 3 minutes at 1000 rpm and the 
supernatant was removed and resuspended in 250 µl of PBS for twice. The cells were 
transferred to flow cytometry tubes on ice and analysis was conducted by the flow 
cytometer. Each sample was compared with the corresponding control. Each sample, 
representing 10,000 events of counting, was analysed by using appropriate software and 
measured in triplicate. The flow cytometry data are all the averages of triplicate 
experiments. 
(D) Flow Cytometry of Fixed-Cells 
The cells were harvested in a single cell-suspension approach using trypsin. The 
suspension was gently and repeatedly suctioned in and out to break up aggregates. The 
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cells were centrifuged for 5 minutes at 1000 rpm and the supernatant was removed and 
resuspended in 1 ml 2% paraformaldehyde solution in PBS for 20 to 30 minutes with 
occasional mixing motion. The cells were washed by centrifuging them for 5 minutes at 
1000 rpm. The supernatant was removed and resuspended in the blocking buffer. (This 
was repeated to wash away excess paraformaldehyde if necessary). The non-specific 
binding was blocked by using sufficient volume of 500 µl of 4% goat serum solution in PBS 
and incubating for 15 minutes at room temperature. (If it is staining nuclear markers, the 
cells require permeabilisation by being incubated in 0.1% Triton X-100 in PBS incubates for 
5 minutes at room temperature.) The cells were washed by centrifuging them for 3 minutes 
at 1000 rpm and the supernatant was removed and resuspended in 1 ml of PBS twice. Next, 
the primary antibodies were diluted in a blocking buffer for 1 hour at room temperature or 
4oC overnight. For controls, only secondary antibodies or vehicles were used. The cells 
were washed by centrifuging them for 3 minutes at 1000 rpm and the supernatant was 
removed and resuspended in 1 ml of PBS twice for 30 minutes at room temperature. Next, 
the secondary antibodies were diluted to appropriate working concentration in a blocking 
buffer before added to the cells for 30 minutes at room temperature. The cells were washed 
by centrifuging them for 3 minutes at 1000 rpm and the supernatant was removed and 
resuspended in 250 µl of PBS for twice. The cells were transferred to flow cytometry tubes 
for further analysis undergone by the flow cytometer. Each sample was compared with its 
corresponding control. Each sample, representing 10,000 events of counting, was analysed 
using proper software and measured in triplicate. The flow cytometry data are all the 
averages of triplicate experiments. 
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3.18 Lactate Production and Glucose Consumption 
In order to assess lactate production and glucose consumption, 1x105 cells were 
seeded for 24 hours before medium collection and filtration through a 0.22um filter. 
Triplicate samples were then analysed by using YSI Glucose/Lactate Analyser (YSI 2300 
STAT Plus). L-lactate and glucose consumption per cell were calculated according to the 
standard curve and converting their concentration (mg/l) to mM by dividing with their 
molecular weight (i.e. molecular weight of L-lactate and glucose are 90.08 and 180.15588, 
respectively). Cell medium only and normalised control are all subtracted from the 
calculation values. 
3.19 Detection of Intracellular Total and Oxidised Glutathione (GSH) in Cells 
For quantification of the ratio between oxidized glutathione (GSSG) and reduced 
glutathione (GSH), cells were trypsined and collected in tubes for counting processes. Cells 
were lyzed by adding 100 ul of 5% metaphosphoricacid (MPA, 2.5 g/50 ml) and sonciated 
for 10 seconds with 10 seconds of break on ice. Supernatant of each sample was placed on 
ice after centrifugation. Aliquots of each sample and standards were then incubated with 40 
mM of 4-vinylpyridine at room temperature for 1 hour. Kinetic monitor of optical density was 
carried out following the addition of reaction mix that contained 5,5‘-dithiobis-2-nitrobenzoic 
acid. The sulfhydryl group of GSH reacted with DTNB (5,5‘-dithiobis-2-nitrobenzoic acid, 
Ellman‘s reagent) to produce a yellow colored 5-thio-2-nitrobenzoic acid (TNB) that would 
absorbed the fluorescence at 405 nm. The rate of TNB production was directly proportional 
to the concentration of glutathione in the samples. Changes in the OD 405 nm values per 
minute were converted into the total oxidized glutathione concentrations using the GSH 
standard curve (Griffith 1980) (Assay designs). 
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3.20 Intracellular ATP and ADP Concentrations of Mitochondrial Depleted Cells 
ATP was measured using bioluminescence based on the procedures of the 
luciferin-luciferase reaction (Higashi, Isomoto et al. 1985). The reaction was catalyzed by 
luciferase and would emit 450 nm light. Experiments were carried out in triplicate in opaque 
384-well tissue culture opaque plates. First, trypsinised cells were collected in tubes and 
resuspended in 200 µl PBS. Then is sonicated twice for 10 seconds for each plate and 
placed on ice. Cells were centrifuged before beginning the ATP/ADP (EnzyLight ADP/ATP 
Ratio Assay Kit, Bioassay Systems, Hayward, CA) and Bradford protein concentration 
(Sigma-Aldrich) assays. In 384-well plates, 10 µl of samples or standard, respectively 
(Sigma-Aldrich) in the 24.4 µl of the reaction mixture, includes 0.3 µl substrate and 0.3 µl 
ATP enzyme. Samples were mixed and incubated at room temperature for 10 minutes. The 
ATP signal was allowed to undergo spontaneous decay for 10 minutes in order to reach a 
steady state and then measured by a SpectraMax M5 microplate spectrophotometer 
(Molecular Devices, Australia) to express by values of relative light units (RLU). After 10 
minutes, the ADP in the well was converted to ATP after addition of 2.5 µl ADP converting 
reagent. The 2.25 µl of the reaction mixture consisted of 0.25 µl of ADP enzyme. After 
10-minute incubation, RLUs were recorded and converted to the amount of ADP with an 
ADP standard curve. Under optimal conditions and at concentrations of ATP and ADP from 
0 to 30 µM, the RLUs were directly proportional to the amount of ATP and ADP presents 
(data not shown). The mean value and standard deviation (SD) of the triplicate samples 
were recorded by the SoftMaxPro software and then calculated and normalised to the 
protein concentration by Excel (Microsoft).  
 
112 
 
 
3.21 Statistical Analysis 
Data are presented in the form of the mean ± standard deviation (SD) or standard 
error (SEM). The statistical differences between two groups were tested by Student‘s t-test. 
The statistical differences among more than two groups were tested by two way ANOVA 
or student t-test. P value less than 0.05 was considered to show significant differences in 
all experiments for multiple comparisons (n=3). Analysis of the data was done using 
GraphPad software (version 5, University of Queensland). The plotting of the figures was 
done using SigmaPlot or Excel software (Version 8.0, Chicago, IL, U.S.A).  
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Chapter 4: Results 
Objective 1: Mitochondrial-Encoded and Mitochondrial Biogenesis-Related Gene 
Expression During Lineage-Specific Differentiation of Human Embryonic Stem 
Cells 
4.1  Phase I: Mitochondrial Changes in Differentiating hESCs 
For this study, hESCs (cell line hES3) were allowed to differentiate spontaneously by 
withdrawing the pluripotency maintenance factor (basic fibroblast growth factor, bFGF) 
from the culture medium or by adding retinoic acid (RA) at the time points shown in Figure 
4.1. Differentiation of ESCs is characterized by the loss of pluripotency and upregulation of 
lineage-specific transcription factors. Here, cell differentiation was monitored using the 
surface antigen marker (or a pluripotency marker) TRA-1-60 (Table 4.1). Flow cytometric 
analysis showed a significant decrease in the expression of TRA-1-60 in cells treated with 
RA or upon withdrawal of bFGF (Figure 4.2), indicating that the cells underwent 
differentiation (Figure S1).  
Since it is known that mitochondria provide the energy required for cell differentiation, 
their mass is expected to increase during differentiation. We determined the mitochondrial 
mass by flow cytometry using fluorescent MitoTracker Red (a dye specific to mitochondria) 
and demonstrated a significant increase in mitochondrial mass at day 7, but not at day 14, 
during the differentiation (P < 0.05 compared with control, Figure 4.2 and Table 4.1). These 
data indicated that there is a temporary increase in mitochondrial mass in the early stage of 
spontaneous differentiation (day 7) and a decrease at day 14 of spontaneous 
differentiation.  
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Quantitative real-time PCR (qPCR) was then conducted to determine whether and how 
the differentiation process (spontaneous and RA-treated) affected mitochondrial gene 
expression. We showed that POU5F1 (a pluripotency gene) expression was dramatically 
reduced after 7–14 days of spontaneous differentiation and after 3 days of RA treatment 
(Figure 4.3A and Table 4.2). Interestingly, mtDNA copy number, determined using D-loop 
as a template for PCR, was elevated at day 7, but decreased at day 14 (Figure 4.3 and 
Table 4.2). Such profile changes, however, were not seen in cells treated with RA for 3 
days, suggesting that the underlying mechanisms of action of these two commonly used 
techniques to induce ESC differentiation are quite different. 
To test whether the profile changes in mitochondrial genes are dependent on cell line 
during differentiation, we next examined two different stem cell lines, hES3 and Mel 1, to 
determine whether the effect of differentiation on mitochondrial gene expression could be 
duplicated between these two cell lines.  
First, we observed that the expression patterns between the mitochondrial genes, ND1 
and CYTB, were quite similar in differentiated hES3 cells (Figure 4.3A and Table 4.2). At 
day 7 of spontaneous differentiation, the expression level of ND1 remained the same as 
that of the control. The level of CYTB in the hES3 cells was 1.36-fold higher (P < 0.05) than 
that in the control (Figure 4.3A and Table 4.2). At day 14, the expression of ND1 and CYTB 
was almost identical to that of controls. At day 3 of RA treatment, ND1 expression was not 
significantly different to that in the control, while CYTB expression showed a 4-fold 
reduction (P < 0.05). From our results, the mitochondrial responses of hESCs to 
spontaneous differentiation differed widely depending on the hESC lines being used.  
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At day 7 of spontaneous differentiation, ND1 expression in the cell line Mel 1 
decreased 2.5-fold relative to that in the control (P < 0.05), but this reduction was not 
observed for CYTB (Figure 4.3A and Table 4.2). At day 14 of spontaneous differentiation, 
the expression of ND1 was not significantly different from the control, but there was a 3-fold 
increase in the expression of CYTB (P < 0.05). At day 3 of RA treatment, the expression of 
ND1 was reduced by 10-fold (P < 0.05) in contrast to that of CYTB, which showed a 10-fold 
increase (P < 0.05) compared with the control. Our data indicated that mitochondrial gene 
expressions may be varied in response to differentiation as well as to the differentiation 
method employed. There are differences between cell lines and between differentiation 
protocols in terms of mtDNA gene expression.   
To examine the genes that regulate mitochondrial biogenesis, expression levels of 
TFAM, NRF1, and POLG were assessed (Figure 4.3A and Table 4.2). In the hES3 cell line, 
at day 7 of spontaneous differentiation, the expression levels of TFAM, NRF1, and POLG 
were reduced by 1.3-, 7-, and 6-fold (P < 0.05), respectively, relative to that in the control 
(Figure 4.3A and Table 4.2). At day 14, TFAM expression was reduced by 4-fold (P < 0.05), 
and NRF1 and POLG expression reduced by 8- and 7-fold, respectively (P < 0.05). At day 3 
of RA treatment, TFAM expression was reduced by 2-fold (P < 0.05), whereas expression 
of NRF1 and POLG was not significantly reduced. Despite the inconsistent pattern of 
mitochondrial-encoded gene expression, the expression of transcription factors involved in 
mitochondrial biogenesis seemed to be steadily decreasing  
In Mel 1, the expression level of TFAM remained the same as that of control at day 7 of 
spontaneous differentiation, while the expressions of NRF1 and POLG showed a 10-fold 
decrease (P < 0.05) (Figure 4.3A and Table 4.2). At day 14, TFAM and NRF1 expression 
remained the same as that in the control, but POLG expression increased by 1.1-fold (P < 
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0.05). After three days of RA treatment, TFAM and NRF1 expression remained the same 
as that in the control and POLG expression decreased by 3-fold (P < 0.05). Collectively 
these data indicated that the expression of known mitochondrial biogenesis-related 
transcriptional factors do not necessarily coincide with changes in mitochondrial mass, 
mitochondrial copy number, and mitochondrial-encoded genes. 
PGC1α is a master regulator in mitochondrial biogenesis and energy expenditure, and 
in most cell types, it facilitates the differentiation process by positively regulating the 
expression of TFAM and NRF1 (Goffart and Wiesner 2003, Scarpulla 2011). To determine 
the role of PGC1α expression during differentiation, hES3 and Mel 1 cell lines were initially 
used for the study. In hES3 cells, the expression level of PGC1α showed 14.3- and 7-fold 
increase at days 7 and 14, respectively (Figure 4.3A and Table 4.2). After RA treatment, 
the expression of PGC1α was markedly elevated by 7.5-fold. In Mel 1 cells, the expression 
level of PGC1α mRNA was also significantly elevated at days 7 and 14 during spontaneous 
differentiation (1.7- and 2.7-fold, respectively) relative to that in the control (Figure 4.3A and 
Table 4.2). At day 3 of RA treatment, the expression level of PGC1α was slightly elevated 
(1.2-fold) relative to that in the control. Collectively, these data indicated that mitochondrial 
mass and PGC1α expression were transiently elevated during the early stages of hESC 
differentiation, suggesting that differentiation is highly dependent on energy consumption. 
Surprisingly, PGC1α affects mitochondrial biogenesis in hESCs without influencing TFAM 
levels. Thus, PGC1α expression may be an early indicator of mitochondrial biogenesis 
during cell differentiation. 
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Morphological Changes in Mitochondria during Differentiation 
Changes in mitochondrial morphology during cell differentiation remain mostly 
unknown thus far. By TEM, we examined the morphology of hESCs (Mel 1) during 
differentiation. Figure 4.3B reveals that mitochondria exhibited an immature morphology 
with only few cristae in the cells before differentiation (Figure 4.3B). They possessed more 
mature cristae with an orthodox morphology at day 14 of the differentiation process (Figure 
4.3C), indicating that mitochondria mature morphologically during spontaneous 
differentiation.  
We hypothesized that an increase in cellular energy may drive an initial differentiation 
of mitochondria or alternatively, it may simply be a consequence of differentiation. One of 
the interesting findings in murine erythroleukemia cell differentiation is that the 
mitochondrial membrane potential appears to be important in the control of the 
differentiation (Levenson, Macara et al. 1982). This finding shows that mitochondria may 
regulate cytoplasmic calcium levels at the initiation of differentiation. Therefore, we 
attempted to measure the mitochondrial membrane potential in order to address the 
hypothesis mentioned above. In general, an accumulation of ratiometric fluorescent dye, 
JC-1, within the mitochondrial matrix can be used to assess membrane potential. When the 
potential is high, JC-1 aggregates and emits fluorescence in red. In contrast, under low 
potential, JC-1 forms monomers and emits fluorescence in green (Salvioli, Ardizzoni et al. 
1997, Mandal, Lindgren et al. 2011). In undifferentiated hESCs, we showed that the 
mitochondrial membrane potential was low and generally clustered near the center of 
hESC colonies (Figure 4.3D). Interestingly, after spontaneous differentiation for 14 days, 
cells exhibited a marked increase in membrane potential on the edges of the hESC 
colonies with low membrane potential scattered throughout the colonies (Figure 4.3E). The 
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observation suggests that mitochondria become depolarized during the differentiation 
process. The mitochondrial transmembrane potential of a subset of differentiated hESCs 
has been changed during the differentiation. It is clear that additional work will be required 
before achieving a complete understanding of the changes in membrane potential. 
Phase II: Mitochondrial Biogenesis during Lineage-Specific Differentiation 
During early embryogenesis, stem cells are exposed to different growth factor regimes 
to induce the growth of primitive mesendodermal, endodermal, and ectodermal precursor 
cells (Thomson, Itskovitz-Eldor et al. 1998). In phase II of the study, we attempted to 
evaluate whether mitochondrial-encoded and mitochondrial biogenesis-related 
transcription factors are correlated with various between differentiations into the three germ 
layers. A general experimental design was carried out with the time points given in Figure 
4.1. Expression of cell type-specific genes was used to track the lineage differentiation as 
previously described (Reubinoff, Pera et al. 2000).  
Ectoderm, endoderm, and mesoderm differentiation were monitored by determining 
the expression of POU5F (pluripotency), paired box 6 (PAX6, ectoderm), SRY-box 17 
(SOX17, endoderm), insulin-like growth factor 2 (IGF2, endoderm), GATA binding protein 4 
(GATA4, endoderm), mix paired-like homeobox (MIXL1, mesoderm), and brachyury (BRY 
mesoderm). 
Ectoderm Differentiation 
When stem cells differentiate into ectoderm cells, they are initially processed from 
neural progenitor cells into the neurosphere. The expression of neural-specific markers 
during ectoderm differentiation has been previously reported (Briggs, Sun et al. 2013). 
Figure 4.4 shows that the mRNA level of PAX6 (neuronal biomarker) was dramatically 
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elevated after 8 and 12 days of differentiation by 517- and 357-fold, respectively, relative to 
the control (Figure 4.4 and Table 4.3), a result which is consistent with our previous finding 
(Briggs, Sun et al. 2013). The expression of a pluripotency marker, POU5F1, was 
attenuated at days 8 and 12 by 4.5- and 16.7-fold, respectively. Mitochondrial-encoded 
ND5 and COX3 were transcriptionally upregulated 12-fold and 13-fold, respectively, at day 
8 of neural induction (P < 0.05), but returned to baseline levels 4 days after neurosphere 
formation. The expression of genes involved in mitochondrial biogenesis, TFAM and NRF1, 
were not significantly affected. However, POLG was upregulated 1.6-fold (P < 0.05) at day 
8, but its expression returned to baseline levels 4 days after neurosphere formation. 
PGC1α mRNA was upregulated 7.8-fold and 2-fold at days 8 and 12, respectively, during 
neuronal differentiation. Because gene expression increased and subsequently returned to 
baseline, it is suggested that mitochondrial-encoded genes and mitochondrial 
biogenesis-related transcription factors are transiently increased during neuronal 
differentiation. 
Endoderm Differentiation 
To induce endoderm differentiation, activin A and bone morphogenetic protein 4 
(BMP4) were added into hESCs culture (D‘Amour, Agulnick et al. 2005). We showed that 
the mRNA level of SOX17, a member of the SOX family of transcription factors that 
contains a high-mobility DNA binding domain, was markedly elevated from days 1 to 3, 
whereas expression of POU5F1, a marker for pluripotency, decreased over time (Figure 
4.5 and Table 4.4). The expression of genes encoded from mtDNA was either slightly 
attenuated (ND5) or remained unchanged (COX3). This finding suggests that SOX17, a 
transcription factor encoded by nuclear DNA, plays a role in or its expression may serve as 
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a pivotal marker for endoderm differentiation. The expression of mitochondrial 
biogenesis-related genes does not change during definitive endoderm differentiation. 
Mesendoderm Differentiation 
To investigate the changes in gene expression during mesoderm differentiation, 
expression of markers of mesoderm (MIXL1 and BRY), endoderm (IGF2 and GATA4), and 
ectoderm (PAX6) were monitored (Figure. 4.6 and Table 4.5). First, we showed that the 
levels of mRNA of the mesoderm marker MIXL1 was significantly raised at days 3 and 5 
(40- and 7-fold, respectively) and returned to baseline level from days 7 to 16. BRY mRNA 
expression was markedly elevated in the early stage at days 3 and 5 (15- and 13-fold, 
respectively) and its level returned to baseline value from days 5 to 16. Surprisingly, 
expression of endoderm markers (IGF2 and GATA4) increased substantially throughout the 
16 days of differentiation, with the levels being much greater than those of mesoderm 
markers. The expressions of the latter two genes also lasted longer for up to 16 days. No 
changes were found in the ectoderm marker PAX6. The data suggest that stem cells may 
differentiate into a mixture of mesodermal and endodermal cell types under our 
experimental condition.  
Expression of POU5F1 was significantly decreased over the 16 days of 
differentiation. On the other hand, ND1, encoded by mtDNA, was upregulated after 7 days 
of mesendoderm differentiation (2.2-fold). Most interestingly, the expression of genes 
involved in mitochondrial biogenesis (TFAM, NRF1 and POLG) was not affected by the 
differentiation into mesoderm.  
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Cardiomyocyte Differentiation 
The expression of cardiac-specific markers during cardiomyocyte differentiation 
have been previously reported (Hudson, Titmarsh et al. 2012). We investigated the 
changes in mitochondrial-related gene expression during cardiac-specific differentiation. 
Figure 4.6 shows the expression of genes encoded by mtDNA, in which ND5 was 
upregulated 2-fold at day 7, but its expression decreased 10-fold at day 16. In contrast, 
COX3 expression did not change significantly during the 16 days of cardiomyocyte 
differentiation. Transcription of the mitochondrial biogenesis gene TFAM was significantly 
reduced throughout 16 days of cardiomyocyte differentiation. Interestingly, PGC1α mRNA 
expression was dramatically elevated (252-fold) after 16 days of cardiomyocyte 
differentiation (Figure 4.7 and Table 4.6). These results suggest that ND5 and PGC1α may 
primarily affect the early stages of mesoderm differentiation and suggest that PGC1α is a 
driver of cardiomyogenesis, which is accompanied by an early upregulation of ND5. 
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Objective 2: Regulation of Mitochondrial Biogenesis in Chloramphenicol- and 
EtBr-treated Primary Human Fibroblasts 
4.2 Morphology and Karyotyping of Mitochondria-Depleted Cells  
Human fetal fibroblasts were cultured for six weeks in the presence of 100 ng/mL EtBr, 
an agent that inhibits the replication of mtDNA, or 100 µg/mL chloramphenicol, a widely 
used antibiotic that inhibits mitochondrial protein synthesis. The fibroblast culture exhibited 
a large amount of dead cells in the presence of EtBr or chloramphenicol within six weekss. 
After recovery for two weeks, the proliferation rate of EtBr-treated fibroblasts recovered 
significantly more slowly relative to the chloramphenicol-treated cells. Both EtBr- and 
chloramphenicol-treated fibroblasts displayed normal karyotypes (Figure 4.8).  
Expression of Mitochondrial-Encoded and Mitochondrial Biogenesis-Related Genes 
of Mitochondria-Depleted Cells 
Human fetal fibroblasts were cultured for six weeks in the presence of EtBr to block 
DNA synthesis or in the presence of chloramphenicol to inhibit mitochondrial protein 
synthesis, which mimics the six-week antibiotics treatment. To evaluate the ability of 
primary human fibroblasts to recover from these mitochondrial insults, fibroblasts were then 
cultured under standard conditions for an additional two weeks following the removal of the 
drugs. Samples were collected for analysis after six weeks of treatment and after two 
weeks of recovery to determine the effect on the expression of mtDNA-encoded genes 
posed by EtBr and chloramphenicol, performed via qPCR. As shown in Figure 4.9 and 
Table 4.7, both EtBr and chloramphenicol treatments inhibited transcription of 
mitochondrial genes, but to various extents. qPCR analysis of the D-loop was used to 
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estimate the mtDNA copy number (i.e., the number of mtDNA molecules per cell). The 
analysis revealed that mtDNA was almost completely abolished in EtBr-treated cells, 
whereas the mtDNA copy number in chloramphenicol-treated fibroblasts was not 
significantly affected.  
After cells were treated with EtBr for six weeks, expressions of ND1 and ND4 (both 
encoded by mtDNA) were undetectable (Figure 4.9 and Table 4.7). After two weeks of 
recovery, however, the expression of these genes rose slightly to 0.07 and 0.11 times that 
of untreated control levels, respectively (Figure 4.9 and Table 4.7). Similarly, expression of 
CYTB was undetectable after six weeks of EtBr treatment, but increased to only 0.08 times 
that of control levels after two weeks of recovery. Expression of COX2 was undetectable 
after six weeks of EtBr treatment, but rose to 0.36 times that of control levels after two 
weeks of recovery. Following chloramphenicol treatment for six weeks, expressions of ND1 
and ND4 were both undetectable. After two weeks of recovery, however, expression levels 
of these genes rose to 0.35 and 1.81 times that of untreated controls, respectively (Figure 
4.9 and Table 4.7). Expression of CYTB decreased to 0.50 times that of the control levels 
after six weeks of chloramphenicol treatment, but did not change after two weeks of 
recovery. Expression of COX2 decreased to 0.02 times that of control levels after six weeks 
of chloramphenicol treatment, but rebounded to 1.34 times that of control levels after two 
weeks of recovery (Figure 4.9 and Table 4.7).  
Taken together, these results showed that both EtBr and chloramphenicol lead to a 
virtual cessation of mitochondrial gene transcription. The only exception was for CYTB, the 
expression of which dropped by only 50% in response to chloramphenicol. After two weeks 
of recovery from EtBr treatment, expressions of ND1, ND4, CYTB, and COX2 were still 
considerably lower than the corresponding experimental control group. In contrast, after 
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two weeks of recovery from chloramphenicol treatment, expressions of ND1 and CYTB 
recovered by 50%. Expression of ND4 and COX2 increased relative to control levels after 
recovery from chloramphenicol treatment. It was concluded that inhibition of both protein 
synthesis and mtDNA replication would effectively eliminate mtDNA-derived gene 
expression with the exception of CYTB in the chloramphenicol treatment condition. 
Following the removal of the drug from the medium, mRNA levels began to recover, 
although the rate of recovery was highly variable. These findings led us to test how these 
different treatments and recoveries were related to mitochondrial biogenesis responses in 
the nucleus.  
To this end, qPCR was used to evaluate the expression of nuclear-encoded 
mitochondrial biogenesis genes, including TFAM, NRF1, and POLG. Expression levels 
were determined after six weeks of EtBr or chloramphenicol treatment, and after two weeks 
of recovery (Figure 4.9 and Table 4.7), TFAM was chosen because it regulates the 
transcription of genes within the mitochondrial genome and interacts with other 
transcription factors. TFAM is also a direct transcriptional target of NRF1. After six weeks of 
EtBr treatment, TFAM expression levels decreased to 0.42 times that of untreated control 
levels, but rebounded to 5.09 that of control levels following two weeks of recovery. 
Expression of NRF1 decreased to 0.19 times that of control levels after six weeks of EtBr 
treatment, but increased to 2.92 times that of control levels after two weeks of recovery. 
Expression of POLG decreased to 0.10 times that of control levels after six weeks of EtBr 
treatment, but increased to 1.15 times that of control levels after two weeks of recovery. 
After cells were treated with chloramphenicol for six weeks, expression of TFAM decreased 
to 0.53 times that of control levels, but increased to 3.53 times that of control levels after 
two weeks of recovery. Expression of NRF1 decreased to 0.02 times that of control levels 
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after six weeks of chloramphenicol treatment, but increased to 0.83 times that of control 
levels after two weeks of recovery. Expression of POLG decreased to 0.34 times that of 
control levels after six weeks of chloramphenicol treatment, but increased to 2.02 times that 
of control levels after two weeks of recovery.  
Collectively, these data showed that mRNA levels of TFAM, NRF1, and POLG were 
downregulated in response to EtBr or chloramphenicol treatment. Recovery from EtBr 
treatment, however, involved the upregulation of TFAM and NRF1, whereas recovery from 
chloramphenicol treatment involved the upregulation of TFAM and POLG. Thus, primary 
human fibroblasts may employ different strategies of mitochondrial biogenesis to recover 
from EtBr or chloramphenicol treatment. 
Lactate Production, Glucose Consumption, Redox Status, Oxygen Consumption, 
and Energy Production   
Next, we determined whether the two distinct recovery responses were correlated with 
specific metabolic or cellular parameters. Effects of EtBr and chloramphenicol treatment on 
mitochondrial function in primary human fibroblasts were investigated with respect to 
lactate production and glucose consumption. We showed that the lactate production and 
glucose consumption were 2.38 × 10–8 µmmol/cell/h and 1.36 × 10–8 µmmol/cell/h, 
respectively, at 48 h (Figures 4.10A, 4.10B and Table 4.8). Reduced GSH and GSSG 
levels were 8.46 × 10–4 pmol/cell and 7.46 × 10–5 pmol/cell, respectively (Figure 4.10C and 
Table 4.8). EtBr treatment increased lactate production (3.43 × 10–8 µmmol/cell/h), glucose 
consumption (2.07 × 10–8 µmmol/cell/h), and the GSSG/GSH ratio. In contrast, 
chloramphenicol treatment did not significantly affect the production of lactate (2.49 × 10–8 
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µmmol/cell/h), glucose metabolism (1.25 × 10–8 µmmol/cell/h), or the GSSG/GSH ratio 
(Figure 4.10C and Table 4.8).  
The next aim was to determine the respiratory activity in control, EtBr-treated, and 
chloramphenicol-treated fibroblasts. Figure 4.10D shows that EtBr-treated cells displayed a 
90% reduction in oxygen consumption, whereas chloramphenicol-treated cells showed only 
approximately a 20% reduction. To compare the effects of EtBr and chloramphenicol 
treatment on mitochondrial function in primary human fibroblasts, the ratio of ATP/ADP was 
measured. This difference in mitochondrial energy production level directly reflected the 
energy status of the cells, with EtBr-treated cells displaying a 76% reduction in the 
ATP/ADP ratio and chloramphenicol-treated cells exhibiting a more modest 30% reduction 
in the ATP/ADP ratio (Figure 4.10E and Table 4.8). These results suggest that 
mitochondrial dysfunction is higher in fibroblasts treated with EtBr than in those treated with 
chloramphenicol and are consistent with the observation that EtBr results in a greater redox 
imbalance and severely alters glycolytic flux.  
Mitochondrial Membrane Potential (Δψm) 
Δψm was visualized using JC-1 staining and quantified via FACS analysis. In fibroblast 
treated with EtBr, red fluorescence associated with JC-1 (high Δψm) was decreased to 0.68 
times that of the control value, whereas green fluorescence (low Δψm) was similar to control 
levels. Neither high nor low IMM potentials were significantly affected in 
chloramphenicol-treated cells. These data indicated that EtBr treatment reduced the 
number of mitochondria with a high Δψm (Figure 4.11 and Table 4.9). Such effect was not 
observed in cells treated with chloramphenicol.  
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Transmission Electron Microscopy of Mitochondria 
Both EtBr- and chloramphenicol-treated fibroblasts displayed normal karyotypes and 
morphologies (Figure 4.8). At the ultra-structural level, however, differences between EtBr- 
and chloramphenicol-treated cells were observed. Transmission electron microscopy 
indicated that control cells contained homogeneous, elongated mitochondria with an oval, 
budding, or spindle appearance. In addition, wild-type mitochondria had transverse or 
oblique parallel cristae. In contrast, EtBr-treated fibroblasts contained round, fragmented 
mitochondria and were very few in number. Cristae within these mitochondria were either 
absent, generating ghost-like mitochondrial scaffolding, or formed a disorganized whorled 
pattern. Chloramphenicol-treated cells possessed a normal number of mitochondria, but 
they seemed immature with morphologically abnormal cristae (Figure 4.12) (King, Godman 
et al. 1972). Collectively, these data indicated that EtBr treatment caused oxidative stress, 
loss of mitochondria with high Δψm, and morphological impairments to mitochondria. The 
effects of EtBr treatment were much more severe than those observed after exposure to 
chloramphenicol. 
128 
 
 
 
Objective 3: Manipulation of TFAM Expression in Human Embryonic Stem Cells 
4.3 TFAM overexpression in hESC lines 
hESCs were engineered to overexpress recombinant TFAM in ESCs (Norrman, 
Fischer et al. 2010) using human elongation factor-1α (EF1α) as a promoter. This process 
was achieved by constructing TFAM cDNA with the pLenti6 vector. hESCs expressing 
green fluorescent protein (GFP) served as vehicle controls. hESCs were transduced with 
these lentiviruses and selected for stable overexpression of TFAM by culturing in medium 
containing 1 μg/mL blasticidin for one week. qPCR was then used to measure both 
endogenous and exogenous TFAM mRNA levels in blasticidin-resistant clones of hESCs.  
In three distinct hES cell lines (Mel 1, hES3, and H9), the EF1α-TFAM construct 
increased TFAM expression (2.06-, 1.71-, and 1.65-fold, respectively) (Figure 4.13, Table 
4.10 and Figure S2). In addition, the mtDNA copy number determined using D-loop as a 
template increased 28-fold in hES3 and 5-fold in H9 compared with controls, but did not 
increase in Mel 1 cells. Essentially, overexpression of TFAM did not affect the morphology 
of hESCs, but resulted in increased cell proliferation in all three cell lines. However, these 
cells had low viability after being frozen for storage. During the first 2–3 passages, the 
plating efficiency was reduced to <3%. The sensitivity of the TFAM-overexpressing hESCs 
in the condition of freezing and/or thawing created a substantial technical barrier for the 
study.  
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TFAM repression in hESC Line: Development of cell line with constitutive repression 
of TFAM  
Lentiviral transduction was used to assess the effects of both constitutive and inducible 
repression of TFAM in hESCs (Figure S9). Preliminary data demonstrated that TFAM 
expression was repressed at different levels by different shRNAs. Unexpectedly, the 
expression of TFAM was elevated 2.5-fold and 2-fold when targeted by shRNA to the 
sequence 266–286 and 591–611 in Mel 1 cells, respectively (Figure 4.14). When the 
position 618–638 was targeted, the expression of TFAM was reduced by 20% (Figure 4.14). 
Moreover, constitutive knockdown of TFAM in hESCs substantially induced cell death, 
making subsequent experimentation difficult. Inducible knockdown of TFAM expression in 
hESCs was used to circumvent these difficulties.  
TFAM Repression in hESC Lines: Development of cell lines with inducible repression 
of TFAM 
Genetic knockout of Tfam resulted in mouse embryonic death (Larsson, Wang et al. 
1998). In addition, constitutive knockdown of TFAM in hESCs appeared to affect their 
survival and pluripotency, making it difficult to analyze these cells. To circumvent these 
difficulties, an inducible system was used to suppress TFAM expression in hESCs (Figure 
4.15, Table 4.11 and Figure S3). With this strategy, transfected cell lines were apparently 
stable. To induce knockdown, the cells were treated with doxycycline (4 μg/mL) for three 
days. Cells without doxycycline treatment were used as a control. Vector transformation 
was selected using 2 μg/mL puromycin for one week. The results of qPCR analysis 
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indicated that all hESC clones selected by the antibiotic expressed the TFAM knockdown 
construct (Figure 4.15 and Table 4.11). 
To assess the efficiency of the shRNA-mediated TFAM knockdown, hESCs were 
exposed to doxycycline and the levels of TFAM mRNA were determined. The effects were 
different in the three hESC lines. In addition, different target sites within the TFAM mRNA 
resulted in different levels of repression. When exon 5 was targeted (TFAMi-3), TFAM 
expression was repressed 5-, 1.3-, and 1.8-fold in Mel 1, hES3, and H9 cells, respectively 
(Figure 4.15A and Table 4.11). Targeting exon 7 (TFAMi-5) resulted in 30- and 2-fold 
repression in Mel 1 and H9 cells, respectively.  
Flow cytometry was also used to determine the levels of TFAM in these cells. 
Targeting exon 5 reduced the TFAM levels 7-fold in Mel 1 cells, 1.8-fold in hES3 cells and 
2-fold in H9 cells (Figure 4.15B-C and Table 4.11). Targeting exon 7 reduced the TFAM 
protein levels 6-fold in Mel 1 cells and 2-fold in H9 cells.  
The effects of reduced TFAM expression on the morphology of hESCs were also 
examined. The morphologies of Mel 1 cells were not affected by reduced TFAM expression 
(Figure 4.16). The proliferation rates appeared to be similar between the control without 
virus transduction and the virus-transduced cell lines without any addition of doxycycline. 
Next, the proliferation rates between virus-transduced cell lines in the presence and 
absence of doxycycline were mutually compared. The proliferation rate was slower in 
virus-transduced cells in the presence of doxycycline compared with those in the absence 
of doxycycline.  
More extensive reduction in the expression of TFAM was seen in H9 cells than in the 
two other cell lines (Figure 4.16). A similar observation was made when TFAM was 
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inducibly repressed via exon 7 targeting. These inducible knockdown lines were easier to 
grow after being frozen in contrast to those constitutively expressed for TFAM. However, 
high levels of cell death were still seen in these TFAM knockdown cells in culture. Once 
again, this result created a considerable technical barrier for the study on the effect of 
TFAM downregulation on cell differentiation. 
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Objective 4: Mitophagy in Human Embryonic Stem Cells  
4.4  Characterization of Autophagosome in GFP Reporter Cell Line 
The establishment of an hESC line expressing the LC3-GFP fusion protein has been 
previously reported (Tra, Gong et al. 2011) and yet, it was difficult to recover the 
hES-LC3-GFP cells from the frozen storage. A new hES3 cell line that expresses the 
LC3-GFP fusion protein was therefore prepared and adapted in our study to allow single cell 
growth as described in the Materials and Methods. Punctuated green dots within these cells 
represent autophagosomes (Figure 4.17A). Under normal culture conditions, this 
hES-LC3-GFP line exhibited a diffused distribution of GFP fluorescence throughout the 
cytosol with typically one or two fluorescence punctates (Figure 4.17A). The expression of 
pluripotency markers POU5F1 and TRA-1-60 in these cells is also shown (Figure 4.17B and 
Figures S4 and S5) 
Mitophagy in hESCs by Time-Lapse Microscope  
Since mitochondrial turnover remained to be investigated, levels of autophagy and 
mitophagy in hESCs were assessed next. To determine the extent of mitophagy, the 
hES-LC3-GFP reporter line was labeled with MitoTracker Red and the extent of 
co-localization of GFP and MitoTracker Red was analyzed. First, hES-LC3-GFP cells were 
treated with reagents known to induce mitochondrial damage, such as rapamycin (an 
inducer of autophagy), carbonyl cyanide m-chlorophenyl hydrazone (CCCP, a mitochondrial 
membrane potential uncoupler) (Figure S6), and EtBr (a mtDNA replication inhibitor). 
Time-lapse microscopic examination of MitoTracker-labeled hES-LC3-GFP cells treated 
with CCCP or EtBr revealed that these agents triggered mitophagy in an asynchronous 
133 
 
 
manner within the individual cells from 0 to 10 minutes followed by changes in the colonies 
(Figure 4.18A–D, Videos 4.1–4.4 and Figures S7 and S8). The occurrence of mitophagy 
during differentiation was examined. Mitophagic events were increased between 0 to 20 
minutes of differentiation compared with the control (Figure 4.18E, Video 4.5 and Figures S7 
and S8). Therefore, mitophagy appears to be a dynamic process.  
The biological significance of mitophagy taking place in hESCs was further 
investigated. First, a time course analysis of EtBr treatment was conducted in hESCs. EtBr 
triggers widespread and rapid mitophagy across the colonies of the cells within the first 16 
hours (Figure 4.18F, Video 4.6 and Figures S7 and S8). After one week of exposure to 100 
ng/ml EtBr, cell death occurred in a significantly higher number of hESCs than the controls 
(Figure 4.18G-H, Video 4.7-4.8 and Figures S7 and S8).  
Quantification of Mitophagy Using Live Cell Cytometry  
The number of autophagosomes was subsequently determined using AMNIS 
live-imaging flow cytometry in order to quantify mitophagic events. Compared with that in the 
DMSO-treated control, the number of autophagosomes was clearly higher in hESCs treated 
with rapamycin, CCCP, or EtBr (Figures 4.19A and 4.20 and Table 4.12). Because it is 
technically difficult to determine spot count using the AMNIS live cytometer (as a result of 
the two fluorescence images), >500 images captured under each experimental condition 
were manually scored. The number of autophagosomes that were positively stained for 
MitoTracker was determined. In control samples, hESCs possessed an average of one 
autophagosome and one mitophagosome per cell. The majority of the cells contained zero 
to two autophagosomes, whereas some cells exhibited as many as five or more 
autophagosomes (Figures 4.19B and 4.20 and Table 4.12). In samples treated with 
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rapamycin, CCCP, or EtBr, the number of autophagosomes increased to one to two per cell. 
In addition, the average number of mitophagosomes also increased to one to two per cell (P 
< 0.05, Figures 4.19B and 4.20 and Table 4.12). In samples treated with rapamycin, CCCP, 
or EtBr, the majority of cells possessed two to three autophagosomes, whereas some cells 
exhibited up to fifteen autophagosomes. The average number climbed to three to four per 
cell (P < 0.05, Figures 4.19B and 4.20 and Table 4.12). Therefore, induced mitochondrial 
dysfunction (i.e., dysfunction brought about by the addition of rapamycin, CCCP, or EtBr) 
resulted in an enhanced autophagic process, which was related to mitophagy.  
As indicated above, control levels of autophagosomes and mitophagosomes within 
hESCs were 0.69 and 0.65 per cell, respectively (Figure 4.19B and 4.20 and Table 4.12). In 
RA-treated or spontaneously differentiated cells, at days 7 and 14, the average number of 
autophagosomes was 1.6, 1.4, and 0.83 per cell and that of mitophagosomes was 1.4, 1.2, 
and 0.8 per cell, respectively (Figure 4.19B and 4.20 and Table 4.12). For autophagosomes, 
at days 7 and 14, most cells exhibited one to two autophagosomes, whereas some cells 
possessed up to five autophagosomes per cell. Average values climbed to 3.1, 3.0, and 2.1, 
respectively (Figure 4.19B and 4.20 and Table 4.12). The number of autophagosomes 
ranged from two to three. These data demonstrated that during the early stages of hESC 
differentiation, both autophagosome formation and mitophagy increased. TEM analysis 
showed that hESCs treated with rapamycin, CCCP, or EtBr (24 hours) had fragmented 
mitochondria with very few cristae (Figure 4.19C). Furthermore, more mitochondria inside 
the autophagic vacuoles were detected in these cells as compared with controls (Figure 
4.19C).  
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Chapter 5: Discussion 
Objective 1: Mitochondrial-Encoded and Mitochondrial Biogenesis-Related Gene 
Expression During Lineage-Specific Differentiation of Human Embryonic Stem 
Cells 
The levels of mtDNA can affect oocyte maturation, which occurs after fertilization, 
and embryo differentiation (Spikings, Alderson et al. 2007). A number of studies have 
shown that mitochondrial maturation is involved in the differentiation process (Cho, Kwon et 
al. 2006). However, the role of mitochondrial-encoded genes and genes related to 
mitochondrial biogenesis remains mostly unknown. To the best of our knowledge, our study 
is the first to describe the expression profiles of these genes during spontaneous 
differentiation, lineage-specific differentiation (in the ectoderm, endoderm, and mesoderm), 
and specific cell-type differentiation (neuronal and cardiomyocytic). The first objective was 
to determine the gene expression patterns of mitochondrial-encoded and mitochondrial 
biogenesis-related genes during spontaneous and directed lineage-specific differentiation. 
MtDNA Copy Number and mtDNA-Encoded Gene Expression during Spontaneous 
Differentiation 
Dynamic changes (e.g. downregulation of pluripotency genes, upregulation of 
differentiation genes and a shift to a different set of metabolic enzymes) in the early phase 
of cellular differentiation have been recently observed (Prigione and Adjaye 2010, Prigione, 
Lichtner et al. 2011). Yet, differentiation and changes in mitochondrial gene expression 
may not always occur concurrently (Facucho-Oliveira, Alderson et al. 2007). We have 
shown that the mtDNA copy number was significantly elevated at the 7th day of 
spontaneous differentiation and gradually reduced by the 14th day (Figure 4.3). In addition, 
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the expression of the pluripotency markers TRA-1-60 and POU5F1 was downregulated 
during differentiation, thus suggesting that the expression of mitochondrial-related genes 
may be transient. We studied the expression of two mitochondrial-encoded genes, ND1 
and CYTB, and found that ND1 expression was significantly downregulated at day 7 in 
spontaneous and RA-induced differentiation of the Mel 1 cell line; however, there was no 
significant subsequent change in its expression at day 14. The level of CYTB, however, 
was significantly upregulated at day 14 (Figure 4.3 and Table 4.2). This result suggests that 
the expression of mitochondrial-related genes may be transient. 
It has been reported that different cell lines at various stages of pluripotency may show 
similar gene expression (Giritharan, Ilic et al. 2011). Our finding, however, has shown that 
different hES cell lines exhibited different mitochondrial-encoded gene expression at the 
same time point during differentiation. Different copy numbers of mtDNA were observed 
when the cells were differentiated using different induction protocols. Amplification of the 
D-loop region also seemed to trigger transcription of genes encoded by mtDNA. It was 
surprising to find that dynamic changes in gene expression were seen in different cell lines 
at various time points. We further showed that the apparent discrepancy of mtDNA copy 
number obtained by using different treatments might be due to the level of differentiation 
obtained with the different treatments at various time points, which affected the level of 
mitochondrial replication. However, there is limited information attributed to this finding; 
hence, additional work is required to achieve a complete understanding of this result. 
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Expression of Mitochondrial Biogenesis-Related Genes during Spontaneous 
Differentiation 
In recent years, several reports have described mitochondrial biogenesis-related gene 
expression during differentiation of hESCs. When hESCs are allowed to differentiate 
spontaneously (by removing the basic fibroblast growth factor 2 (bFGF2), KOSR and the 
feeder layer), the expression of both mtDNA-encoded and mitochondrial biogenesis-related 
genes is upregulated (Cho, Kwon et al. 2006). However, our results suggest that the 
expression of genes encoding mitochondrial biogenesis-related transcription factors (TFAM, 
NRF1 and POLG) may not coordinate with the expression of mitochondrial 
biogenesis-related transcription factors upon spontaneous differentiation. Undoubtedly, it 
remains to be determined whether the difference is due to the use of different cell lines or 
differentiation protocols. 
The changes in gene expression at various time points during spontaneous hESC 
differentiation remain elusive. The differentiation of mESCs is initially associated with 
decreased mtDNA copy number, but this number gradually increases as pluripotency 
markers are downregulated (Facucho-Oliveira, Alderson et al. 2007). Our data are 
consistent with the notion that there may have been a difference in mitochondria number in 
undifferentiated and differentiated stem cells. The transcription levels of TFAM, NRF1 and 
POLG, which may not be the main mitochondrial biogenesis-related transcription factors, 
were not increased during hESC differentiation. 
Cellular differentiation is often accompanied by changes in gene expression and 
enzymatic activities associated with the mitochondrial oxidative phosphorylation process 
(Wieckowski, Giorgi et al. 2009). The results obtained in the present study further 
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demonstrated that mitochondria in undifferentiated hESCs exhibit an immature morphology. 
In addition, differentiated hESCs possessed more JC1 aggregates than undifferentiated 
cells, indicating a higher mitochondrial membrane potential in the differentiated cells. These 
results suggest that mitochondrial differentiation is associated with early cellular 
differentiation; this could indicate that energy produced from mitochondria is needed during 
the differentiation process, as proposed in the study by Tormos et al (Tormos, Anso et al. 
2011). Genes involved in mitochondrial biogenesis (e.g. polymerase RNA (POLRMT), 
mitochondrial transcription termination factor (MTERF), TFBM1/2, NRF1/3 and UCP2/4) 
are downregulated upon differentiation (Zhang, Khvorostov et al. 2011). Our results 
demonstrated that mitochondrial-content increases in response to early spontaneous 
differentiation and that the master of mitochondrial biogenesis-related genes (PGC1α) is 
also responsible for early spontaneous differentiation. 
Lastly, ROS can function as a signal that triggers adipogenesis (Tormos, Anso et al. 
2011). During the early stages, adipocyte differentiation, oxygen consumption and ATP 
production were upregulated and a PPAR-gamma-dependent transcriptional cascade was 
initiated. This implied that changes in mitochondrial metabolism, which occurred during 
differentiation, might have resulted from the evolving energy demands or from the 
production of ROS; this could lead to characteristics of aging as a result of ROS 
overproduction (i.e. the mitochondrial theory of aging) (Adhya, Mahato et al. 2011, Yamada, 
Furukawa et al. 2011). Therefore, the increase in ROS production upon differentiation may 
be implied.  
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MtDNA-Encoded and Mitochondrial Biogenesis-Related Gene Expression during 
Lineage-Specific Differentiation 
Mitochondrial properties are altered during the process of lineage-specific 
differentiation in early gastrulation (Baker 1964) and neurogenesis (Cordeau-Lossouam, 
Vayssiere et al. 1991). The increase in mitochondrial mass that accompanies each step of 
neurogenesis produces large variations in mitochondrial protein levels (Cordeau-Lossouam, 
Vayssiere et al. 1991). In this section, the results of the study on lineage-specific 
differentiation help to understand that the mitochondrial biogenesis also requires precise 
coordination between the mitochondrial and nuclear genomes. 
Neural differentiation: 
Neurons are metabolically active cells with high energy demands, but the expression 
profiles of mitochondrial-encoded and mitochondrial biogenesis-related genes remain to be 
determined. Our results revealed that the expression of genes, which were involved in 
mitochondrial biogenesis, was elevated after 8 days of neurosphere formation, but reduced 
at day 12. First, we showed that the differentiation may result in an increase in 
mitochondrial-encoded gene expression, suggesting that the mitochondrial genome has 
been replicated. Second, one of the most significantly upregulated mitochondrial 
biogenesis-related genes, which we identified as PGC1α, had elevated expression after 8 
days of neuronal-specific differentiation, whereas the expression of TFAM, NRF1 and 
POLG was not significantly upregulated when compared to PGC1α. The latter result is 
similar to that reported by Marchetto et al. in 2010 (Marchetto, Carromeu et al. 2010), which 
revealed that the expression levels of TFAM, NRF1 and POLG either remained the same or 
decreased. The results suggest that PGC1α is probably one of the early genes potentially 
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involved in the upstream regulation of mitochondrial biogenesis upon neuronal 
differentiation. However, PGC1α expression was upon neural differentiation, and therefore, 
further investigation is needed to study the relative ROS production, antioxidant-related 
gene expression, and protein expression. Our data indicated that PGC1α could be a driver 
for mitochondrial biogenesis-related gene expression in mitochondrial regulation during 
neural differentiation. 
Endoderm differentiation 
Next, we demonstrated that mitochondrial-encoded and mitochondrial 
biogenesis-related genes played important roles in the early differentiation of hESCs into 
the endoderm. TFAM, NRF1, POLG and PGC1α have been reported to be involved in and 
be responsible for the distinct regulation of endoderm differentiation (Kanai-Azuma, Kanai 
et al. 2002, Grapin-Botton and Constam 2007, Kim, Yoon et al. 2011, Spence, Mayhew et 
al. 2011, Teo, Arnold et al. 2011). The results of our study are similar to those of the study 
by Spence et al. which showed low TFAM, NRF1, POLG and PGC1α expression upon 
activin-induced definitive endoderm formation and mimicking embryonic intestinal 
development (Spence, Mayhew et al. 2011). As shown in previous studies, mRNAs derived 
from mtDNA (e.g. CYB and ND1) are expressed throughout the small intestine and colonic 
epithelium in humans (Macpherson, Mayall et al. 1992) and expression levels of 
mitochondrial rRNAs and mRNAs in these tissues are somewhat similar to those in 
immature enteroblasts. Interestingly, some researchers also reported higher levels of 
mitochondrial mRNA and TFAM expression in immature enteroblasts as compared with the 
mature cells of the villus (D‘Amour, Agulnick et al. 2005). We observed a different result in 
our study of the early endoderm-specific differentiation (Figure 4.5); this discrepancy is due 
to the fact that the maturation of villus cells occurs only 50–60 days after differentiation. In 
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addition, mitochondrial biogenesis-related gene expression patterns within specific 
endodermal cell types were not analyzed. Therefore, in future studies, the duration of 
endoderm differentiation could be extended in order to further understand the mechanism 
involved in enterocyte maturation related to mitochondrial biogenesis. 
Mesendodermal or cardiomyocyte differentiation 
The heart is a very important organ that is heavily dependent on oxidative energy 
generated from mitochondria. Distorted structure and dysfunction of the mitochondria are 
found in patients associated with cardiovascular diseases. The heart is also the first organ 
to mature in an embryo. For this reason, it was our strategy to utilize differentiating 
cardiomyocytes in this study to investigate the expression of mitochondrial-encoded and 
mitochondrial biogenesis-related genes in order to understand the role of mitochondria in 
cell differentiation. In addition, the study may provide an insight for regenerative medicine 
since cardiomyocytes cannot be reproduced in patients with ischemic damage. Our results 
are consistent with those obtained by Salomonis et al. (Salomonis, Nelson et al. 2009) that 
showed that the expression of PGC1α was markedly upregulated, whereas that of TFAM 
and NRF1 was is downregulated upon mesendoderm and cardiomyocyte differentiation. 
On the other hand, there were no significant changes in the expression of POLG. PGC1α is 
known to be a key factor involved in the induction of mitochondrial biogenesis in many 
tissues (Kelly and Scarpulla 2004) and its expression is upregulated after osteogenic 
differentiation of human mesenchymal stem cells or after cardiomyocytic differentiation of 
mESCs (Pietila, Lehtonen et al. 2010). PGC1α is proposed to be acting, upstream of both 
TFAM and NRF1, as a master genetic switch. However, our study showed that upregulation 
of PGC1α expression was not accompanied by increased TFAM and NRF1 expression, 
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suggesting that PGC1α utilizes an alternative signal transduction pathway, which is 
independent of TFAM and NRF1, to upregulate mitochondrial activity. 
During cellular differentiation, mitochondria must also differentiate and mature via 
processes involving both structural and functional changes, such as changes in the 
mitochondrial membrane potential. In developing cardiomyocytes, changes in 
mitochondrial activity occur at both the pre- and post-natal stages of development, which 
are associated with the upregulation of oxidative phosphorylation and an increase in 
mtDNA copy number. We showed that the mitochondrial-encoded genes (ND1 and ND5) 
were upregulated at the 7th day of mesendoderm and cardiomyocyte differentiation. Here, 
we attempted to study the correlation between mitochondrial-encoded genes and 
mitochondrial biogenesis-related transcription factors in cardiomyocyte differentiation. 
We examined several genes encoded by mtDNA and genes related to mitochondrial 
biogenesis. It was surprising to find that, during hESC differentiation, the expression levels 
of several mitochondria-related genes did not correlate with levels of PGC1α. Interestingly, 
PGC1α is consistently upregulated in spontaneous, RA-induced, ectoderm-specific, or 
cardiomyocyte-specific differentiation, but not in endoderm-specific differentiation. 
Differences in the temporal expression patterns during the transition of undifferentiated to 
differentiated hESCs might have been the result of the variable half-lives of mitochondrial 
mRNAs (Nagao, Hino-Shigi et al. 2008). Different lineage-specific differentiations, such as 
ectoderm-specific and cardiomyocyte-specific differentiations, displayed different patterns 
in mitochondrial biogenesis. In summary, we conclude that the specific nucleus-encoded 
mitochondrial biogenesis-related transcription factors have different gene expression 
patterns upon lineage differentiation. Therefore, in future studies, we will focus primarily on 
evaluating the feasibility of changes in mitochondrial biogenesis upon differentiation of 
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hESCs in a time manner and gain a better understanding of the role of mitochondria during 
differentiation. 
This study did not address the molecular mechanism explaining how mitochondrial 
maturation is associated with differentiation (St John, Ramalho-Santos et al. 2005, Cho, 
Kwon et al. 2006, St John, Amaral et al. 2006). Many researchers indicated their 
observation of mitochondrial maturation upon differentiation. In this study, we measured 
gene expression levels, but we were unable to find enough evidence to explain the 
molecular mechanism of role of mitochondrial maturation in differentiation. Therefore, 
additional studies will need to be carried out to determine the possible effect of mtDNA 
copy number and to explore whether mitochondrial maturation is responsible for the 
mitochondrial activity in different hESC lines. First, the protein levels of the pluripotency 
markers (TRA-1-60 and POU5F1), lineage-specific biomarkers, mitochondrial-encoded 
genes, and mitochondrial biogenesis-related genes should be analyzed using a western 
blot to determine their significance in the process of differentiation. Another consideration is 
to examine mitochondrial functions by looking into mitochondrial respiration, membrane 
potential, energy metabolism (ATP/ADP, glucose uptake and lactate production), and the 
level of reactive oxygen species (DCF or mitoSOX red staining or GSH/GSSG) in order to 
gain an insight on mitochondrial metabolism during differentiation. Finally, the molecular 
mechanism of PGC1α in the mitochondrial biogenesis signaling pathway (Scarpulla 2008) 
could be investigated to explain how it could respond to lineage-specific differentiation. 
PGC1α seems to be an early indicator of the upregulation of mitochondrial biogenesis in 
the lineage-specific differentiation of hESCs. Overall, a combination of these experimental 
results would provide unique and valuable insights into the regulation of mitochondrial 
biogenesis in stem cell differentiation. 
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Objective 2: Regulation of Mitochondrial Biogenesis in Chloramphenicol- and 
EtBr-treated Primary Human Fibroblasts 
Defects in mitochondrial function due to mtDNA mutations or chemicals that affect 
mitochondrial protein function lead to a range of pathologies, often serious (Zeviani and 
Antozzi 1997, Lane 2006). The exact mechanism by which mitochondrial impairments 
cause the wide range of observed pathologies remains to be determined. Some studies 
have shown that, during the early preimplantation stage, there is limited or no active 
mitochondrial replication (Cao, Shitara et al. 2007, Wai, Ao et al. 2010). A minimum mtDNA 
copy number threshold is required before the cells of the fertilized oocyte can differentiate 
into various tissues. The second objective was to investigate the effects of mitochondrial 
depletion on human fibroblasts and hESCs. The novel finding in this study was that there is 
compensation in the expression of mitochondrial-encoded and mitochondrial 
biogenesis-related genes after removing the treatments.  
In the present study, mitochondrial functions were impaired by treating the cells with 
EtBr (an inhibitor of mtDNA replication) or chloramphenicol and the impacts of these two 
drugs on mitochondrial function and nuclear expression of mitochondrial biogenesis 
regulators was compared. Both drugs impaired mitochondrial function, albeit to a different 
extent, and led to the differential expression of both mtDNA-encoded genes and nuclear 
transcription factors that control mitochondrial biogenesis. This study is the first to 
demonstrate that established human fibroblast cell lines devoid of characteristic mtDNA 
markers can be obtained from cell populations exposed to EtBr for a long time. Each cell 
may contain different mitochondrial content, and each mitochondrion may contain 1–10 
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mtDNA. The mitochondrial mass or content of a cell will affect its mtDNA copy number. 
Here we report the generation of characterized primary human fibroblasts, which exhibited 
a substantial reduction in mtDNA levels and a concomitant reduction in respiratory-chain 
enzyme activities.  
The data derived in this study showed that the inhibition of protein synthesis (by 
chloramphenicol) or of mtDNA synthesis (by EtBr) caused severe reductions in the 
transcription of mtDNA genes, with the exception of CYTB, after chloramphenicol exposure. 
After two weeks of recovery from chloramphenicol treatment, some genes encoded by the 
mitochondrial genome (ND1 and CYTB) exhibited partial recovery of expression. Other 
mtDNA genes (ND4 and COX2) exhibited an overcompensation (i.e. expression levels 
were higher after recovery than those before the treatment). However, the cells only 
showed a minor recovery from mitochondrial genome depletion by EtBr treatment. EtBr and 
chloramphenicol, therefore, had different effects on mitochondrial transcription in human 
fibroblasts. In response to both treatments, TFAM expression was upregulated. In contrast, 
POLG expression was upregulated by chloramphenicol and NRF1 expression was 
upregulated by EtBr. We do not know why the cells choose to employ these different 
compensatory mechanisms. Seeking to identify cellular parameters underlying these 
different responses, we found that EtBr-treated cells exhibited a reduced Δψm, an 
increased lactate/glucose ratio, morphologically abnormal mitochondria, and increased 
oxidative stress-effects that were generally not observed in chloramphenicol-treated cells 
(Soslau and Nass 1971, Storrie and Attardi 1973, Stuchell, Weinstein et al. 1975, Lipton 
and McMurray 1977, Wiseman and Attardi 1978). The EtBr data closely resembles that 
previous studies performed with HeLa and C2C12 cells (Hayashi, Ohta et al. 1991, Joseph, 
Rungi et al. 2004), which showed that the elimination of mtDNA causes deficiencies within 
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the electron transport chain, an increase in intracellular ROS, a metabolic shift towards 
glycolysis, increased lactate production, reduced ATP synthesis and lower Δψm. These 
changes collectively resulted in the upregulation of NRF1 and TFAM expression. It should 
be noted, however, that increases in NRF1 and TFAM mRNA expression do not 
necessarily affect protein levels (Davis, Ropp et al. 1996, Miranda, Foncea et al. 1999). 
TFAM may be less stable in the absence of mtDNA (Miranda, Foncea et al. 1999). 
Replication and transcription of mtDNA depend on proteins encoded by genes on the 
nuclear genome, such as NRF1 and TFAM (Scarpulla 2006, Scarpulla 2008). In agreement 
with this notion, disruption of NRF1 or TFAM in mice leads to reduced levels of mtDNA and 
lethality during early stages of embryogenesis (Larsson, Wang et al. 1998, Huo and 
Scarpulla 2001).  
Chloramphenicol inhibits mitochondrial protein synthesis and delays muscle 
regeneration (Wagatsuma, Kotake et al. 2011) and in a reversible manner (Rebelo, 
Williams et al. 2009). Surprisingly, the data obtained in this study revealed, after the 
chloramphenicol treatment was stopped, NRF1 was not up-regulated during recovery. 
Rather, this recovery process involved POLG and TFAM, suggesting that the inhibition of 
mitochondrial protein synthesis elicits a different retrograde signal than that triggered by 
mtDNA depletion. The data in this study suggest that the chloramphenicol-based signal 
does not involve the ATP/ADP ratio, the Δψm, altered glycolytic flux, or altered oxygen 
consumption, as these parameters were not affected by chloramphenicol treatment. 
As the mtDNA copy number goes down, so do respiratory chain activities. In 
EtBr-treated fibroblasts, respiratory activity dropped more rapidly than in 
chloramphenicol-treated ones, possibly because of the toxic side effects associated with 
EtBr. Similar decreases in respiratory function (including complex activities and oxygen 
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consumption) have been observed in ρ° cells (King and Attardi 1989). EtBr-treated cells 
exhibited lower levels of mtDNA expression and respiratory activity. Once mtDNA levels 
dropped beneath a certain level, the cell‘s bioenergetic status rapidly deteriorated. This 
result suggests that each cell has a mtDNA threshold beneath which it cannot maintain a 
sufficient level of energy production. It is likely that cells have a surplus of mtDNA 
molecules that extend well above this mtDNA threshold, which could protect the cell from 
sporadic mutations to the mtDNA. The results in this study have shown that reductions in 
Δψm, together with the elevation in lactate formation, suggested oxidative phosphorylation 
(OXPHOS) impairment. However, there was a clear decrease in the red/green fluorescence 
ratio in the treated group, and some cells failed to show a lower Δψm after EtBr treatment. 
Interestingly, some cells with ρ° status maintained a normal Δψm independent of impaired 
OXPHOS. Despite the apparent impairment in OXPHOS in the treated groups, the amount 
of mtDNA per cell did not decrease over time with EtBr treatment (Buchet and Godinot 
1998). According to King and Attardi (1996) (King and Attardi 1996), it is impossible to 
isolate ρ° derivate of all human cell lines using EtBr. Our results suggest that the 
mitochondrial content may not be erased completely and some mitochondrial activity 
remains in some cells. 
Depletion of mtDNA genes resulted in the reduction of mitochondrial-encoded gene 
expression. In the present objective, the fibroblasts initially showed a decrease in the 
amount of mtDNA when treated with EtBr, but they subsequently regained normal levels of 
mtDNA after being withdrawn from treatments. The amount of mtDNA was increased in 
treated cells compared with controls, as exemplified by a lower ΔΨm and higher levels of 
lactate production. The higher levels of lactate production might correspond to a cellular 
alternative for the generation of ATP by the glycolytic process. In both treatments, the 
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mtDNA replication might be due to the failure of RNA polymerase to transcribe mtDNA, 
leading to a decline in Δψm. Finally, the data in this thesis could provide insights into the 
response of human cells to mtDNA depletion  
In future, additional studies should be carried out to determine if other effects on the 
depletion of mtDNA copy number are observed with different dosages of EtBr and 
chloramphenicol in different cell lines; these studies should include the use of two or more 
fibroblasts and two or more hES cell lines. A higher resolution of mitochondrial 
morphologies examined by TEM would also benefit us with more information in this study. 
Recently, few practitioners and researchers have become aware that the mutant 
mitochondrial DNA can carry over and affect the differentiation of embryonic stem cells into 
various cell types, a discovery that can possibly help prevent the transmission of 
mitochondrial diseases to one‘s offspring (Tanaka, Sauer et al. 2013).  
In summary, the results presented in this thesis demonstrated that treatment with EtBr 
and chloramphenicol affect the mtDNA replication to different degrees. By characterizing 
the mitochondrial-encoded and the nucleus-encoded mitochondrial biogenesis-related 
genes in mitochondria-depleted cells subjected to two different treatments, it is shown that 
chloramphenicol interferes with mtDNA replication and results in a moderate depletion of 
mtDNA copy number and function to a larger extent as compared with EtBr. The 
observations guide us to understand that the reduction in mitochondrial gene expression 
could be a signal of the retrograde recovery of mitochondrial biogenesis-related 
transcription factors as an example of altered nuclear gene expression. However, 
additional mechanisms of retrograde mitochondrial signaling, such as mitochondrial 
autophagy, remain to be investigated. 
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Objective 3: Manipulation of TFAM Expression in Human Embryonic Stem Cells 
When generatingrho-minus cells with which to investigate how the mtDNA copy 
number affects hESC survival, one of the main challenges is that cells cannot survive 
without mitochondria. The third objective waso establish hESC lines in which TFAM was 
overexpressed or knocked down and to characterize the effects of TFAM expression on 
mitochondrial biogenesis during the proliferation of hESCs. The purpose of this study was 
to test the hypothesis that TFAM expression is associated with mtDNA copy number and 
cell proliferation in hESCs. The study was the first to manipulate TFAM expression in 
hESCs. An expression vector was used to overexpress TFAM, while TFAM-specific short 
hairpin RNAs (shRNAs) were used to suppress TFAM expression in three hESC lines (Mel 
1, hES3, and H9).  
We observed different expression levels of TFAM in various hESC lines, suggesting 
that these cells use different mechanisms to regulate mtDNA. The results presented here 
showed that TFAM overexpression results in an increase in mtDNA copy number to various 
degrees in different hESC lines. EF1α-TFAM hESCs exhibited higher rates of proliferation 
relative to control cells. Previous studies have shown that the overexpression of TFAM in 
other cell types resulted in an increase in mtDNA copy number (Larsson, Wang et al. 1998, 
Ekstrand, Falkenberg et al. 2004, Kanki, Ohgaki et al. 2004), whereas the knockdown of 
TFAM resulted in a decrease in mtDNA. Interestingly, it has been reported in the study by 
Ylikallio et al. (2010) that the high mtDNA copy number is associated with cell death 
(Ylikallio, Tyynismaa et al. 2010) which is possibly, because C-MYC (MYC) binds to the 
TFAM promoter (Li, Wang et al. 2005) to regulate cell proliferation and energy metabolism 
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by regulating glycolysis (Zeller, Jegga et al. 2003). This result suggests that MYC may 
upregulate TFAM expression in hESCs, thereby acting as a master switch to control 
mitochondrial biogenesis and to couple the metabolic needs of a cell to its growth and 
proliferation. 
This observation is supported by a previous demonstration that the C-terminal tail of 
TFAM is critical for binding to the light-strand and heavy-strand promoters (Malarkey, 
Bestwick et al. 2012). TFAM that lacks a C-terminal tail retains the ability to bind DNA, but 
does not activate transcription (Pastukh, Shokolenko et al. 2007). Overexpression of TFAM 
restores memory impairment (including working memory and hippocampal long-term 
potentiation), attenuates the mitochondrial production of ROS and limits mtDNA damage in 
aged mice (Hayashi, Yoshida et al. 2008). The optimal stoichiometry is five molecules of 
TFAM per copy of mtDNA. However, TFAM-mediated transcriptional activity is reduced or 
eliminated if the TFAM:mtDNA ratio exceeds five (Garrido, Griparic et al. 2003, Kanki, 
Nakayama et al. 2004) Both endogenous and exogenous TFAM bind mtDNA to form a 
mitochondrial-nucleoid complex (kanki, Nakayama et al. 2004). Consequently, a decrease 
in TFAM expression may lead to reduced mtDNA copy number, which may disrupt 
oxidative phosphorylation in organs. This result may explain that the overexpression of 
TFAM in hESCs was not compatible with survival well after thawing. It is possible that 
overexpression of TFAM stimulates cell proliferation, which may lead to insufficient levels of 
ATP production. However, EF1α-TFAM hESCs typically had low survival rates during the 
first 24 hours for 1–2 passages. hESCs that overexpress TFAM could grow, but they could 
not be re-thawed; this may have been a result of increased levels of ROS during the early 
stages of plating. Additional experiments are needed to determine the level of cell 
proliferation and the rate of ATP and ROS production before and after freezing.   
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 Because TFAM may affect mitochondrial transcription and replication, inhibition of 
TFAM would result in some mitochondrial dysfunction. The extent of the damage caused by 
mitochondrial dysfunction can vary greatly depending on the type of tissue or cell, but 
muscle and heart tissues are particularly sensitive to this effect. In mice, homozygous 
TFAM knockout embryos exhibited severe mtDNA depletion with abolished oxidative 
phosphorylation and died before complete embryo development at day 7.5, whereas the 
heterozygous mice exhibited reduced mtDNA copy number and respiratory chain 
deficiency in the heart (Larsson, Wang et al. 1998). Our preliminary data indicated that 
downregulation of TFAM affected the in vitro survivability and proliferation of hESCs.  
 Several factors could have also influenced the outcome of this study (cell death 
induced after knockdown of TFAM). The experimental design in the present study revealed 
that there are some discrepancies in comparison with previous reports. Therefore, in the 
future, some additional studies should be carried out:  
(1) To analyze and determine the mechanisms by which constitutive and inducible 
repression of TFAM results in cell death, although there are no studies documenting 
cell death in TFAM knockout stem cells; 
(2) To use other strategies for manipulating TFAM expression in different hESC lines in 
order to determine mtDNA copy number, mitochondrial gene transcription, 
mitochondrial respiration, cell proliferation, cell survival, and pluripotency on 
differentiated cells; 
(3) To ultimately determine any other possible changes in mitochondrial function (such as 
changes in mitochondrial respiration and membrane potential), energy metabolism 
(ATP/ADP, glucose uptake and lactate production), and ROS level (DCF, mitoSOX red 
staining, or GSH/GSSG). Moreover, higher resolution investigations of cell and 
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mitochondria morphologies should be conducted using light and transmission electron 
microscopy. 
The importance and role of an upregulated PGC1α expression should be evaluated in 
the lineage-specific differentiation of hESCs. Manipulation of PGC1α expression in these 
cells may provide insights into the mechanism underlying the involvement of mitochondria 
in the differentiation of hESCs into specific cell lineages.  
 In summary, the results of this study revealed that downregulation and upregulation of 
TFAM expression decreased and increased mtDNA expression, respectively, suggesting 
that TFAM must be expressed at tightly controlled levels for cell survival and to maintain 
mitochondrial functions.  
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Objective 4: Mitophagy in Human Embryonic Stem Cells  
The autophagic process breaks down cellular components and plays a particularly 
important role during periods of starvation or when organelles are damaged. 
Autophagosomes allow each cell to maintain a critical balance between the synthesis, 
degradation, and recycling of cellular structures. Therefore, it is not surprising that 
autophagy plays a significant role in cell growth and homeostasis during development. It is 
thought that autophagy is essential for healthy aging and longevity. The last objective was 
to compare mitochondrial turnover (mitophagy) following exposure to mitochondrial toxins 
and during the differentiation of hESCs. This study investigated the processes that occur 
during differentiation- and toxin-induced mitophagy. The primary aims were: (1) to establish 
the LC3-GFP system as a means to measure mitophagy quantitatively; (2) to understand 
the dynamics of mitophagy when cells are challenged with toxins that affect mitochondrial 
function; and (3) to understand the dynamics of mitophagy during hESC differentiation.  
 The fourth objective was to determine whether mitochondrial turnover is essential in 
maintaining optimal cellular function for cell differentiation. In regards to mitochondrial 
turnover, there is little evidence illustrating the mechanism by which it occurs. In this study, 
differentiation and toxic stimuli were used to demonstrate that mitochondrial turnover in 
hESCs occurs via the uptake of mitochondria into autophagosomes, a process called 
mitophagy. To this end, a sensitive method using live-imaging flow cytometry (AMNIS) was 
used for the determination of mitophagy. First, we showed that mitophagy in hESCs is 
triggered by interfering mtDNA replication and mitochondrial membrane potential. Second, 
increased levels of mitophagy were found to be associated with hESC differentiation, either 
spontaneous or RA-induced. Spontaneous differentiation was initiated by removing 
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pluripotency maintenance factors from the culture medium. At day 7 of spontaneous 
differentiation, mitophagy levels were elevated, but they returned to baseline by day 14. The 
short window of mitophagy (during a time of differentiation and mitochondrial biogenesis) 
reflects the removal of mitochondrial components contaminated by free radicals in order to 
ensure that a healthy population of mitochondria is present for cell differentiation.  
 The high rate of mitophagy found in our study seemed to contradict some 
characteristics of differentiated hESCs with elevated mitochondrial gene expression, 
increased mtDNA copy numbers and a more mature mitochondrial morphology. Autophagy 
plays an important role in the degradation of maternal RNA and proteins during mammalian 
embryonic development (Mizushima and Levine 2010). Mitochondria with low membrane 
potentials or excessive ROS production could trigger mitophagy. Furthermore, 
differentiation-induced mitophagy may selectively cull the germ line copies of mtDNA that 
contain mutations, as reported in mouse models (Yang, Przyborski et al. 2008). Here, our 
preliminary data showed that, during the early stage of differentiation, hESCs may 
selectively eliminate defective mitochondria via mitophagy; however, the detailed 
limitations of the mechanisms involved in the initiation of mitophagy during cell 
differentiation remain to be addressed as follows: 
 We need to show the pluripotency status (the loss of stem cell markers POU5F1 and 
TRA-1-60) of the undifferentiated hESCs before and after EtBr and rapamycin 
treatments and the early differentiation of hESCs subjected to retinoic acid treatment. 
 It is necessary to further test whether the upregulation of autophagic or mitophagic 
events are equally associated with treatments and/or retinoic acid treatments, as 
indicated in the early differentiation phase, in relation to time and dosage.  
 Mitophagy-related markers, such as PINK1 and PARK and autophagy markers need to 
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be established in future studies to understand specific mitophagic mechanisms.  
 Since CCCP triggers an increase in the number of autophagosomes and in mitophagic 
activity, we need to use CCCP to depolarize mitochondrial membrane potential and 
fragments, as described by (Narendra, Tanaka et al. 2008), to further explore 
whether mitophagy plays a role in scavenging the damaged mitochondria and, thus, 
in maintaining the quality of hESCs. Furthermore, it is important to examine whether 
mitophagy precedes the expansion of mitochondria upon differentiation and 
selectively removes damaged mitochondria to prevent the accumulation of mtDNA 
mutations. Interestingly, PTEN-induced putative kinase 1 (PINK1) has been shown to 
be selectively accumulated in damaged mitochondria that possess a low membrane 
potential due to depolarization] caused by CCCP (Acton, Jurisicova et al. 2004). 
Parkinson protein 2 (PARK2/PARKIN) ubiquitinates the voltage-dependent anion 
channel 1 (VDAC1) and plays a role in generating mitochondrial outer membrane 
potential, and recruits P62, an autophagy receptor, to the mitochondria damaged by 
autophagy. P62 interacts with microtubule-associated protein 1/light chain 3 alpha 
(MAP1LC3A/LC3) on the phagophore surface, leading to engulfment by the 
autophagosomal structure and subsequent lysosomal degradation (i.e. mitophagy). 
The mechanism of mitophagy still remains to be determined and reinforced in which 
an early mitochondrial turnover could associate with the mechanism of 
PINK1/PARK2/P62/LC3-dependent mitophagy upon differentiation of hESCs. 
One of the strategies in this study was to expose hESCs to EtBr for various time 
intervals (short-term exposure, such as 20 minutes, two-hour exposure followed by 
observation for 16 hours, and long-term exposure). Images acquired by time-lapse 
microscopy showed that the early stage of mitophagic events occur within 20 minutes to 
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two hours of EtBr treatment, while a significant upregulation of mitophagic events occurred 
within 16 hours. Eventually, the images revealed that there was significant cell death after 
EtBr treatment for one week. Such mitophagy may be responsible for the high rate of cell 
death observed in this study.  
The identification of mitophagy in hESCs with the modulation of mitochondrial turnover 
in either hESCs exposed to toxins or upon hESC differentiation represents the first steps in 
understanding the role of mitophagy and mitochondria in hESC differentiation. 
Nevertheless, we have shown that: (1) all autophagy in hESCs with EtBr or 
CCCP-treatment appears to be mitophagy, (2) rapamycin could induce mitophagy (Figure 
4.18) and (3) mitophagy increases during hESC differentiation, which may be either 
spontaneous or retinoic acid-induced. The conclusion of this study is that the differentiation 
of hESCs was accompanied by an increase in both mitochondrial biogenesis and 
mitochondrial turnover. In future, some experiments are required to determine whether 
other factors may interfere with mitophagy and indirectly affect mitochondrial quality. It is 
also worth mentioning here that we demonstrated the up-regulation of the expression of 
mitochondrial and autophagy markers in differentiated hESCs. The use of knockdown 
technique to measure expression levels of mitophagy-associated genes (e.g., PARK2 or 
PINK1) could be considered in the future in a parallel study of autophagy-associated genes 
(e.g., Atg5 or LC3). These studies will help to further delineate the similarities and 
differences between mitophagy and autophagy. To this end, we could selectively 
manipulate mitophagy that would be relevant to clinical applications using hESCs or human 
inducible pluripotent stem cells (hiPSCs), particularly the applications involving iPSCs 
obtained from older individuals who have accumulated mtDNA damage.  
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This study demonstrated for the first time that mitophagy occurs in hESCs. It also 
provided evidence that during or immediately preceding hESC differentiation, mitophagy is 
involved in the selective turnover of mitochondria, which may represent a mechanism of 
optimizing or controlling mitochondrial quality within differentiating hESCs. A better 
understanding of the molecular mechanisms that control mitophagy in hESCs may facilitate 
the manipulation and improve the quality of hESCs that can be used in regenerative 
medicine. 
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Chapter 6: Final Conclusion 
While most studies of human pluripotent stem cells have focused on changes in the 
expression of nuclear genes during differentiation (Cho, Kwon et al. 2006, Saretzki, Walter 
et al. 2008), relatively little attention has been paid to mitochondrial gene expression during 
this process. mRNA changes do not necessarily result in protein expression changes 
because protein levels are also controlled by mRNA translation, protein stability, and protein 
turnover. In the present study, we investigated some of the changes in mitochondrial gene 
expression in stem cells differentiating into three specific lineages, namely, ectoderm, 
endoderm, and mesoderm.  
Our results revealed that different hESC lines (hES3 and Mel 1) possess different 
differentiation capabilities and mechanisms for regulating mtDNA expression. We further 
found that the transcription of peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha (PGC1α) gene is upregulated as the cells differentiate into ectoderm or 
mesoderm (Watkins, Basu et al. 2008). Changes in mitochondrial gene expression 
observed during lineage-specific differentiation possibly reflect changes necessary for the 
metabolic maturation of mitochondria.  
 The main finding in the second study was the apparent and different gene expression 
patterns before and after treatmnt in human of fibroblasts with agents that interefere with 
mitochondrial translation or DNA replication. Inhibition of mtDNA or protein synthesis 
resulted in altered expression of both the mtDNA-encoded proteins and the nuclear 
transcription factors that control mitochondrial biogenesis, and the existence of different 
compensatory mechanisms.  
The main discovery in the third study was that the TFAM expression affects the 
survival of hESCs. No study on manipulating the mtDNA copy number or TFAM expression 
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in hESCs and mouse embryonic stem cells (mESCs) exists in the literature. In our work, we 
demonstrated that TFAM expression level has a positive effect on mtDNA copy number. 
Furthermore, these preliminary data suggest that artificially increasing/decreasing mtDNA 
copy number influences cell survival. This information is relevant for developing gene 
therapy approaches for regenerative medicine of mtDNA related diseases.  
Finally, the main finding in the fourth study was that mitophagy is a possible 
mechanism for regulation of mitochondrial turnover during rapamcyin, CCCP or EtBr 
treatment or early differentiation in hESCs. The data also suggest that mitophagy may be 
responsible for the selective removal and quality control of mitochondria in hESCs upon 
differentiation. No study has investigated any of the differences and the mechanisms of 
mitophagy in hESCs in detail. A better understanding of the molecular mechanisms that 
control mitophagy in hESCs may allow manipulation of this process for minimizing the 
number of dysfunctional mitochondria in long-term cultured hESCs for use in 
regenerative medicine.  
Overall, the data in this thesis provide information on the interplay between 
mtDNA copy number, cell-specific differentiation and cell response upon alteration of the 
mtDNA copy number and the expression of nuclear regulators of mitochondrial 
biogenesis. Moreover, these data may provide valuable information to fully understand 
mitochondrial diseases and might be useful for regenerative medicine approaches in the 
future.  
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Tables 
Objective 1: Mitochondrial-Encoded and Mitochondrial Biogenesis-Related Gene 
Expression During Lineage-Specific Differentiation of Human Embryonic Stem Cells 
 
Table 4.1 Comparison of TRA-1-60 and mitochondrial staining in undifferentiated and 
differentiated hESCs.  
Markers for pluripotency (TRA-1-60) and mitochondria (MitoTracker Red) were analyzed in 
hESCs under the indicated treatment conditions. Histogram is also shown in the Figure 4.2. Data 
reflect the mean ± standard deviation (SD, n = 3). *P<0.05 as compared to control. Abbreviations: 
Undiff, undifferentiated hESCs cultured in conditioned medium; Spd. diff-day 7, hESCs cultured 
without basic fibroblast growth factor for 7 days; Spd. diff-day14, hESCs cultured without basic 
fibroblast growth factor for 14 days; RA-day 3, hESCs cultured with retinoic acid (RA) for 3 days. 
 
 Undiff Spd. Diff-day 7 Spd. Diff-day 14 RA-day 3 
Intensity of 
TRA-1-60 
staining 
164,124 ±  7110  
(1.00 ± 0.04) 
168,146 ±  
18,775  
(1.01 ± 0.16) 
91,091 ±  4406 *  
(0.56 ± 0.05 *) 
14,841 ± 188 *  
(0.09 ± 0.01 *) 
Intensity of 
MitoTracker 
staining  
6,518,461 ±  
189,787  
(1.00 ± 0.03) 
11,216,946 ±  
1,410,269 * 
 (2.01 ± 0.16 *) 
757,6781 ± 
181,829  
(1.16 ± 0.02) 
6,577,975 ±  
121,149 „ 
(1.01 ± 0.02) 
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Table 4.2 Changes in gene expression upon hESC differentiation.  
RT-PCR analysis was used to determine gene expression levels within undifferentiated and 
differentiated hESCs. Both the Mel 1 and hES3 cell lines were examined. Expression levels were 
normalized to β-ACTIN (ACTB). Histogram is also shown in the Figure 4.3. Data were the mean ± 
SD. *P<0.05 as compared to control. Abbreviations: POU5F1, POU class 5 homeobox 1; ND1, 
NADH dehydrogenase 1; CYTB, cytochrome b; TFAM, mitochondrial transcription factor A; NRF1, 
nuclear respiratory factor 1; POLG, DNA polymerase subunit gamma; PGC1α, peroxisome 
proliferator-activated receptor gamma coactivator 1 alpha; β-ACTIN(ACTB), beta-actin; D-loop, 
displacement loop. 
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Mel 1 line Undiff. Spd. diff.-day 7 Spd. diff.-day 14 RA-day 3 
POU5F1 
1.00 ± 0.10 0.01 ± 0.01 **** 0.01 ± 0.01 **** 0.01 ± 0.001 
**** 
ND1 
1.00 ± 0.10 0.38 ± 0.01 * 1.11 ± 0.85 0.01 ± 0.001 
**** 
CYTB 
1.00 ± 0.13  0.97 ± 0.03 3.32 ± 0.09 **** 2.79 ± 0.07 
**** 
TFAM 1.00 ± 0.88  0.60 ± 0.10 1.18 ± 0.16 0.14 ± 0.04 
NRF1 1.00 ± 0.04  0.08 ± 0.07 * 0.37 ± 0.58 0.34 ± 0.02  
POLG 
1.00 ± 0.01  0.05 ± 0.05 **** 1.11 ± 0.02 ** 0.30 ± 0.01 
**** 
PGC1α 1.00 ± 0.13 1.67 ± 0.20 * 2.66 ± 0.80 ** 1.20 ± 0.32 * 
D-loop 1.00 ± 0.51  2.61 ± 0.66 * 1.30 ± 0.27  N/A 
hES3 line Undiff. Spd. diff.-day 7 Spd. diff.-day 14 RA-day 3 
POU5F1 1.00 ± 0.62 0.21 ± 0.10 0.19 ± 0.02 0.06 ± 0.02 * 
ND1 1.00 ± 0.50 1.10 ± 0.30 0.66 ± 0.46 1.29 ± 0.54 
CYTB 1.00 ± 0.03 1.36 ± 0.04 * 0.99 ± 0.06 0.66 ± 0.19 * 
TFAM 1.00 ± 0.15 0.63 ± 0.03 ** 0.25 ± 0.02 **** 0.48 ± 0.03 *** 
NRF1 1.00 ± 0.03 0.14 ± 0.09 ** 0.12 ± 0.04 ** 0.59 ± 0.34 
POLG 1.00 ± 0.25 0.16 ± 0.17 ** 0.14 ± 0.13 ** 0.67 ± 0.29 
PGC1α 1.00 ± 0.27 14.25 ± 1.40 **** 6.98 ± 0.27 *** 7.47 ± 1.32 *** 
D-loop 1.00 ± 0.23 31.49 ± 2.47 **** 2.11 ± 0.12 0.46 ± 0.05 
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Table 4.3 Changes in gene expression associated with ectoderm-specific differentiation of hESCs.  
Expression and qPCR expression fold changes were shown for gene associated with 
pluripotency (POU5F1), ectoderm-differentiation (PAX6), genes encoded by mitochondria (ND5 
and COX3) and mitochondrial biogenesis–related genes (TFAM, NRF1, POLG and PGC1α). Data 
were normalised to β-Actin (ACTB). Histogram is also shown in the Figure 4.4. Data were the mean 
± SD. *P<0.05 as compared to control. Abbreviations: PAX6, paired box 6; ND5, NADH 
dehydrogenase 5; COX3, Cytochrome oxidase 3. 
Genes Day 0 Day 8 Day 12 
PAX6 1.00 ± 0.39 517.19 ± 116.64 *** 357.55 ± 9.77 ** 
POU5F1 1.00 ± 0.12 0.22 ± 0.04 **** 0.06 ± 0.01 **** 
ND5 1.00 ± 0.08 11.69 ± 0.92 **** 1.33 ± 0.13 
COX3 1.00 ± 0.05 12.74 ± 0.40 **** 1.45 ± 0.13 
TFAM 1.00 ± 0.12 1.10 ± 0.17 0.86 ± 0.09 
NRF1 1.00 ± 0.21 1.59 ± 0.68 0.93 ± 0.08 
POLG 1.00 ± 0.02 1.56 ± 0.27 * 0.61 ± 0.04 
PGC1α 1.00 ± 0.16 7.76 ± 0.32 **** 2.03 ± 0.25 ** 
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Table 4.4 Changes in gene expression associated with endoderm-specific differentiation of hESCs.  
Expression and qPCR expression fold changes were shown for gene associated with 
pluripotency (POU5F1), endoderm differentiation (SOX17), genes encoded by mitochondria (ND5 
and COX3) and mitochondrial biogenesis–related genes (TFAM and PGC1α). Data were normalised 
to β-Actin (ACTB). Histogram is also shown in the Figure 4.5. Data were the mean ± SD. *P<0.05 
as compared to control. Abbreviations: SOX17, SRY-box 17. 
Genes Day 0 Day 1 Day 2 Day 3 
SOX17 1.00 ± 0.14 5.57 ± 0.48 * 12.95 ± 2.43 **** 21.09 ± 0.85 **** 
POUT5F1 1.00 ± 0.22 0.54 ± 0.13 * 0.63 ± 0.05 * 0.40 ± 0.03 ** 
ND5 1.00 ± 0.16 0.45 ± 0.03 *** 0.54 ± 0.01 *** 0.52 ± 0.01 *** 
COX3 1.00 ± 0.02 0.92 ± 0.03 0.95 ± 0.08 0.89 ± 0.04  
TFAM 1.00 ± 0.06 0.64 ± 0.07 * 0.69 ± 0.21 * 0.57 ± 0.01 ** 
PGC1α 1.00 ± 0.39 0.56 ± 0.11 0.85 ± 0.21 0.42 ± 0.08 
 
194 
 
Table 4.5 Changes in gene expression associated with mesendoderm-specific differentiation of 
hESCs.  
qPCR analysis was used to determine expression fold changes for genes associated with 
pluripotency (POU5F1), ectoderm differentiation (PAX6), mesoderm differentiation (BRY and 
MIXL1), endoderm differentiation (IGF2 and GATA4) and mitochondrial biogenesis (TFAM, NRF1 
and POLG). A gene encoded by mtDNA (ND1) was also examined. Data were normalised to 
β-Actin (ACTB). Histogram is also shown in the Figure 4.6. Data were the mean ± SD. *P<0.05 as 
compared to control. Abbreviations: BRY, Brachyury; MIXL1, Mix paired-like homeobox; IGF2, 
Insulin-like growth factor 2; GATA4, GATA binding protein4. 
 
Genes Day 0 Day 3 Day 5 Day 7 Day 16 
PAX6 1.00 ± 0.45 0.60 ± 0.15 0.32 ± 0.30 0.32 ± 0.38 3.07 ± 0.55 *** 
BRY 1.00 ± 0.30 
40.38 ± 0.22 
**** 
7.19 ± 0.40 **** 0.90 ± 0.14 0.27 ± 0.25 
MIXL1 1.00 ± 0.23 
14.70 ± 0.08 
**** 
13.35 ± 0.06 
**** 
7.83 ± 0.10 
**** 
2.86 ± 0.28 
**** 
IGF2 1.00 ± 0.09 
27.94 ± 0.21 
**** 
305.36 ± 0.11 
**** 
924.35 ± 0.09 
**** 
2210.79 ± 0.18 
**** 
GATA4 1.00 ± 0.24 
510.59 ± 0.13 
**** 
133.68 ± 0.22 
**** 
173.61 ± 0.12 
**** 
485.15 ± 0.15 
**** 
POU5F1 1.00 ± 0.05 0.50 ± 0.25 ** 0.14 ± 0.10 **** 
0.03 ± 0.06 
**** 
0.00 ± 0.08 
**** 
ND1 1.00 ± 0.29 0.45 ± 0.20  N/A 2.21 ± 0.61** 1.02 ± 0.27 
TFAM 1.00 ± 0.24 0.39 ± 0.58 0.46 ± 0.35 0.46 ± 0.59 0.30 ± 0.52 
NRF1 1.00 ± 0.34 0.64 ± 0.24 0.57 ± 0.41 0.78 ± 0.22 0.64 ± 0.20 
POLG 1.00 ± 0.08 0.86 ± 0.27 1.21 ± 0.07 1.68 ± 0.22 ** 1.13 ± 0.14 
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Table 4.6 Changes in gene expression associated with cardiomyocyte-specific differentiation of 
hESCs.  
qPCR analysis was used to determine expression fold changes for genes encoded by mtDNA 
(ND5 and COX3) and genes related to mitochondrial biogenesis (TFAM and PGC1α). Data were 
normalised to β-Actin (ACTB). Histogram is also shown in the Figure 4.7. Data were the mean ± SD. 
*P<0.05 as compared to control.  
Genes Day 0 Day 3 Day 7 Day 16 
ND5 1.00 ± 0.22 0.92 ± 0.05 1.97 ± 0.22 *** 0.02 ± 0.01 *** 
COX3 1.00 ± 0.54 0.95 ± 0.08 0.80 ± 0.10 0.61 ± 0.14 
TFAM 1.00 ± 0.06 0.58 ± 0.07 *** 0.56 ± 0.11 *** 0.02 ± 0.01 **** 
PGC1α 1.00 ± 0.59 1.01 ± 0.24 1.22 ± 0.21 252.75 ± 63.97 **** 
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Objective 2: Regulation of Mitochondrial Biogenesis in Chloramphenicol- and EtBr-treated 
Primary Human Fibroblasts 
 
Table 4.7 Gene expression and qPCR expression fold changes of mitochondria-encoded genes, 
transcription factors, and mtDNA copy number in control, ethidium bromide– or 
chloramphenicol-treated cells after treatment for 6 weeks and release from treatment for 2 weeks.  
Expression of mitochondria-encoded genes (ND1, ND4, CYTB and COX2) and mitochondrial 
biogenesis transcription factors (TFAM, NRF-1 and POLG) in each sample was normalised to 
β-Actin (ACTB). Histogram is also shown in the Figure 4.9. Data were the mean ± SD. *P<0.05 as 
compared to control. Abbreviations: ND4, NADH dehydrogenase subunit IV; COX2, cytochrome c 
oxidase subunit II; control, human fibroblasts; EtBr-treated, human fibroblasts treated with 100 
ng/ml ethidium bromide; and CAP-treated, human fibroblasts treated with 100 µg/ml 
chloramphenicol. 
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Genes Control-6w EtBr-treated-6w  CAP-treated-6w 
ND1 0.12 ± 0.04 (1.00) 
3.50x10
-6
 ± 1.50x10
-6 
* 
(0.00) 
8.33x10
-4
 ± 1.49x10
-4 
* (0.01) 
ND4 0.16 ± 0.04 (1.00) 
4.00x10
-7 
± 1.00 x10
-7
 * 
(0.00) 
3.11x10
-5
 ± 4.80x10
-6
 * (0.00) 
CYTB 0.91 ± 0.04 (1.00) 
6.52x10
-4
  ± 4.79x10
-5 
* 
(0.00) 
0.45 ± 0.11* (0.50) 
COX2 0.10 ± 0.02 (1.00) 
6.00x10
-7
 ± 3.00x10
-7
 * 
(0.00) 
2.08x10
-3
 ± 2.56x10
-4 
* (0.02) 
TFAM 
1.70x10
-6
 ±  8.00 
x10
-7  
(1.00)
 
7.00x10
-7
± 4.00x10
-7  
(0.42)
 9.00x10
-7
 ± 4.00x10
-7  
(0.53)
 
NRF1 
2.95x10
-6
 ±  5.30 
x10
-6  
(1.00)
 
5.60x10
-6
  ± 8.00x10
-7
 * 
(0.19) 
5.00x10
-7
 ± 1 x10
-8
 * (0.02) 
POLG 
2.13x10
-4
 ± 5.76 x10
-5  
(1.00)
 
2.16x10
-5
  ± 9.50x10-
6
 * 
(0.10) 
7.33x10
-5
 ± 1.83x10
-5 
*
 
(0.34)
 
D-loop 0.21  ± 0.11 (1.00) 
5.28x10
-4
 ± 3.60x10
-4 
* 
(0.00) 
0.18 ± 0.03 (0.28) 
 Control-6+2w EtBr-treated-6+2w CAP-treated-6+2w 
ND1 0.63 ± 0.12 (1.00) 0.04 ± 0.01 * (0.06) 0.19 ± 0.02* (0.30) 
ND4 0.27 ± 0.03 (1.00) 0.02 ± 0.08 * (0.08) 0.42 ± 0.05 (1.56) 
CYTB 0.04 ± 0.01 (1.00) 0.01 ± 0.001 * (0.06) 0.02 ± 0.01 (0.44) 
COX2 0.35 ± 0.01 (1.00) 0.10 ± 0.03 * (0.28) 0.40 ± 0.18 (1.15) 
TFAM 0.01 ± 0.001(1.00) 0.01 ± 0.001 * (4.05) 0.01 ± 0.001 * (3.09) 
NRF1 0.01 ± 0.001 (1.00) 0.01 ± 0.001 * (2.29) 0.01 ± 0.001 (0.71) 
POLG 0.01 ± 0.001 (1.00) 0.01 ± 0.001 * (0.92) 0.01 ± 0.002 * (1.77) 
D-loop 0.91 ± 0.09 (1.00) 0.09 ± 0.03 * (0.10) 0.39 ± 0.04 * (0.42) 
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Table 4.8 Relative amounts of glucose, lactate, GSH, and GSSG, and intracellular ATP, ADP 
concentrations in control, ethidium bromide– or chloramphenicol-treated cells after treatment for 6 
weeks and release from treatment for 2 weeks.  
The quantities of intracellular ATP concentration, intracellular ADP concentration, and 
intracellular ATP/ADP ratio per cell were expressed in mg. The rate of lactate production or 
glucose consumption per cell was expressed in pmol/cell. The background was subtracted from all 
measurements, which were performed in triplicate. The quantities of GSH and GSSG per cell were 
expressed in fmol/cell. Histogram is also shown in the Figure 4.10. Data were the mean ± SD. 
*P<0.05 as compared to control.  
 
 Control EtBr-treated  CAP-treated  
Total GSH (fmol/cell) 0.92 ± 0.05 0.55
 
± 0.04 * 3.84 ± 0.03 * 
Oxidized GSSG (fmole/cell) 0.07
 
± 0.01 0.54± 0.03 * 0.05
 
± 0.02 
Reduced GSH (fmol/cell) 0.85± 0.03 0.02
 
± 0.002 * 3.78 ± 0.03 * 
Oxidized GSSG / reduced GSH 
(ratio) 
0.09 35.00 * 0.01 
ATP avg (uM) / protein (mg) 80.08 ± 36.82 1.20 ± 0.59 * 3.47 ± 1.26 * 
ADP avg (uM) / protein (mg) 44.90 ± 14.88 2.75 ± 0.46 * 2.76 ± 0.55 * 
ATP / ADP (ratio) 1.78 0.44 * 1.26 * 
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Table 4.9 Comparison of the mitochondrial membrane potential in control, ethidium bromide– or 
chloramphenicol-treated cells after treatment for 6 weeks and release from treatment for 2 weeks.  
Mitochondrial membrane potential staining by JC1: JC1-monomers and JC1-aggregates 
indicate low and high mitochondrial membrane potential, respectively. The fluorescence intensity 
of JC1-monomers and JC1-aggregates was indicated in mean ± SD.  *P<0.05 as compared to 
control. Histogram is also shown in the Figure 4.11. 
 
Avg ± SD (Folds) JC1-monomers JC1-aggregates  
Control 1892.00 ± 228.33  (1.00) 681.43 ± 130.90 (1.00) 
Ethidium bromide-treated 1669.77 ± 98.98 (0.88)  397.20 ± 23.32 * (0.58 *)  
Chloramphenicol-treated 2124.97 ± 39.65 (1.12) 577.30 ± 18.10 (0.85)   
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Objective 3: Manipulation of TFAM Expression in Human Embryonic Stem Cells 
 
Table 4.10 Levels of TFAM expression in hESC lines (gain-of-function).  
(A) TFAM expression and (B) mtDNA copy number (D-loop) were normalised to β-Actin (ACTB). 
(C) TFAM protein levels were determined by flow cytometer, and were normalised to the negative 
control. Histogram is also shown in the Figure 4.13. Data were the mean ± SD. *P<0.05 as 
compared to control.  
 
(A) TFAM mRNA expression 
 Mel 1 hES3 H9 
hESCs 1.00 ± 0.10 1.00 ± 0.03 1.00 ± 0.14 
hESC-Vector 0.32 ± 0.10 *** 0.76 ± 0.15 ** 0.95 ± 0.20 
hESC-EF1α-TFAM 2.06 ± 0.03 **** 1.71 ± 0.15 * 1.65 ± 0.43  
(B) D-loop expression 
hESCs 1.00 ± 0.29 1.00 ± 0.10 1.00 ± 0.11 
hESC-Vector 0.69 ± 0.07   0.67 ± 0.10 0.86 ± 0.15 
hESC-EF1α-TFAM 1.42 ± 0.32   28.34 ± 0.51 **** 5.44 ± 0.50 ** 
(C) TFAM protein expression (fluorescence intensity) 
hESCs N/A 22894.95 ± 4675.06 29,186.07 ± 5223.61 
hESC-Vector N/A 4186.15 ± 1093.36 * N/A 
hESC-EF1α-TFAM N/A 50394.71 ± 8123.81 ** 114737.50 ± 28940.68 * 
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Table 4.11 Levels of TFAM expression in hESC lines (loss-of-function).  
(A) TFAM mRNA levels were normalised to β-Actin (ACTB). (B) TFAM protein levels were 
determined via flow cytometer, and were normalised to the negative control. Histogram is also 
shown in the Figure 4.15. Data were the mean ± SD. Abbreviations: dox, doxycycline. *P<0.05 as 
compared to control.  
TFAM mRNA expression 
 Mel 1 hES3 H9 
(A)  Without 
dox 
With dox Without 
dox 
With dox Without dox With dox 
hESCs 1.00 ± 
0.07 
0.60 ± 0.02 1.00 ± 0.34 1.23 ± 0.11 1.00 ± 0.07 3.22 ± 0.64 * 
TFAMi
-3 
1.00 ± 
0.09 
0.17 ± 0.02 
* 
1.00 ± 0.23 0.84 ± 0.18 
* 
1.00 ± 0.19 0.55 ± 0.19 * 
TFAMi
-5 
1.00 ± 
0.39 
0.03 ± 0.01 
* 
N/A N/A 1.00 ± 0.25 0.17 ± 0.04 * 
TFAMi
-6 
N/A N/A 1.00 ± 0.01 0.92 ± 0.02 1.00 ± 0.15 1.22 ± 0.21 
TFAM protein expression (fluorescence intensity) 
 Mel 1 hES3 H9 
(B) Without 
dox 
With dox Without 
dox 
With dox Without dox With dox 
hESCs 4.17x10
4
 
± 
1.27x10
3
 
5.50x10
4
 
± 8.05x10
3
 
1.97x10
4
 
± 7.46x10
2
 
2.01x10
4
 
± 3.27x10
2
 
1.58x10
4
 
± 1.23x10
3
 
1.58x10
4
 
± 8.05x10
2
 
TFAMi
-3 
6.77x10
4
 
± 
2.28x10
3
* 
9.76x10
3
 
± 5.06x10
2 
* 
1.11x10
5
 
± 1.30x10
3
 
7.39x10
4
 
± 4.44x10
3 
* 
8.31x10
3
 
± 1.30x10
2
 
7.01x10
3
 
± 2.93x10
2 
* 
TFAMi
-5 
2.82x10
4
 
± 
2.62x10
3
* 
5.16x10
3
 
± 1.71x10
2 
* 
N/A N/A 1.28 x10
4
 
± 5.03x10
2
 
7.62x10
3
 
± 4.65x10
2 
* 
TFAMi
-6 
N/A N/A 2.16x10
4
 
± 5.72x10
2
 
2.21x10
4
 
± 3.28x10
2
 
8.25x10
3
 
± 6.63x10
1
 
8.25x10
3
 
± 2.31x10
2
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Objective 4: Mitophagy in Human Embryonic Stem Cells  
Table 4.12. The number of autophagosomes and mitophagy events per hES cell.  
Following the indicated treatment, the number of autophagosomes was calculated either from 
the statistical data with the ANOVA or from images of single cells, which were exported from 
AMNIS, respectively. The average number of mitophagy events was calculated manually from 
live-cell flow cytometry images. Histogram is also shown in the Figure 4.20. *P<0.05 as compared 
to control. Abbreviations: control, hES-LC3-GFP cells treated with DMSO; Rap, hES-LC3-GFP 
cells treated with rapamycin; CCCP, hES-LC3-GFP cells treated with carbonyl cyanide 
3-chlorophenylhydrazone; EtBr, hES-LC3-GFP cells treated with ethidium bromide; RA-3, 
hES-LC3-GFP cells culture treated with retinoic acid for 3 days; Spd. Diff-7, hES-LC3-GFP cells 
culture without basic fibroblast growth factor for 7 days; Spd. Diff-14, hES-LC3-GFP cells culture 
without basic fibroblast growth factor for 14 days. 
 Number of autophagosomes 
per cell was counted from 
statistical data, exported from 
AMNIS. 
Number of autophagosomes and mitophagic 
events per cell was manually counted from 
images of single cell, exported from AMNIS. 
Treatment Sample 
size 
Autophagosomes 
(mean  SEM) 
Sample 
size 
Autophagosome
s (mean  SEM) 
Mitophagosomes 
(mean  SEM) 
Control 995 1.87  1.00 * 270 0.69  0.02 * 0.65  0.02 * 
Rap 1300 3.65  0.07 * 322 1.63  0.01 * 1.46  0.01 * 
CCCP 1156 3.64  0.07 *  481 1.49  0.01 * 1.30  0.01 * 
EtBr 1453 3.42  0.07 *  474 1.43  0.01 * 1.30  0.01 * 
RA-3 1560 3.06  0.07 *  693 1.59  0.01 * 1.42  0.01 * 
Spd. Diff-7 1906 3.02  0.06 * 613 1.37  0.02 * 1.24  0.02 * 
Spd. Diff-14 209 2.08  0.12 *  86 0.83  0.03 0.81  0.03 * 
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Figures 
Objective 1: Mitochondrial-Encoded and Mitochondrial Biogenesis-Related Gene Expression 
During Lineage-Specific Differentiation of Human Embryonic Stem Cells 
 
 
Figure 4.1. Schematic drawing of the experimental design for spontaneous and lineage-specific 
differentiation in hESCs.  
Time courses are shown for the protocols to induce (A) spontaneous differentiation, (B) 
ectoderm-, (C) endoderm-, and (D) mesendoderm- and cardiomyocyte-differentiation in days. 
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Figure 4.2 Comparison of TRA-1-60 and mitochondrial staining in undifferentiated and 
differentiated hESCs.  
(A) Markers for pluripotency (TRA-1-60) and (B) mitochondria (MitoTracker Deep Red) were 
analyzed in live hESCs. Analyzed samples included undifferentiated (control), 7 and 14 days of 
spontaneous differentiation, and 3 days of RA treatment. Dot plots were analyzed by ACCURI 
software. Black and red lines represent unstained and stained samples, respectively. (C) Graph 
represents the fluorescence intensity associated with TRA-1-60 immunoreactivity (black) and 
MitoTracker Red (grey). Data were normalised to the control, and reflect the mean ± standard 
deviation (SD, n = 3). *P<0.05 as compared to control. 
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Figure 4.3 Characterization of mitochondria in undifferentiated and differentiated hESCs. D-loop 
expression in Mel 1 and hES3.  
(A) Gene expression of pluripotency (POU5F1), mtDNA-encoded genes (ND1 and CYTB), and 
nuclear-encoded mitochondrial biogenesis genes (TFAM, NRF1, PLOG and PGC1α) in Mel 1(bar 
without diagonal lines) and hES3 (bar with diagonal lines) cell lines was subjected to qPCR 
analyzes both before and after differentiation, respectively. Analyzed samples of hESCs include 
undifferentiated (white), 7 days of spontaneous differentiation (light grey), 14 days of spontaneous 
differentiation (dark grey), and 3 days of RA treatment (black). Gene expression levels were 
normalised to β-Actin (ACTB). Gene expression values are also shown in the Table 4.2. Data reflect 
the mean ± SD. *P<0.05 as compared to control.  
TEM analysis of mitochondria (M) in (B) undifferentiated and (C) 14 days of spontaneously 
differentiated hESCs. JC-1 staining was used to assess mitochondrial-membrane potential of (D) 
undifferentiated and (E) 14 days of spontaneously differentiated hESCs. Low and high membrane 
potentials are indicated by green and red staining, respectively. Arrows indicate JC-1 staining. 
Representative images are shown. Scale bars represent either 500 nm (B, C) or 100 m (D, E). 
Abbreviations: POU5F1, POU class 5 homeobox 1; ND1, NADH dehydrogenase 1; CYTB, 
cytochrome b; TFAM, mitochondrial transcription factor A; NRF1, nuclear respiratory factor 1; 
POLG, DNA polymerase subunit gamma; PGC1α, peroxisome proliferator-activated receptor 
gamma coactivator 1 alpha; β-Actin (ACTB), beta-actin; D-loop, displacement loop. 
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Figure 4.4 Mitochondrial biogenesis profiles during ectoderm differentiation.  
A time course of ectoderm differentiation is shown. Undifferentiated hESC (white), day 8 (light 
grey), and day 12 (black) of differentiation are shown. Gene expression values are also shown in the 
Table 4.3. Analyzed genes included an ectoderm marker (PAX6), a pluripotency marker (POU5F1), 
mtDNA-encoded genes (ND5 and COX3), and mitochondrial biogenesis genes (TFAM, NRF1, 
POLG and PGC1α). All qPCR values were normalised to β-Actin (ACTB). Gene expression values 
are also shown in the Table 4.3. Data are the mean ± SD. *P<0.05 as compared to control. 
Abbreviations: PAX6, Paired box 6; ND5, NADH dehydrogenase 5; COX3, Cytochrome oxidase 3. 
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Figure 4.5 Mitochondrial biogenesis profiles during endoderm differentiation.  
Time courses of ectoderm and endoderm differentiation are shown. Undifferentiated hESC 
(white), day 1 (light grey), day 2 (dark grey), and day 3 (black) of differentiation are shown. 
Analyzed genes included a gene associated with endoderm (SOX17), a pluripotency marker 
(POU5F1), mtDNA-encoded genes (ND5 and COX3), and mitochondrial biogenesis genes (TFAM 
and PGC1α). All qPCR values were normalised to β-Actin (ACTB). Gene expression values are also 
shown in the Table 4.4. Data are the mean ± SD. *P<0.05 as compared to control. Abbreviations: 
SOX17, SRY-box 17.  
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Figure 4.6 Mitochondrial biogenesis profiles during mesendoderm differentiation.  
   Time courses of ectoderm and mesendoderm differentiation are shown. Undifferentiated hESC 
(white), day 3 (light grey), day 5 (dark grey), day 7 (black), and day 16 (white with diagonal lines) 
of differentiation are shown. Analyzed genes included genes associated with the primitive streak 
(BRY and MIXL1), an ectoderm marker (PAX6), endoderm markers (IGF2 and GATA4), a 
pluripotency marker (POU5F1), a mtDNA-encoded gene (ND1), and mitochondrial biogenesis 
genes (TFAM, NRF1 and POLG). All qPCR values were normalised to β-Actin (ACTB). Gene 
expression values are also shown in the Table 4.5. Data are the mean ± SD. *P<0.05 as compared to 
control. Abbreviations: BRY, Brachyury; MIXL1, Mix paired-like homeobox; IGF2, Insulin-like 
growth factor 2; GATA4, GATA binding protein 4. 
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Figure 4.7 Mitochondrial biogenesis profiles during cardiomyocyte differentiation.  
Time courses of cardiomyocyte differentiation are shown. Undifferentiated hESC (white), day 
3 (light grey), day 7 (dark grey), and day 16 of differentiation (black) are represented. Analyzed 
genes included mtDNA-encoded genes (ND5 and COX3), and mitochondrial biogenesis genes 
(TFAM and PGC1α). All qPCR values were normalised to β-Actin (ACTB). Gene expression values 
are also shown in the Table 4.6. Data are the mean ± SD. *P<0.05 as compared to control. 
 
 
 
 
 
212 
 
Objective 2: Regulation of Mitochondrial Biogenesis in Chloramphenicol- and EtBr-treated 
Primary Human Fibroblasts 
 
Figure 4.8 Morphology and karyotypes of human rho minus cells.  
(A and B) Image of control and (E and F) ethidium bromide-treated and (I and J) 
chloramphenicol-treated cells were taken by inverted microscopy (Olympus) with a 10x objective 
lens. (C and D) G-band karyotypes of control and (G and H) ethidium bromide-treated and (K and L) 
chloramphenicol-treated cells. Abbreviations: control, human fibroblasts; Ethidium bromide-treated, 
human fibroblasts treated with 100 ng/ml ethidium bromide; and Chloramphenicol-treated, human 
fibroblasts treated with 100 µg/ml chloramphenicol.  
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Figure 4.9 Relative expressions of mitochondrial-encoded and mitochondrial biogenesis-related 
genes after treatment for 6 weeks (6w) and release from treatment for 2 weeks (6+2w, bar with 
diagonal lines).  
Mitochondria-encoded genes (ND1, ND4, CYTB and COX2), mitochondrial biogenesis 
transcription factors (TFAM, NRF1 and POLG), and mitochondrial content (D-loop) in control 
(black), EtBr-treated (grey), and CAP-treated fibroblasts (black) at 6 weeks (6w) and release from 
treatment for 2 weeks (6+2w). Gene expression of each sample was normalized to β-ACTIN (ACTB). 
Gene expression values are also shown in the Table 4.7. Data are the mean ± SD. *P<0.05 as 
compared to control. Abbreviations: ND4, NADH dehydrogenase subunit 4; COX2, cytochrome c 
oxidase subunit 2. 
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Figure 4.10 Metabolic effect of ethidium bromide and chloramphenicol treatment on human 
fibroblasts after treatment for 6 weeks and release from treatment for 2 weeks.  
(A) The lactate production, (B) glucose consumption, and (C) ratio of oxidized GSSG to 
reduced GSH after treatment for 6 weeks and release from treatment for 2 weeks. The background 
was subtracted from all measurements, which were performed in triplicate. (D) Comparison of the 
effect of ethidium bromide and chloramphenicol treatment on oxygen consumed by human 
fibroblasts. The plot shows the oxygen concentration in the cell culture medium with time. The 
decrease in oxygen concentration with time seen in the chloramphenicol-treated samples was due to 
oxygen uptake by the cells. No oxygen uptake by cells treated with ethidium bromide (red) was 
detectable with this assay. Red line indicates ethidium bromide-treated fibroblasts, and blue line 
indicates chloramphenicol-treated fibroblasts. (E) Intracellular ATP/ADP ratio. The values are also 
shown in the Table 4.8. Data are the mean ± SD. *P<0.05 as compared to control.  
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Figure 4.11 Mitochondrial membrane potential in ethidium bromide– or chloramphenicol-treated 
cells after treatment for 6 weeks and release from treatment for 2 weeks.  
Low membrane potential is indicated by JC-1 monomers (green), and high membrane potential 
is indicated by JC-1 aggregates (red). (A) Fluorescent image of control, ethidium bromide-treated 
and chloramphenicol-treated human fibroblasts cells. Images were taken with a 20× objective lens 
with an Olympus IX81 microscope and analyzed with Cell
^
 software (Olympus). (B) Mitochondrial 
membrane potential was analyzed by WEASEL software. (C) Histogram represents mean intensity 
of JC1-monomers and -aggregates in control (white bar), ethidium bromide- (black bar) or 
chloramphenicol-treated cells (grey bar). The values are also shown in the Table 4.9. Data are the 
mean ± SD. *P<0.05 as compared to control.  
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Figure 4.12 Assessment of mitochondrial ultrastructure transmitted by electron microscopy after 
treatment for 6 weeks and release from treatment for 2 weeks (Figure S10). Ultrastructure of 
mitochondria of (A) control, (B) ethidium bromide-treated and (C) chloramphenicol-treated human 
fibroblasts cells. The original magnification was 12 kV.
A: Control           B: EtBr-treated        C: CAP-treated 
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Objective 3: Manipulation of TFAM Expression in Human Embryonic Stem Cells 
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Figure 4.13 Levels of TFAM expression in hESC lines (gain-of-function).  
(A) TFAM gene expression and mtDNA copy number (D-loop) for Mel 1 (white), hES3 (grey), 
and H9 (black) single cells. Data were normalised to β-ACTIN (ACTB). (B) TFAM protein levels 
were determined by flow cytometer. Data were normalised to the negative control. Data are the 
mean ± SD. Gene expression values are also shown in the Table 4.10. Data are the mean ± SD. 
*P<0.05 as compared to control. Abbreviations: Ctrl, hESCs without viral transduction; vector, 
hESCs transduced with the vector backbone; TFAM, hESC transduced with EF1α-TFAM viral 
particles.  
 
 
 
 
 
222 
 
 
Figure 4.14 Constitutive knockdown of TFAM levels in hESCs (Figure S9).  
Three TFAM shRNA (TFAM-shRNA-1, TFAM-shRNA-2, and TFAM-shRNA-3) are targeted 
to position 266-286, 591-611 and 618-638, respectively. (A) Western blot analysis of TFAM 
expression in the control and lentivirus-transduced hESCs was performed using antibodies against 
the proteins indicated on the left. β-ACTIN (ACTB) was included as a loading control. Untreated 
hESCs were analyzed as a negative control. (B) TFAM expression in hESCs was quantified by 
phosphor-imager analysis of the western blots. 
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Figure 4.15 Levels of TFAM expression in hESC lines (loss-of function, Figure S9).  
(A) Levels of TFAM mRNA were determined for each sample using PCR. (B) Levels of 
TFAM protein were determined for each sample using flow cytometry. (C) TFAM was analyzed by 
CFLOW software. Different cell lines (Mel 1, hES3 or H9) transfected by different TFAM shRNA 
(control: black; TFAMi-3: red; TFAMi-5: blue; TFAMi-6: green) are shown. mRNA levels (both 
endogeneous and exogenous) were normalised to β-ACTIN (ACTB), whereas protein levels were 
normalised to the negative controls. Gene expression values are also shown in the Table 4.11. Data 
are the mean ± SD. *P<0.05 as compared to control. Abbreviations: dox, doxycycline; 1-TFAMi-3, 
Mel 1 single cells transduced with TFAMi-3; 3-TFAMi-3, hES3 single cells transduced with 
TFAMi-3; 9-TFAMi-3, H9 single cells transduced with TFAMi-3; 1-TFAMi-5, Mel 1 single cells 
transduced with TFAMi-5; 9-TFAMi-5, H9 single cells transduced with TFAMi-5; 1-TFAMi-6, 
Mel 1 single cells transduced with targetless shRNA; 3-TFAMi-6, hES3 single cells transduced 
with targetless shRNA; 9-TFAMi-6, H9 single cells transduced with targetless shRNA.  
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Figure 4.16 Morphological phenotypes associated with TFAM loss- and gain-of function in hESC 
lines. 
Images represent hESCs incubated in the presence or absence of doxycycline (controls). TFAM 
knockdown (TFAMi-3 of targeting exon 5; TFAMi-5 of targeting exon 7; TFAMi-6 of targetless) is 
shown for Mel 1, and H9 cells. Images were acquired using inverted microscopy (Olympus) and a 
10 x objective.  
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Objective 4: Mitophagy in Human Embryonic Stem Cells  
  
 
Figure 4.17 Characterization of the hES-LC3-GFP reporter cell line.  
(A) LC3-GFP localisation within hESCs. (B) Localisation of POU5F1 (left, red) and TRA-1-60 
(right, green) within the hES-LC3-GFP cell line. Nuclei are counterstained with DAPI (blue). 
Representative images are shown. Scale bars represent 50 m. 
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H  Control   
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Figure 4.18 Mitochondrial toxin and differentiation-induced mitophagy in hES-LC3-GFP cells.  
Images represented from left to right in time manner. Images are combination of LC3-GFP 
signal (green), and MitoTracker Red signal (red) channels. Treatment conditions are listed at left: (A) 
control (DMSO), (B) rapamycin (positive control, 200 nM) in 0, 5 and 10 minutes, respectively, (C) 
CCCP (mitophagy induction, 50 µM) in 0, 7 and 15 minutes, (D) EtBr (mitophagy induction, 100 
ng/ml) treatment, (E) 7 days of bFGF withdrawal (spontaneous differentiation) in 0, 10 and 20 
minutes, (F) EtBr (100 ng/ml) treatment in 0, 8 and 16 hours, (G) EtBr (100 ng/ml for 1 week) 
treatment in 0, 8 and 16 hours, and (H) control in 0, 8, 16 hours, respectively. Representative images 
from supplementary videos and Appendix Figures 7 and 8 are shown and mitophagy events are 
circled by red circles. Scale bars represent 50 m. Abbreviations: control, hES-LC3-GFP cells 
treated with DMSO; Rap, hES-LC3-GFP cells treated with Rapamycin; CCCP, hES-LC3-GFP cells 
treated with carbonyl cyanide 3-chlorophenylhydrazone; EtBr, hES-LC3-GFP cells treated with 
ethidium bromide; Spd. Diff-7, hES-LC3-GFP cells culture without basic fibroblast growth factor 
for 7 days. 
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Figure 4.19 Quantification of mitophagy in hES-LC3-GFP cells using live-imaging flow-cytometer.  
(A) Representative images of single cells are shown. From left to right, images are bright-field, 
LC3-GFP signal (green), MitoTracker Red signal (red), and combined green and red channels. (B) 
The number of autophagosomes per cell was determined for each treatment condition. Data were 
displayed as a histogram. Compared to control cells, each treatment condition resulted in a 
statistically significant increase in autophagic events (p < 0.05). Treatment conditions are listed at 
left and included control (DMSO, blue), rapamycin (positive control), CCCP (mitophagy induction), 
EtBr (mitophagy induction), 3 days of retinoic acid (RA) treatment (induced differentiation), 7 days 
of bFGF withdrawal (spontaneous differentiation), and 14 days of bFGF withdrawal (spontaneous 
differentiation), (C) TEM images of mitochondrial ultrastructure following treatment with 
rapamycin, CCCP, or EtBr. Autophagic vacuoles containing mitochondria (black arrows) were 
found for all treatment conditions. Scale bars represent 1 m. Abbreviations: control, 
hES-LC3-GFP cells treated with DMSO; Rap, hES-LC3-GFP cells treated with rapamycin; CCCP, 
hES-LC3-GFP cells treated with carbonyl cyanide 3-chlorophenylhydrazone; EtBr, hES-LC3-GFP 
cells treated with ethidium bromide; Spd. Diff-7, hES-LC3-GFP cells culture without basic 
fibroblast growth factor for 7 days; Spd. Diff-14, hES-LC3-GFP cells culture without basic 
fibroblast growth factor for 14 days; RA-3, hES-LC3-GFP cells culture treated with retinoic acid 
for 3 days. 
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Figure 4.20 Quantification of autophagosomes and mitophagosomes in hESCs.  
The average number of autophagosomes per cell was calculated automatically using the 
ImageStream system software (white), the average number of autophagosomes (grey) and the 
average number of mitophagosomes (black) were calculated manually from live-cell flow cytometry 
images. The values are also shown in the Table 4.12. Data are the mean ± SD. *P<0.05 as compared 
to control.  
 
* * * * * * * * * * * * * * 
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Videos: 
Video 4.1: Live-imaging of mitophagy in hES-LC3-GFP.  
Representative video of combination of LC3-GFP signal (green), and MitoTracker Red signal 
(red) is shown. Images were captured every 1 minute for 10 cycles. Scale bars represent 50 m.  
 
Video 4.2: Live-imaging of mitophagy in hES-LC3-GFP with 200 nM rapamycin.  
 Representative video of combination of LC3-GFP signal (green), and MitoTracker Red signal 
(red) is shown. Images were captured every 1 minute for 10 cycles. Scale bars represent 50 m. 
 
Video 4.3: Live-imaging of mitophagy in hES-LC3-GFP with 50 µM CCCP.  
Representative video of combination of LC3-GFP signal (green), and MitoTracker Red signal 
(red) is shown. Images were captured every 1 minute for 15 cycles. Scale bars represent 50 m. 
Abbreviation: CCCP, carbonyl cyanide 3-chlorophenylhydrazone 
 
Video 4.4: Live-imaging of mitophagy in hES-LC3-GFP with 100 ng/ml EtBr.  
 Representative video of combination of LC3-GFP signal (green), and MitoTracker Red signal 
(red) is shown. Images were captured every 1 minute for 20 cycles. Scale bars represent 50 m. 
Abbreviation: EtBr, ethidium bromide. 
Video 4.5: Live-imaging of mitophagy in spontaneously differentiated hES-LC3-GFP without basic 
fibroblast growth factor for 7 days.  
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Representative video of combination of LC3-GFP signal (green), and MitoTracker Red signal 
(red) is shown. Images were captured every 1 minute for 20 cycles. Scale bars represent 50 m.  
 
Video 4.6: Live-imaging of mitophagy in hES-LC3-GFP with 100 ng/ml EtBr.  
 Representative video of combination of LC3-GFP signal (green), and MitoTracker Red signal 
(red) is shown. Images were captured in 0, 8
th
 and 16
th
 hour.  
 
Video 4.7: Live-imaging of mitophagy in hES-LC3-GFP with 100 ng/ml EtBr for one week.  
 Representative video of combination of LC3-GFP signal (green) and MitoTracker Red signal 
(red) is shown. Images were captured in 0, 8
th
 and 16
th
 hour.  
 
Video 4.8: Live-imaging of mitophagy in hES-LC3-GFP for one week.  
Representative video of combination of LC3-GFP signal (green) and MitoTracker Red signal 
(red) is shown. Images were captured in 0, 8
th
 and 16
th
 hour.  
 
 
 
235 
 
Appendix 
Appendix Table 1. List of Abbreviations 
Units  
h Hours 
w Weeks 
bp Base pairs 
SDS Sodium dodecyl sulphate 
SD Standard deviation 
rRNA Ribosomal RNA 
tRNA Transfer RNA 
Β-ACTIN (ACTB) Actin, beta 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
Dox Doxycyclin 
VSV-G Vesicular stomatitis virus glycoprotein G 
VP Viral particles 
WPRE Woodchuck hepatitis virus post-transcriptional regulatory element 
PB Phosphate buffer 
PBS Phosphate-buffered saline 
DMEM Dulbecoo‟s Modified Eagle‟s Medium 
EGFP Enhanced green fluorescent protein 
GFP Green fluorescent protein 
HEK 293 Human embryonic kidney cell line 
  
Stem cells  
dpc Days post coitum 
ASC Adult stem cells 
ASCC Australian Stem Cell Centre 
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b-FGF Basic Fibroblast Growth Factor 
CM Conditioned medium 
E Embryonic day 
EC Embryonal carcinoma 
EBs Embryonic bodies 
hESCs Human embryonic stem cells 
hiPSCs Human induced pluripotent stem cell 
HSCs Haemoatopoietic stem cells 
HTERT Human telomerase reverse transcriptase 
ICM Inner cell mass 
ID Inhibitor of differentiation 
IVF In vitro fertilization 
KSR Knockout serum replacement 
NANOG Nanog homeobox 
NEAA Non-Essential Amino Acids 
NFκB Nuclear Factor Kappa B 
MESC Mouse embryonic stem cell 
PGCS Primordial germ cells 
PSCS Pluripotent stem cells 
POU5F1 or OCT4 POU class 5 homeobox 1 
SCID Severe combined immunodeficient  
SOX2 SRY (sex determining region Y)-box 2 
SSEA Stage-specific embryonic antigen 
TOR The Target Of Rapamycin 
  
Mitochondrion  
ΔΨ Mitochondrial membrane potential 
ADP Adenosine diphosphate 
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ATP Adenosine triphosphate 
ATP6 ATP synthase subunit VI (Complex V) 
ATP8 ATP synthase subunit VIII (Complex V) 
CAP Chloramphenicol 
CCCP Carbonyl cyanide 3-chlorophenylhydrazone 
COX1-3 Cytochrome c oxidase subunit I-III (Complex IV) 
CYTB Cytochrome b (Complex III) 
D-loop Displacement loop 
ER Endoplasmic reticulum 
EtBr Ethidium bromide 
ETC Electron transport chain 
HMG High-mobility group 
IMM Inner mitochondrial membrane 
JC1 
5, 5‟, 6, 6‟-tetrachloro-1, 1‟, 3, 3‟-tetraethylbenzimidazolylcarbocyanine 
iodide 
MD Mitochondrial dysfunction 
MDS Mitochondrial depletion syndromes 
MRC Mitochondrial respiratory chain 
mtDNA Mitochondrial DNA 
ND1-6 NADH dehydrogenase subunit I-VI (Complex I) 
NRF-1 Nuclear respiratory factor I 
NRF-2 (GABP) GA binding protein transcription factor, alpha subunit  
ρ˚ cells Mitochondrial depleted cells 
PD Parkinson disease 
PGC1α/PGC1A Homo sapiens peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha (PPARGC1A), mRNA 
POLG Polymerase gamma 
POLRMT Polymerase (RNA) mitochondrial (DNA directed) 
PPP Pentose phosphate pathway 
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ROS Reactive oxygen species 
TFAM Mitochondrial transcription factor A 
SOD Superoxide dismutase 
  
Autophagy  
ATG Autophagy-related genes 
LC3 Microtubules-associated protein light chain 3 
PAS Pre-autophagosomal structure 
TOR Target of rapamycin 
  
Techniques  
FACS Fluorescence-activated cell sorting 
PCR Polymerase chain reaction 
qPCR Quantitative polymerase chain reaction 
RISC RNA-induced silencing complex 
RNAi RNA interference 
SCNT Somatic cell nuclear transfer 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SCNT Somatic cell nuclear transfer 
TEM Transmission electron microscopy 
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Appendix Table 2. Cell lines used in this study 
Cell lines Description Reference 
Normal human 
dermal fibroblasts 
(HFF) 
Normal human dermal fibroblasts and cultured 
with F-DMEM. 
ATCC: ATCC 
PCS-201-012 
Human 
fibroblast-treated 
with EtBr 
Human fetal fibroblast cells and cultured with 
F-DMEM, addition of uridine. 
In-House 
Human 
fibroblast-treated 
with chloramphenicol 
(CAP) 
Human fetal fibroblast cells and cultured with 
F-DMEM, addition of uridine. 
In-House 
HEK 293T 
Called as 293T/17, Human embryonic kidney 
cells (Clone 17) expressing T antigen for plasmid 
episomal replication and cultured with 
F-DMEM. 
Invitrogen,  
ATCC: CRL-11268 
Human foreskin 
fibroblasts (hFFi) or 
mouse embryonic 
fibroblasts (mEFi) 
 
Fibroblasts were collected and irradiated in 0.33 
Х 106 cells/cm2 and cultured. They are 
co-cultured with hESC or conditioned medium 
collection purpose. 
ASCC 
Mel, hES3, H9  
Human embryonic stem cells and cultured with 
KSR on hEFi or culture with conditioned 
medium on Matrigel. 
ASCC 
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Appendix Table 3-A. Cell Culture Medium Recipes: The various culture medium compositions 
and recipes used in this thesis are listed as below, respectively. Where required, medium 
formulations were filtered using a 0.22 μm low protein binding syringe filter to ensure sterility. 
Materials Abbreviatio
n 
Company Cat. No Description 
Tissue culture flasks  
and plates 
 B&D 
Bioscience 
NA Tissue culture plastic for 
cell culture 
Tissue culture plates  B&D 
Bioscience 
NA Tissue culture plastic for 
cell culture 
High glucose Dulbecco‟s 
Modified Eagles Medium 
HG-DMEM Invitrogen 11965 DMEM containing high 
glucose (4 g/l) with sodium 
pyruvate 
Low glucose Dulbecco‟s 
Modified Eagles Medium 
LG-DMEM Invitrogen 11865 DMEM containing high 
glucose (1 g/l) with sodium 
pyruvate 
Phosphate buffered saline PBS Invitrogen E404 Buffered saline with 
required pH and osmolarity 
for cells 
Fetal Bovine Serum FBS Invitrogen 10099-
141 
FBS used in this was from 
Australian cows with no 
BVDV and demonstrated 
ability of culture HEK293, 
and fibroblasts cells. 
Knockout Serum 
Replacement 
KSR Invitrogen 10828-
028 
 
KSR used to culture human 
embryonic stem cells and 
conditioned medium 
collection. 
TrypLE Express TrypLE Invitrogen 12605 Recombinant trypsin 
solution 
Dimethylsulphoxide DMSO Sigma-Ald
rich 
D2438 Solvent used for efficient 
cryopreservation of cells to 
dissolve reagents. 
Ethanol  Sigma-Ald
rich 
E7023 Solvent used for efficient 
to dissolve reagents. 
Basic fibroblast growth 
factor 
bFGF Millipore GF-003
-AF 
Growth factor for 
maintaining hESCs. 
Activin A  R&D 
Systems 
338-A
C 
Growth factor for the 
differentiation of hESCs 
into primitive streak cells 
Bone morphogenic BMP-4 R&D 314-BP Growth factor for the 
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protein-4 Systems differentiation of hESCs 
into primitive streak cells 
Bovine serum albumin BSA Sigma-Ald
rich 
A9647 Protein presented at a very 
high concentrations in 
serum 
Sodium pyruvate  Sigma-Ald
rich 
P5607 Non-glucose substrate for 
cells 
Penicillin/Strptomycin P/S Invitrogen 1750-0
63 
Antibiotic formation for 
cell in cell culture to 
reduce contamination  
MEM Non-Essential Amino 
Acids Solution 
NEAA Invitrogen 11140-
050 
 
Supplement for culture 
hESCs. 
β-mercaptoethanol B-Me Sigma-Ald
rich 
M6250 Supplement for culture 
hESCs. 
L-Glutamine L-Glu Invitrogen 250300
81 
Supplement for culture 
hESCs. 
Puromycin dihydrochloride Puromycin Sigma-Ald
rich 
P7130 Antibiotic formation for 
selecting the stable hESC 
lines 
Blasticidin  Invitrogen R210-0
1 
Antibiotic formation for 
selecting the stable hESC 
lines 
Geneticine  Invitrogen 10131-
027 
 
Antibiotic formation for 
selected the stable hESC 
lines 
Chloramphenicol  CAP Sigma-Ald
rich 
C0378 Reagent for depleting 
mitochondria in cell culture  
Ethidium bromide  EtBr Sigma-Ald
rich 
E7637 Reagent for depleting 
mitochondria in cell culture 
Carbonyl cyanide 
3-chlorophenylhydrazone 
CCCP Sigma-Ald
rich 
C2759 Uncoupler of oxidative 
phosphorylation in 
mitochondria 
Rapamycin Rap Sigma-Ald
rich 
R8781 Induced autophagosomes 
in hESCs 
Uridine   Sigma-Ald
rich 
U3003 Supplement for 
mitochondrial-depleted 
cells 
 
Appendix Table 3-B. Cell Culture Medium Recipes 
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hESCs growth medium:  
80% KnockOut Dulbecco‟s modified Eagle‟s medium nutrient mixture 
F-12, (KO-DMEM F-12, Invitrogen) 
394 ml 
20% Knock-Out Serum Replacement (KOSR) (Invitrogen) 100 ml 
1% NEAA (Gibco BRL) 5 ml 
0.1 mM β-mercaptoethanol (Sigma-Aldrich) 928 μl 
4 ng/ml human recombinant basic fibroblast growth factor (bFGF) 
(Invitrogen) (fresh addition) 
 
60,000 cells/cm
2
 of mEFi or hFFi were seeded for conditioned medium 
collection for 7 days and filtered before used. 
 
Inactivated human foreskin fibroblast (hFFi) as feeder growth medium 
90% Dulbecco‟s modified Eagle‟s medium, (KO-DMEM F-12, 
Invitrogen) 
440 ml 
10% FBS (Invitrogen) 50 ml 
1% L-Glu (Gibco BRL) 5 ml 
1% NEAA (Gibco BRL) 5 ml 
Human fibroblast cells (hFF) growth medium:  
90% Dulbecco‟s modified Eagle‟s medium, (DMEM, Invitrogen) 435 ml 
10% FBS (Invitrogen) 50 ml 
1% L-Glu (Gibco) 5 ml 
1% NEAA (Gibco) 5 ml 
1mM Sodium pyruvate (Gibco) 5 ml 
Human fibroblast cells (hFF) with ethidium bromide or chloramphenicol-treated growth 
medium 
90% Dulbecco‟s modified Eagle‟s medium, (DMEM, Invitrogen) 430 ml 
10% FBS (Invitrogen) 50 ml 
1% L-Glu (Gibco) 5 ml 
1% NEAA (Gibco) 5 ml 
1mM Sodium pyruvate (Gibco) 5 ml 
1% of 50 mg/ml uridine (Sigma-Aldrich) 5 ml 
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Ethidium bromide (EtBr) (100 ng/ml) or chloramphenicol (CAP) (100 
μg/ml) (Sigma-Aldrich) 
 
HEK 293T (ATCC: CCRL-11268) growth medium:  
90% Dulbecco‟s modified Eagle‟s medium, (DMEM, Invitrogen) 445 ml 
10% FBS (Invitrogen) 50 ml 
500 ng/ml Geneticine (Gibco) 5 ml 
Cryopreservation medium for hFF, mEFi, and HEK293T  
90% FBS 900 µl 
10% DMSO 100 µl 
Cryopreservation medium for hESCs  
Conditioned media 900 µl 
10% DMSO 100 µl 
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Appendix Table 4. Molecular Biology Reagents 
Materials Abbreviation Company Cat. No Description 
Luria Broth Base LB Sigma-Aldric
h 
L1900 Bacteria 
growth 
QIAquick Gel 
Extraction Kit  
 QIAGEN 28704 Gel extraction  
NucleoSpin
®
 Plasmid 
QuickPure 
 Macherey 740615.10 Plasmid 
extraction for 
viruses 
production 
purpose 
NucleoBond
®
 Xtra Midi / 
Maxi 
 Macherey 740410.10 Plasmid 
extraction 
from bacteria 
RNeasy Mini Kit  QIAGEN 74104 Total RNA 
extraction 
DNeasy Blood & Tissue 
Kit 
 QIAGEN 69504 Total genomic 
DNA 
extraction 
MMLV Reverse 
transcriptase 
MMLV Invitrogen AM2043 Moloney 
Murine 
Leukemia 
Virus Reverse 
Transcriptase 
for cDNA 
synthesis 
Oligo d(T)12-18 
Primers 
 
 Invitrogen 
Integrated 
DNA 
Technologies 
(IDT) 
12577011 
N/A 
Primers for 
cDNA 
synthesis or 
PCR 
reactions. 
RNase  Sigma-Aldric
h 
R6513 Apply for 
DNA and 
plasmid DNA 
extraction. 
Protease K  Roche 03115828001 Dissolve 1 
mg/ml of 
protease K in 
1 ml of 
double-distille
d water. 
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Protease inhibitors 
cocktail 
 Roche 05 892 791 001 Combination 
of protease 
inhibitors in 
10 ml of PBS 
in cell lysate 
for Western 
Blot  
DNase 
Deoxynucleotide 
solution mix 
1 kb and 100 bp DNA 
ladders 
Restriction enzymes 
 
dNTP 
 
 
New England 
Biolabs 
(NEB) 
M0303L 
N0447 
N332, N3231 
Molecular 
biology 
purpose 
SoSoFast SYBR reagent 
SYBR green 
 
 Bio-Rad 
ABI 
172-5200 
4309155 
For 
quantitative 
real-time 
PCR. 
Goat Serum 
 
 Sigma-Aldric
h 
G9023 Blocking 
reagent for 
immunostaini
ng 
Bromophenol Blue 
β-mercaptoethanol 
 
BME 
Sigma-Aldric
h 
B0126 
M6250 
Dye 
BME is 
suitable for 
reducing 
protein 
disulfide 
bonds prior to 
polyacrylamid
e gel 
electrophoresi
s and apply in 
protein lysis 
buffer.  
Tween-20  Sigma-Aldric
h 
P1379 Buffer 
detergent 
Triton X-100  Sigma-Aldric
h 
T9284 Cell 
permeabilisati
on detergent 
Milli-Q water  In house NA Ultra-pure 
water 
Tris 
(hydroxymethyl-amino
TRIS Amerseco 0234 Buffer salt 
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methane 
Ethylenediaminetetraace
tic acid 
EDTA Ajax 
Finechem 
A180 Metal chelator 
Hydrogen chloride HCl Ajax 
Finechem 
256-2.5L-GL Buffer salt 
Tryphan Blue  Sigma-Aldric
h 
T8254 Satins dead 
but not live 
cells 
Glycerol  Sigma-Aldric
h 
5516 Used in slide 
embedding 
solution 
Permount Mounting 
medium 
 Invitrogen 00810 Slide 
mounting 
medium 
Doxycycline Dox Sigma-Aldric
h 
D9891 Doxycycline 
is a member of 
the 
tetracycline 
antibiotics 
group, and 
applied in 
tet-on induce 
system. 
Retinoic Acid RA Sigma-Aldric
h 
R2625 Retinoic Acid 
applied for 
hESCs 
differentiation 
Lipofectamine
TM 
LTX & 
Plus Reagent  
 Invitrogen 15338-199 For plasmid 
DNA delivery. 
Total Glutathione 
Detection Kit 
 Assay 
Designs 
900-160 Total 
Glutathione 
Detection in 
mitochondrial 
–depleted 
fibroblast 
cells. 
Paraformaldehyde PFA Sigma-Aldric
h 
P6148 Fixative 
Sodium dodecyl 
sulphate 
SDS Sigma-Aldric
h 
71728 Detergent for 
decellularisati
on process 
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Appendix Table 5. Buffer Receipts Applied in Molecular Biology Techniques 
 
6x DNA loading dye (250 ml)  
80% glycerol 93.6 ml 
0.5 M EDTA 3 ml 
Bromophenol Blue 0.3 g 
Xyanol 0.3 g 
50x TAE (1L)  
Tris base 242 g 
Glacial acetic acid 57.1 ml 
0.5 M EDTA, pH 8.0 100 ml 
0.5 M EDTA, pH 8.0 (M.W. 336.2) (500 ml) 
EDTA 84.05 g 
5 M NaOH 71 ml 
3 M sodium acetate, pH 8.0 (500 ml)  
Sodium acetate 204.15 g 
Glacial acetic acid 90 ml 
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Appendix Table 6. PCR Primer Sequences 
Genes 
Forward 5‟-3‟  
Reverse 5‟ 3‟ 
Tm Eff Size Acc. No. 
Beta-ACTIN GCTGTGCTACGTCGCCCTG  
GGAGGAGCTGGAAGCAGCC  
60 0.983 60 
NM_0011
01   
OCT4 TGAAGCTGGAGAAGGAGAAG 
ATCGGCCTGTGTATATCCC 
60 0.985 134 
NM_0027
01, 
NM_2032
89, 
NM_0011
73531 
NANOG GATTTGTGGGCCTGAAGAAA 
AAGTGGGTTGTTTGCCTTTG 
60 0.984 101 NM_0248
65 
SOX2 AACCCCAAGATGCACAACTC 
CGGGGCCGGTATTTA TAATC 
60 0.996 52 
NM_0031
06 
MtDNA copy number 
D-loop 
CCCTAACACCAGCCTAACCA 
GTTAGCAGCGGTGTGTGTGT 
60 0.997 165 
NC_01292
0 
Mitochondria-encoded genes 
MT-ND1 ATGGCCAACCTCCTACTCCT 
GCGGTGATGTAGAGGGTGAT 
52 0.999 214 
YP_00302
4026   
MT-ND4 
CCTGACTCCTACCCCTCACA 
ATCGGGTGATGATAGCCAAG 
52 0.990 150 
YP_00302
4035 
MT-ND5 
ACATCTGTACCCACGCCTTC 
TCGATGATGTGGTCTTTGGA 
60 0.987 189 
YP_00302
4036 
MT-COX2 
TTCATGATCACGCCCTCATA 
TAAAGGATGCGTAGGGATGG 
52 0.999 186 YP_00302
4029  
MT-COX3 
CCCGCTAAATCCCCTAGAAG 
GGAAGCCTGTGGCTACAAAA 
60 0.990 82 
YP_00302
4032 
MT-CYTB 
TATCCGCCATCCCATACATT 
GGTGATTCCTAGGGGGTTGT 
52 0.996 169 
YP_00302
4038 
Mitochondrial biogenesis-related genes 
TFAM 
CCGAGGTGGTTTTCATCTGT 
TCCGCCCTATAAGCATCTTG 
52 0.995 203 
NM_0032
01 
NRF-1 
ACAGAAGAGCAAAAGCAGAG 
GCTGATCTTCAAAGGCATAC 
60 0.831 111 NM_0010
40110   
POLG CAAGGTCCAGAGAGAAACTG 60 0.951 116 NM 
_0011261
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GCAATGCTCTCAAGCTTATT 31   
PGC1α 
CCATATTCCAGGTCAAGATCAAG 
TCACATACAAGGGAGAATTTCG 
60 0.997 118 
NM_0132
61 
Ectoderm differentiation-markers 
PAX6 
CAGCACCAGTGTCTACCAACCA 
CAGATGTGAAGGAGGAAACCG 
60 0.995 67 NM_0002
80 
Mesoderm differentiation-markers 
BRACHYU
RY (BRY) 
TCAGCAAAGTCAAGCTCACCA 
CCCCAACTCTCACTATGTGGATT 
60 0.98 102 
NM_0031
81 
MIXL1 
CCGAGTCCAGGATCCAGGTA 
CTCTGACGCCGAGACTTGG 
60 0.95 58 
NM_0319
44 
Endoderm differentiation-markers 
GATA4 
TCTCACTATGGGCACAGCAG 
GGGACAGCTTCAGAGCAGAC 
60 0.98 116 
NM_0080
92 
IGF2 TGGCATCGTTGAGGAGTGCTGT 
ACGGGGTATCTGGGGAAGTTGT 
60 0.995 136 
NM_0006
12 
NM_0010
07139 
NM_0011
27598 
SOX17  GGCGCAGCAGAATCCAGA 
CCACGACTTGCCCAGCAT 
60 0.995 59 
NM_0224
54 
Cloning 
GFP 
CTGGTCGAGCTGGACGGCGACG 
CACGAACTCCAGCAGGACCATG 
60 N/A 631 N/A 
TFAM 
CACCATGGCGTTTCT CCGAAG  
TTAACACTCCTCAGCACCATA 
TTTTCGTTG 
60 N/A 741 NM_0032
01 
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Appendix Table 7. Target sequences of shRNAs against human TFAM 
shRNA cloned into constitutive knockdown plasmid (the pLenti5-U6-TFAMi, Invitrogen) 
Name                         Sequence (5‟-3‟) 
TFAMi-1  
(266-286)  
F:CCGGGGGAACTTCCTGATTCAAAGACTCGAGTCTTTGAATCAG
GAAGTTCCCTTTTTG 
R:AATTCAAAAAGGGAACTTCCTGATTCAAAGACTCGAGTCTTTG
AATCAGGAAGTTCCC 
TFAMi-2  
(591-611) 
F:CCGGGGAATTATATATTCAGCATGCCTCGAGGCATGCTGAATA
TATAATTCCTTTTTG 
R:AATTCAAAAAGGAATTATATATTCAGCATGCCTCGAGGCATG
CTGAATATATAATTCC 
TFAMi-3  
(618-638) 
F:CCGGGGACGAAACTCGTTATCATAACTCGAGTTATGATAACGA
GTTTCGTCCTTTTTG 
R:AATTCAAAAAGGACGAAACTCGTTATCATAACTCGAGTTATG
ATAACGAGTTTCGTCC 
shRNA cloned into inducible knockdown plasmid (the pLKO-Tet-on-TFAMi) 
Name                         Sequence (5‟-3‟) 
TFAMi-3  
(489-509) 
F:CCGGCGTTTATGTAGCTGAAAGATTCTCGAGAATCTTTCAGCT
ACATAAACGTTTTTG 
R:AATTCAAAAACGTTTATGTAGCTGAAAGATTCTCGAGAATCTT
TCAGCTACATAAACG 
TFAMi-5  
(7764-784) 
F:CCGGCGTGAGTATATTGATCCAGAACTCGAGTTCTGGATCAAT
ATACTCACGTTTTTG 
R:AATTCAAAAACGTGAGTATATTGATCCAGAACTCGAGTTCTGG
ATCAATATACTCACG 
TFAMi-6 
(Targetless-
shRNA) 
F:CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTT
AACCTTAGGTTTTTG 
R:AATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGG
GCGACTTAACCTTAGG (Sarbassov, Guertin, et al. 2005). 
F: Forward; and R: Reverse 
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Appendix Table 8. Buffers for Immunostaining and Microscopy 
 
Phosphate buffer saline (PBS) 200 ml 
PBS tablet 1 tablet 
Make up with ddH2O to 200 ml 
4% Paraformaldehyde, pH 7.5 100 ml 
Paraformaldehyde 4 g 
Make up with 1x PBS to 100 ml and used NaOH to adjust the pH to 7.5 and aliquot 
for -20°C storage. 
Permeabilization buffer 500 ml 
10% Triton 500 μl 
Make up with 1x PBS to 500 ml. 
Hoechst 33258 or DAP 1 ml 
Hoechst 33258 or DAPI 10 mg 
Make up with ddH2O to 1 ml and aliquot into small aliquots. 
Blocking buffer  
5% skim milk power in PBS or 1% bovine serum albumin (BSA)  
Make up with 1x PBS  
10x Phosphate buffer (PB) 1 L 
1.37 M NaCl 80 g 
30 mM KCl 2 g 
65 mM Na2HPO4H2O 17.8 g 
15 mM KH2PO4 2.4 g 
Make up with ddH2O to 1 L. 
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Appendix Table 9-A. Working Concentrations for fixed-cell-immunostaining 
 
Antibody Application Company 
Animal 
Source 
Dilution 
Anti-human-TRA-1-60 IC; FC Millipore mouse 
1:500 (to 1 
mg/ml)  
Anti-human-POU5F1 IC; WB Sigma-Aldrich rabbit 1:500 
Anti-human-β-ACTIN  
(45 kDa) 
WB 
Cell Signaling 
Biotechnology 
rabbit 1:2000 
Anti-human-TFAM (24 
kDa) WB; FC 
Cell Signaling 
Biotechnology 
rabbit 1:2000  
Anti-mouse IgG Alexa 
Fluro 488 IC 
Invitrogen goat 1:2000   
Anti-rabbit IgG Alexa 
Fluro 568 IC 
Invitrogen goat 1:2000 
Anti-mouse IgG HRP WB 
Santa Cruz 
Biotechnology 
goat 
1:4000 (to 200 
μg/0.5 ml) 
Anti-rabbit IgG HRP WB 
Santa Cruz 
Biotechnology 
goat 
1:4000  (to 200 
μg/0.5 ml) 
Note: skim milk was used as blocking in Western Blotting, and 1% BSA was used as blocking 
in fixed-cell immunostaining and flow cytometry. 
IC, Immunocytochemistry; FC, Flow cytometry; WB, Immunoblotting 
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Appendix Table 9-B. Working Concentrations for live-cell-staining   
Materials Application Company Cat. No Description 
MitoTracker 
Red IC; IFC 
Invitrogen M22425 
Mitochondria staining dye 
excitated at 581 nm for 
imaging purpose: (Flow 
cytometry use 100 nM final 
concentration; 
immunocytochemistry use 100 
nM final concentration) 
MitoTracker 
Deep Red FC 
Invitrogen M22426 
Mitochondria staining dye 
excitated at 644 nm for 
AMNIS purpose: (Flow 
cytometry use 100 nM final 
concentration; 
immunocytochemistry use 100 
nM final concentration) 
Mitochondria 
staining kit 
(JC-1) 
IC; FC Sigma-Aldrich CS0390 
For mitochondrial potential 
changes detection: (Flow 
cytometry use 0.1 µg/ml final 
concentration of 
JC1;immunocytochemistry use 
0.1 µg/ml final concentration 
of JC1) 
IC, Immunocytochemistry; IFC, Imaging flow cytometry; FC, Flow cytometry 
 
Reference: 
Sarbassov, D. D., D. A. Guertin, S. M. Ali and D. M. Sabatini (2005). “Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex.” Science 307 (5712):1098-1101. 
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Supplementary Method 
Immunoblotting 
Western blot analysis was performed on cytosolic of hESCs with drugs as described in 
this thesis. First the cells were lyzed with an extraction buffer (Tris 10 mM, pH 7.0, NaCl 140 
mM, PMSF 2 mM, DTT 5 mM, NP-40 0.5%, pepstatin A 0.05 mM and leupeptin 0.2 mM) for 
protein extraction, and then centrifuged at 12,500 g for 30 min. To measure the expression 
levels of proteins, the total proteins were extracted and Western blotting analyses were 
performed as established in the Wolvetang laboratory. An aliquot of 20 μg total protein of 
each cell lysates was loaded and separated on 10-15% Tris-Glycine-SDS polyacrylamide 
gels and electroblotted onto PVDF membranes (PALL Life, Science, Pensacola, FL). After 
the incubation with 5% fat-free skim milk in TBS buffer (10mM Tris, 150mM Nacl, pH7.4) for 
1 hour at room temperature, primary antibodies, which consisted of β-ACTIN (1:2000, Cell 
Signaling Biotechnology), TFAM (1:2000, Cell Signaling Biotechnology), OCT4 (1:500, 
Sigma-Aldrich) were applied to probe the blots (Appendix Table 9). After incubation at 4 
degree overnight, the membrane were washed with TBS-T (0.05% Tween-20 in TBS buffer) 
three times and then incubated with horseradish peroxidase (HRP)-conjugated secondary 
antibodies (1:4000, Santa Cruz Biotechnology). The membranes were then developed 
using Western Pico Super ECL reagent (Pierce). Images were developed by the Typhoon 
scanner (GE Healthcare), and signal intensity quantification was performed by Image J 
software (http://rsb.info.nih.gov/ij/).  
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Supplementary Figures 
 
 
Figure S1 Characterization of the hESC with Tra-1-60 in undifferentiated and differentiated 
hESCs.  
   Markers for pluripotency (TRA-1-60, green) and mitochondria (MitoTracker Red, red) 
were analyzed in fixed hESCs. (A) Undifferentiated hESCs exhibited significantly protein 
expression of TRA-1-60 immunoreactivity and low in mitochondrial staining in the fixed 
sample, and (B) 14 days differentiated hESCs exhibited significantly reduction in TRA-1-60 
immunoreactivity and significantly increased in mitochondrial staining. Nuclei are 
counterstained with DAPI (blue). Representative images are shown. Scale bars represent 
50 m. 
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Figure S2 Constitutive overexpression of TFAM protein levels in hES cell lines (Mel 1, hES3 
and H9).  
Three samples were hESC without lentivirus-transduction (negative control), hESC 
transduced with EF1α-GFP and hESC transduced with EF1α-TFAM, respectively. (A) 
Western blot analysis of TFAM expression in the control and lentivirus-transduced hESCs 
was performed using antibodies against the proteins indicated on the left. β-actin was 
included as a loading control. Untreated hESCs were analyzed as a negative control. (B) 
TFAM expression in hESCs was quantified by phosphor-imager analysis of the western 
blots. Western blot analysis confirmed that the level of TFAM was higher by overexpressing 
TFAM in three different hES cell lines. 
 
259 
 
 
 
260 
 
Figure S3 Inducible knockdown of TFAM levels in hES cell lines (Mel 1, hES3 and H9).  
Three TFAM shRNA were TFAM-shRNA-3, TFAM-shRNA-5 and TFAM-shRNA-6 
(targetless), respectively. (A) Western blot analysis of TFAM expression before and after 
doxycycline addition in the control and lentivirus-transduced hESCs was performed using 
antibodies against the proteins indicated on the left. β-ACTIN was included as a loading 
control. Untreated hESCs were analyzed as a negative control. (B) TFAM expression in 
hESCs was quantified by phosphor-imager analysis of the western blots. Western blot 
analysis confirmed that the level of TFAM can be knockdown by TFAM-shRNAi-3 and 
TFAM-shRNAi-5 in three different hES cell lines. 
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Figure S4 Expression of relative OCT4 expression in the cell lysates detected by using 
Western blot assay (A), and quantified analysis represented in histogram (B). Untreated 
hESCs were analyzed as a negative control. β-ACTIN was included as a loading control. 
Western blot analysis confirmed that the level of POU5F1 protein was not affect in a 
short-term treatment, and decreased dramatically upon 3 days of RA-induced differentiation 
and spontaneously differentiation. 
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Figure S5 Characterization of 
the hES-LC3-GFP reporter 
cell line.  
(A) Localisation of 
TRA-1-60 (green) (B) 
Localisation of POU5F1 (red) 
within the hES-LC3-GFP cell 
line. Nuclei are 
counterstained with DAPI 
(blue). Representative 
images are shown. Scale 
bars represent 50 m. 
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Figure S6 Characterization of mitochondria in undifferentiated hESCs with 50 μM CCCP in 2 
hours or 24 hours.  
   (A) Undifferentiated hESCs treated with 2 hours of CCCP and stained with JC-1. (B) 
Undifferentiated hESCs treated with 24 hours of CCCP and stained with JC-1. The 
JC-aggregates form (Red) had shown significantly reduction in 24 hours of CCCP compared 
with 2 hours of CCCP in hESCs. This suggested that CCCP significantly depolarised the 
mitochondrial membrane potential in hESCs. Low and high membrane potentials are 
indicated by green and red staining, respectively. Nuclei are counterstained with DAPI (blue). 
Representative images are shown. Scale bars represent 50 m inverted confocal 
laser-scanning microscope (Zeiss LSM 710).  
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Figure S7 Scheme of different treatments in hES3-LC3-GFP cells videos by imaging 
fluorescence microscopy.  
Data were displayed as in images. Abbreviations: control, hES3-LC3-GFP cells treated 
with DMSO; Rap, hES3-LC3-GFP cells treated with rapamycin; CCCP, hES3-LC3-GFP 
cells treated with carbonyl cyanide 3-chlorophenylhydrazone; EtBr, hES3-LC3-GFP cells 
treated with ethidium bromide; Spd. Diff-7, hES3-LC3-GFP cells culture without basic 
fibroblast growth factor for 7 days. 
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Figure S8 A more detailed dosage of treatment toxin and differentiation-induced mitophagy 
in hES-LC3-GFP cells.  
Images represented from left to right. Images are combination of LC3-GFP signal 
(green) and MitoTracker Red signal (red) channels. Treatment conditions are listed at left: 
(A) control (DMSO), (B and C) rapamycin (positive control, 200nM and 500 nM) in 0, 5 and 
10 minutes, respectively, (D-F) CCCP (mitophagy induction, 10, 5, and 100 µM) in 0, 7 and 
15 minutes, (G) EtBr (mitophagy induction, 100 ng/ml) treatment, (H) 7 days of bFGF 
withdrawal (spontaneous differentiation) in 0, 10 and 20 minutes, (I) control in 0, 8, 16 hours, 
(J-L) EtBr (10, 50, and 100 ng/ml) treatment in 0, 8 and 16 hours, (M) EtBr (100 ng/ml for 1 
week) treatment in 0, 8 and 16 hours, respectively. Representative images from 
supplementary videos are shown and mitophagy events are circled by red circles. Scale 
bars represent 50 m. Abbreviations: control, hES-LC3-GFP cells treated with DMSO; Rap, 
hES-LC3-GFP cells treated with Rapamycin; CCCP, hES-LC3-GFP cells treated with 
carbonyl cyanide 3-chlorophenylhydrazone; EtBr, hES-LC3-GFP cells treated with ethidium 
bromide; Spd. Diff-7, hES-LC3-GFP cells culture without basic fibroblast growth factor for 7 
days. 
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Figure S9 Schematic structure of TFAM. TFAM is composed of seven exons (indicated as 
“E” inside blue boxes). The first HMG-motif contains Ex1 to Ex 4 and second HMG-motif 
contains end of Ex4 to Ex 6. There had a small linker region connected between two 
HMG-motifs and a small carboxy-terminal tail at the end of the second HMG-motif. 
There are two sets of shRNA that are constructed in either a constitutive repression 
vector or an inducible-repression vector. The shRNA construct in the constitutive 
expression vector are 1 (266-286), 2 (591-611), and 3 (618-638) as indicated by the green 
arrows. The shRNA construct in the inducible expression vector are 3 (489-509), and 5 
(764-784), as indicated by the red arrows.  
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